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The functions of neuronal sodium channels can be antagonised by blocking the 
ion flux. It is hypothesized that all compounds that exhibit blockade activity against 
the neuronal sodium channels, as characterized by the BTX assay, share a common 
pharmacophore, and that such a pharmacophore is able to discern good blockers from 
weaker blockers. As such, the main objective of the study was to derive and validate a 
pharmacophoric model for sodium channel blockers, by computer-aided molecular 
modelling. The pharmacophoric model was derived from five good neuronal sodium 
channel blockers, and was subsequently validated with 20 compounds. The model 
consists of one H-bond donor (D), one H-bond acceptor (A) and one hydrophobic 
group (H), and the A-H, A-D and D-H distances are 4.02 ± 1.26Å, 5.65 ± 1.26Å, and 
3.27 ± 1.26Å respectively. Results from correlation studies between Relative Binding 
Potential (RBP) and Total Difference (TD) values were used to separate the good 
blockers from the weaker blockers.  
The study was able to demonstrate that the pharmacophoric model could 
identify potential sodium channel blockers. According to the model, active sodium 
channel blockers should have the three stipulated pharmacophoric elements, a TD 
value less than 3.50, and a charged nitrogen at physiological pH. The model identified 
the 4,6-diamino-1,2-dihydro-2,2-substituted-1-phenyl-1,3,5-triazines (phenyldihydro-
1,3,5-triazines) as good blockers. In addition, the pharmacophoric model was also used 
to help in optimising the blockade activity of the phenyldihydro-1,3,5-triazines. 4,6-
diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazine was synthesized and its 
sodium channel blockade activity was observed at an IC B50B value of 195.1 ± 10.8µM. 
The pharmacophoric model suggested the substitution of the dimethyl group at the 2-
position, with a more hydrophobic group, would give better binding affinity to the 
 vii
sodium channels. Among the new phenyldihydro-1,3,5-triazines synthesized, the most 
potent compound was 1-(m-chlorophenyl)-2,2-cyclohexyl-4,6-diamino-1,2-dihydro-
1,3,5-triazine (compound 34) and its ICB50B value was 4.0 ± 0.5µM. In contrast, the 
benzyloximes were predicted to be weak blockers. All the 11 benzyloximes 
synthesized exhibited poor sodium channel blockade activity and the most active 
compound (compound 51) had an ICB50B value of 0.44 ± 0.02mM.  
Finally, the study also investigated the pharmacological activities of the new 
compounds. The phenyldihydro-1,3,5-triazines did not show epileptic protection in the 
Maximal Electroshock (MES) assay but were found to have antinociceptive properties 
in the hot-plate assay. Phenyldihydro-1,3,5-triazines 38 and 41 have mean hot-plate 
latency values of 13.6s and 13.1s at the dose of 50mg/Kg, in comparison to morphine 
sulphate (positive control), which has a mean hot-plate latency value of 13.9s at 
5mg/Kg. The benzyloximes displayed epileptic protection in the MES assay, with 
compound 51 providing full epileptic protection (MES score of 4) at the dose of 
150mg/Kg. However, compound 51 only have a mean hot-plate latency value of 9.3s 
at the dose 100mg/Kg. 
Keywords: neuronal sodium channels, pharmacophore, model, triazines, 
benzyloximes, BTX, MES, hot-plate, screening. 
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1. COMPUTER-AIDED DRUG DESIGN IN THE DRUG 
DISCOVERY PROCESS 
1.1 Definition and Role of Computer-aided Drug Design in the Drug Discovery 
Process 
 Drug discovery is a long and costly process, requiring about US$802 million to 
bring a new drug to the end of a phase III clinical testing.1 The traditional approach to 
drug design starts with the screening of a large number of compounds, for one or more 
biological targets, until a suitable lead compound is identified. Lead identification is 
usually the most time-consuming and expensive stage of the drug discovery process. 
Rational drug design, also known as structure-based design, is a more time and cost 
efficient alternative. For rational drug design, structural information on a target 
receptor is first elucidated, which is then used to design specific ligands to interact 
with it. When compared to the traditional trial and error method of drug discovery, 
rational drug design drastically reduced the number of compounds synthesized and 
screened in biological assays. 
 One approach to rational drug design is Computer-aided Drug Design (CADD), 
which is the development or improvement of drug candidates with the assistance of 
computers. CADD approaches can be divided into two general categories, those that 
are based on the three-dimensional (3D) structure of the target receptor, and those that 
gained information by studying ligands that bind to the receptors. In the former 
category, the 3D structure of the receptor is first elucidated by techniques such as X-
ray crystallography, before being used for in silico experiments of receptor-ligand 
binding. In the later category, the approaches used were based on the concept of 
molecular recognition, which specifies that in order for ligands to bind well to their 




complementarily to their targets. These approaches usually combine the biological data 
(such as radioligand-binding studies) and in silico data, so as to deduce the geometrical 
and physiochemical requirements for favorable binding to the target receptor. A recent 
example of CADD includes the development of a receptor-based pharmacophore 
model for Bascillus stearothermophilus alanine racemase. 2 The group was able to 
utilize the conformations of the alanine racemase dimer (with a D-alanine and a non-
covalent inhibitor attached to the receptor sites) obtained during molecular dynamics 
simulations to generate a dynamic pharmacophore model. 
 
1.2. CADD Strategies and their Usage 
 The interest in CADD by researchers in academia and industry lead to the 
development of a plethora of CADD strategies. The choice of which strategy to use is 
largely dependent on whether the 3D structure of the target receptor is available, as it 
is often ideal to work with a known receptor structure to avoid questions about the 
reliability of the receptor structure prediction. In practice, however, the structure of the 
receptor is usually unknown, and alternative methods have to be employed. 
 
1.2.1 CADD Strategies based on Known 3D Structures of Target Receptor 
 Knowledge of the 3D structure of a receptor can accelerate the drug discovery 
process tremendously, as can be seen by the development of purine nucleoside 
phosphorylase inhibitors and Human Immuno-deficiency Virus (HIV) reverse 
transcriptase inhibitors. 3-4 The most common method of obtaining information on the 
3D structure is to employ X-ray crystallography. Protein nuclear magnetic resonance 
(NMR) also contributes valuable data on protein-ligand interactions, such as the NMR 




vitamin B12 nucleotide. 5 A homology model of the receptor can be constructed if 
structural information about homologous receptors is available. One example is the 
homology model of thymidine kinase from Varicella zoster virus, using homology 
modelling based on thymidine kinase from Herpes simplex virus type 1 structure as 
template. 6 Another example is the homology model of human cytochrome P450 2E1 
(CYP2E1), based on the CYP2C5 crystallographic template. 7 
 The most common CADD strategy for use with a known 3D structure of a 
target receptor is docking. Docking is a computational method that is used to 
determine the geometry of the receptor-ligand complex. The docking procedure can be 
done manually, using interactive computer graphics. However, this manner of docking 
requires a lot of input from the user, and can be successful only if the user has a good 
idea of the expected binding mode. Automatic docking algorithms are less biased than 
human modellers and usually consider more possibilities. There are many docking 
strategies available, such as those that consider the receptor-ligand complex as being a 
rigid entity. Sometimes only the ligand or the region around the receptor is considered 
as flexible. 8-10 
 Gehlhaar et. al. has described a de novo ligand designer, which made use of the 
3D structure of the target receptor. 11 The group utilized a program, which starts by 
filling the receptor site with a closely packed array of carbon atoms, and subsequently 
makes adjustments to the atoms (adding, removing or changing the types of atoms). 
Their effects on the receptor-ligand interactions assessed the resulting changes, and a 
metropolis algorithm was used to determine whether or not to accept the changes. The 






1.2.2 CADD Strategies based on Ligands 
The problem most familiar to researchers is the one in which the structure of 
the target receptor is unknown, and only little information can be inferred through 
biological screening of compounds. In such situations, CADD can be utilized to 
combine the data from biological screening with in silico data, such as geometrical and 
physicochemical data, to form receptor models or quantitative structure-activity 
relationship (QSAR) models. 
Pharmacophore and pharmacophoric elements are central concepts in medicinal 
chemistry, and have been used for a long time in two dimensional pharmacophoric 
models. CADD has enormously facilitated the 3D use of the concept, and the most 
commonly used strategy is the active analog approach. 12 This approach starts by 
selecting a set of biologically active compounds and then obtaining their energetically 
accessible conformations. These conformations were then superimposed according to 
their pharmacophoric elements and the possible 3D-pharmacophoric models were 
subsequently examined. Pharmacophoric elements used in the development of the 
models are most often atoms or functional groups which may interact with receptor 
binding sites via hydrogen bonds, electrostatic forces or van der waals interactions. 
Examples of pharmacophoric elements include heteroatoms such as oxygen and 
nitrogen and polar functional groups such as carboxylic acids, amides and hydroxyl 
groups. Other approaches to pharmacophoric models have been proposed, and they 
include the ensemble distance geometry method by Sheriden et. al. and the constrained 
minimization of active compounds by Naruto et. al. 13-14 Poulsen et. al. recently 
developed a neurokinin 2 antagonist pharmacophoric model using five non-peptide 




The steric and electrostatic properties of ligands influence their ability to form 
stable receptor-ligand complexes. These properties, together with biological data, can 
be developed into a 3D QSAR model using the comparative molecular field analysis 
(CoMFA) approach. CoMFA begins by aligning a set of compounds of known 
biological data to optimize the overlapping of their steric and electrostatic fields, 
which is then followed by partial least squares analysis. The program will then map 
out 3D areas where particular steric and electrostatic features are either advantageous 
or detrimental to biological activity. The most significant drawback of CoMFA is the 
process of selecting the conformations of the ligands to be used for alignment. The 
selection is either done manually or a weighted average of many conformations will be 
used to determine the molecular fields. Another development of the 3D QSAR 
approach is comparative molecular similarity index analysis (CoMSIA), which differs 
from CoMFA by using some arbitrary ‘descriptors’ that consider the spatial similarity 
or dissimilarity of molecules. CoMFA and CoMSIA are often used together, such as in 
the work of Tsakovska. 16 The author made use of the two 3D-QSAR methods to 
derive models for phenothiazine type multidrug resistance (MDR) modulators in 
P388/ADR cells, confirming the role of hydrophobicity as a 3D property and also 
found that hydrogen bond acceptor interactions contribute to anti-MDR activity. Paier 
et. al. used both CoMFA and CoMSIA to generate models for predicting the catalytic 
abilities of four different bacteria that contain epoxide hydrolase. 17 The models were 
used to predict the enantiomeric ratio of the products of the hydrolysis, and thus can 








1.2.3 Genetic Algorithms in CADD Strategies 
Genetic algorithms (GA) are techniques relatively new to CADD. P18 P The basic 
concept of genetic algorithms is the ‘survival of the fittest’. These techniques start by 
randomly generating a population of solutions, and these solutions were evaluated for 
their ‘fitness’. The program would then select ‘fit’ solutions and ‘breed’ (that is, to 
further explore) them, resulting in a new population of solutions. The whole process 
would be repeated till satisfied solutions were obtained.  
GA can be applied to many CADD strategies, such as pharmacophore 
elucidation, docking and QSAR. Genetic algorithms can differ in their approach to the 
evaluation of ‘fit’ solutions. One approach is to ‘screen’ the solutions in silico, such as 
by docking to a known receptor. Another method is to evaluate the solutions based on 
biological screening. The latter method can be carried out by robotic synthesis, and the 
guiding computer system would direct the contents of the next library based. 
Hou et. al. developed a molecular simulation software package, Peking 
University Drug Design System (PKUDDS), for rationale drug design.P19P The software 
package applied genetic algorithms to various CADD strategies such as molecular 
docking, conformational analysis, 2D-QSAR and CoMFA. The software package was 
verified using molecular docking studies of unbound complexes, a 2D-QSAR study of 
some cinnamamides and a CoMFA study of β–carboline ligands. 
 
1.3 Methodology in Computer-aided Drug Design 
In order to utilize CADD strategies, it is a prerequisite to model the molecules 
used in the study. The process starts by constructing a trial molecular geometry 
(conformation) in silico. For molecular mechanics calculations, the atoms of the 
molecule are then iteratively moved using an energy minimization technique until the 
INTRODUCTION 
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net forces on all atoms vanish and the total energy of the molecule reaches a minimum. 
For quantum mechanics, both the positive nuclei and negative electrons are considered. 
The conformer corresponding to this energy minimum is called the Local Minimum 
Energy Conformer (LMEC). The energy minimization methods cannot move the 
molecule across energy barriers, thus to find other LMECs, the process has to be 
repeated with another starting geometry or more efficiently by using a conformational 
search technique. The LMEC with the lowest energy is known as the Global Minimum 
Energy Conformer (GMEC). 
 
1.3.1 Quantum Mechanics and Molecular Mechanics Calculation Methods 
Calculations of conformational properties of molecules can be done using 
either the quantum mechanics (QM) methods or the molecular mechanics (MM, also 
known as force field) methods. The basis of QM methods is the Schrödinger equation, 
which is solved by treating the molecules as a collection of positive nuclei and 
negative electrons moving under the influence of coulombic potentials. This allowed 
both the calculation of the energy of the molecule and the associated wave function, 
from which electronic properties, such as electron density, can be derived. In the ab 
initio methods, all the electrons were included in the calculations; thus these QM 
methods can be extremely expensive in terms of the computer resources needed. Semi-
empirical methods, which consider only the valence electrons of the system, were 
developed to reduce computation effort. In addition, many terms in the equation were 
omitted, and scaling factors that were derived from experiments were used instead.  
 MM methods consider a molecule as a collection of atoms held together by 





the energy of a system as a function of nuclear positions only. The energy of the 
molecule (EBtotalB) is calculated as a sum of terms as in the equation below. 
 
EBtotalB =  EBstretching B + EBbendingB + EBtorsionB +EBvan der Waals B+ EBelectrostaticB + cross terms  
 
 The first four terms in the sum are the energies due to deviations of bond length, 
bond angles, torsional angles and non-bonded distances, respectively, from their 
reference values. EBelectrostaticB gives the electrostatic attraction or repulsion between bond 
dipoles or partial atomic charges while cross-terms are hybrid terms such as stretch-
bend and torsion-bend. Atom types define reference values used in the above equation, 
which give information about the atomic number, hybridization state, and sometimes 
the local environment of the atom. For example, a carbon atom can be typed as sp, spP2 P, 
sp P3P, carbonyl, or cyclopropane. A carbon atom typed as spP3 P-hybridized will have a 
reference angle of 109.5°.  
 QM methods, like MM methods, can be used for energy minimization or in 
conformational searches. However, QM methods require a far greater amount of 
computer resource than MM calculations. This difference between the two methods 
become more pronounced in cases where a fast and accurate computation of structures 
of appreciably large molecules, an extensive conformational search, dynamic processes 
or docking are the objectives of a study. 
 QM calculations are based on the electrons in the system, thus it is possible to 
derive properties that depend upon the electronic distribution, and can be used in 
situations when covalent bonds are broken or formed. In contrast, MM methods 
consider only the position of the nuclei, and therefore provide no information on the 
INTRODUCTION 
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electronic structure. Furthermore, MM methods cannot be used when the molecule is 
not in the ground state, or when covalent bonds are broken or formed. 
 In view of the strengths and limitations of the two groups of methods, 
researchers combined the two into a QM/MM hybrid, which is used mainly for 
investigating the structure and properties of large systems. 20 The system is divided 
into two regions: a small QM region and a significantly larger MM region. This 
method is well suited for studying biomolecular systems. For example, to simulate the 
mechanisms of enzyme reactions, the active site can be modeled in the QM region, 
while the rest of the macromolecule is modeled in the MM region. The most 
challenging aspect of the QM/MM method is the treatment of the bonds that connect 
atoms positioned on different sides of the QM/MM boundary. Many approaches had 
been suggested, and ongoing research is being performed to solve this problem. 
 
1.3.2 Conformational Search Techniques 
During an energy minimization of a molecule, the molecule changes from the 
initial trial conformation to the closest LMEC. For molecules with three or more 
rotatable bonds, the number of LMECs increases, thus a computer implemented search 
method is necessary. The three main conformational search methods are grid search, 
molecular dynamics and Monte Carlo simulations. 
Grid search generates new conformers by using all combinations of torsional 
angle values at a preset angle increment. The major advantage of this method is that all 
the LMECs are located within the space examined. Being a combinatorial approach, 
the number of conformers handled is equal to (360/m) n, where n is the number of 
rotatable bonds and m is the angle of increment. This method of conformational search 




Most grid search approaches reduce the number of conformers being minimized to 
save computational resources. This can be accomplished by eliminating strained 
conformers, such as when two atoms in the molecule become too close to each other. 
Molecular dynamics make use of Newton’s laws of motion to model a 
trajectory that specifies how the positions and velocities of the particles in the system 
vary with time. Sampling at a series of time points yield conformers which can be 
minimized to their closest LMECs. The time steps used for advancing the atom 
motions, usually in femtoseconds, must be shorter than the highest-frequency 
molecular motion, otherwise two bonded atoms may move too far from each other to 
the extent that they cannot form a bond. Therefore this method can be very time-
consuming if applied to large molecular systems.  
The Monte Carlo method generates conformers by making random changes to 
the 3D positions of the atoms in a structure. The resulting conformers are usually 
highly strained systems, which are then minimized to obtain LMECs. Through 
multiple sampling, an overview of the energy surface is obtained and sufficient 
sampling may place confidence limits on the conformer that is found to be the GMEC.  
Both the molecular dynamics and Monte Carlo methods are suitable for 
flexible molecules and macromolecules, but there are cases where one is more suitable 
than the other. For example, molecular dynamics is required for calculation of time-
dependent quantities such as transport coefficients, while Monte Carlo methods are 
more suitable for performing simulations at exact temperatures and pressures. In 
general, molecular dynamics is more useful for exploration of the local phase space as 
it advances the positions and velocities of all the particles simultaneously, while Monte 
Carlo simulations are more effective for conformational changes, as it jumps to 





3. PHARMACOLOGY AND MEDICINAL 
CHEMISTRY OF NEURONAL VOLTAGE–GATED 
SODIUM CHANNEL BLOCKERS 
2.1 Structure and Function of Voltage-gated Sodium Channels  
3.1.1 Structure 
 The sodium channel consists of a 260-kDa α-subunit, a 36-kDa β1-subunit, a 
33-kDa β2-subunit and a β3-subunit.P21P The α-subunit forms the ion pore and 
demonstrates the basic pharmacology and physiology of the native channel, while β-
subunits appear to be modulators of α-subunit’s function. No drug has been reported to 
interact directly with the β-subunits. The three-dimensional structure of sodium 
channels has not been solved, as attempts to obtain crystallographic information have 
so far been unsuccessful. 
The ion channel (aqueous pore and gating processes) resides in the α-subunit, 
which consists of four repeated sequences of amino acids (homologous domains DI-
DIV). P22P Each of these repeats spans the membrane six times (transmembrane 
segments S1-S6), and it was postulated that DI-DIV form the ‘four walls’ of the 
aqueous pore. Several investigations have enabled the assigning of functions to 
particular regions or even specific amino acids. Mutation studies indicated that the 
lysine and alanine residues in DIII and DIV are critical determinants of the ion 
selectivity of the sodium channel while an intracellular loop that connects DIII and 
DIV is critical for the sodium channel inactivation process. Since the signal for 
activation of the sodium channel is depolarization, the ion channel needs a voltage 
sensor to detect such changes. The S4 regions are highly conserved between sodium 




voltage-gated potassium and calcium channels. Furthermore, it has positively charged 
arginine or lysine at every third position. Therefore the S4 regions are widely accepted 
as the voltage sensor of the sodium channel.  
 
3.1.2 Function 
Information can be transferred throughout the nervous system via neurons, and 
other excitable cells, in the form of action potentials. Such action potentials are in the 
form of all or none signals that are generated by ion channels, such as the voltage-
gated sodium channel. The voltage–gated sodium channels can be visualized as water-
filled tunnels that provide an aqueous route for sodium ions through the hydrophobic 
cell membrane. During depolarization of the membrane, the voltage sensor detects 
electric field changes in the membrane and alters the conformation of the channel 
protein, thus opening the channel. The increase in permeability resulting from 
activation of the sodium channel is biphasic. Upon depolarization, permeability to 
sodium increases dramatically and then decreases to the baseline level. The voltage-
gated sodium channel can exist in three functionally distinct states; resting, active and 
inactivated. Both resting and inactivated states are non-conducting, and channels that 
have been inactivated by prolonged depolarization are refractory unless the cell is 
repolarized to allow them to return to the resting stage. 
 
3.1.3 Neurotoxin Binding Sites 
 Neurotoxins that bind with high affinity and specificity to the channel complex 
were used as molecular probes to determine the subunit structure of the rat brain 
sodium channel. Five groups of neurotoxins that act at different receptor sites on the 




which inhibit transportation of sodium ions across the channels and thus block ion 
conductance, bind to site 1. Batrachotoxin (BTX), veratridine, grayanotoxin, and 
aconitine bind to site 2, resulting in persistent activation of the sodium channel. 
Polypeptide α-scorpion toxins and sea anemone toxins, which enhance persistent 
activation, slow inactivation and/or block inactivation of the sodium channels, bind to 
site 3. A second class of scorpion toxins (β-scorpion toxins) that shift the voltage 
dependence of activation of the sodium channels to more negative membrane 
potentials without modifying sodium channel inactivation binds to site 4. The 
brevetoxins and ciguatoxins, agents that cause repetitive neuronal firing, shift the 
voltage dependence of sodium channel activation, and block sodium channel 
inactivation bind to site 5.  
 More recently, four additional sites were reported, which consist of neurotoxin 
and insecticide binding sites.P24P The δ-conotoxins, which cause inhibition of activation, 
binds to site 6 binds. 1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane (DDT), DDT 
analogues and pyrethroids bind to site 7, which inhibit inactivation of sodium channels 
and shift their voltage dependence. The goniopora coral toxin and conus stratius toxin 
bind to site 8 and inhibit the activation of the sodium channels. The local anaesthetics, 
anticonvulsants and dihydropyrazoles bind to site 9 and inhibit the transportation of the 
sodium ions across the channels. 
 McPhee et al showed that mutations at positions 1764 and1771 in the DIV S6 
of SCN2A segment significantly reduced the binding affinity of the channels for a 
range of sodium channel blocking drugs.P 25P Linford et al further showed that these 
mutated sodium channels have reduced binding affinity for tritiated BTX.P26 P Thus it 
was concluded that the BTX binding site shares overlapping but not identical 
molecular determinants with the binding site of sodium channel blockers. 
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2.2 Medicinal Chemistry of Sodium Channel Blockers 
 Neuronal voltage-gated sodium channels have been targeted for various 
ailments, including epilepsy, stroke and other brain injuries, and neuralgia. The 
discovery of the structure and function of sodium channels allowed better 
understanding of how the functions of the sodium channels can be antagonised. 
Antagonists of sodium channels block the ion flux and therefore are also commonly 
known as sodium channel blockers. As such, the term sodium channel blockers will be 
used throughout the text to represent sodium channel antagonists. Various chemical 
classes of compounds had been developed as sodium channel blockers and multiple in 
vivo and in vitro tests allowed the assessments of potential sodium channel blockers.  
 A much better understanding of sodium channels and drugs interacting with 
them had made it clear that local anaesthetics such as procaine, class I antiarrhythmics 
such as lidocaine and mexiletine, and anticonvulsants such as phenytoin and 
carbamazepine actually work by modulating sodium channel conductance. Phenytoin 
and carbamazepine were important in the characterization of the role of sodium 
channels first in epilepsy, then in neuroprotection, and analgesia.  
Various in vitro and in vivo assay methods have been developed to explore the 
medicinal chemistry of sodium channel blockers. There is a need to differentiate test 
systems for studying the mechanisms of action of sodium channel blockers from test 
systems intended to identify therapeutic sodium channel blockers. Clinical activity of 
sodium channel blockers can be studied definitively only in vivo, whereas analysis of 
the mechanism of action requires in vitro test systems. In vitro test systems have the 
advantage that drug concentrations can be precisely controlled and complications 





2.2.1 In Vitro Test Systems 
In vitro test systems for sodium channel blockers include radioligand binding 
assays, radioactive flux assays, fluorescence-based assays, voltage-sensitive dyes 
assays and the patch-clamp technique. 
 Radioligand binding assays revealed the presence of multiple neurotoxin 
binding sites on sodium channels and were extensively used to measure ability of 
drugs to bind selectively to the channels that were at a particular stage of the activated/ 
inactivated/resting cycle of channel activity. Among the radioligand binding assays 
designed for sodium channel blockers, the most commonly used was the BTX assay.27 
It was shown that sodium channel blockers like phenytoin and carbamazepine were 
able to displace BTX, thus the pharmacological activity of sodium channel blockers 
can be predicted by measuring the ability of these drugs to displace [3H]-BTX. It is 
reasonable to assume that the use of such a high-throughput binding assays should lead 
to the identification of novel sodium channel blockers.  
Exposure to neurotoxins such as veratridine was used to stabilize the sodium 
channels in the open state, thus allowing a flux of radioactive tracers into cells or 
synaptosomal preparations that have sodium channels. The most commonly used 
radioactive tracers are the [22Na] and [14C]-guanidinium. When a sodium channel 
blocker was added to such a preparation, the flux of radioactive tracers was reduced. 
Thus the inhibition of radioactive tracer influx is a valid model for the identification of 
sodium channel blockers, which allows high-throughput analysis of compounds. For 
example, Maillard et. al. expressed the cloned type IIA sodium channels, derived from 
the rat brain, in a Chinese hamster cell line. 28 The authors then examined the ability of 




Fluorescence-based assays are high-throughput screening techniques, which 
provide information content unavailable in other screening techniques due to its high 
sensitivity, use of homogeneous medium and ability to measure true equilibrium 
conditions. The application of this technology to sodium channel studies was mainly 
for measurement of membrane potentials with voltage-sensitive dyes and for the 
measurement of the concentration of particular ions with ion-selective fluorescent dyes. 
For example, Leong et. al. made use of rhodamine 6G fluorescence to calculate 
synaptoneurosomal membrane potential. 29 Knowing that veratridine will increase 
intracellular sodium concentration, Deffois et. al. measured this characteristic using 
fluorescence imaging, with the help of the sodium ion selective dye benzofuran 
isophthalate (SBFI). 30 The authors subsequently showed that the veratridine-induced 
increase in intracellular sodium concentration was inhibited by the addition of sodium 
channel blockers, thereby accessing their ability to block the sodium channel. 
Electrophysiology is a low-throughput/high-information technique, which is 
able to determine the precise binding mode of active species. For example, Haeseler et. 
al. not only measured the extent of sodium channel blockade of ketamine, but also 
concentrated on the difference in affinity between resting and inactivated channel 
states. 31 Another example of high-information output by this technique was 
demonstrated by Grolleau et. al. 32 The group was able to demonstrate that oxaliplatin 
and its metabolite oxalate were able to reduce the inward sodium current amplitude, 
and more importantly, it was shown that their effects were mimicked by intracellularly 
applied bis-(o-aminophenoxy)-N, N, N’, N’-tetraacetic acid (BAPTA). Since BAPTA 
is a chelator of calcium ions, the group was able to conclude that oxaliplatin was 
capable of altering the voltage-gated sodium channels through a pathway involving 




Cell viability can be used as an assay for sodium channel blockers. For 
example, cell death can be caused by addition of high concentrations of veratridine. 
Such cell death possessed characteristics of apoptosis, which can be assessed by 
morphology, or by techniques such as DNA laddering on agarose gel. Ability of 
compounds to block sodium channels can be induced from the extent these blockers 
inhibit the veratridine-induced apoptosis. 
 
2.2.2   In Vivo Test Systems 
White et al summarized the various in vivo test systems for anticonvulsant 
screening.33 The assays described were the Maximal electroshock (MES) test, 
subcutaneous pentylenetetrazol (s. c. Met/PTZ) test and the threshold tonic extension 
(TTE) test. In the MES test, an alternating current was delivered to the mouse (or rat) 
via electrodes, either through connections to the cornea or ear. The shock was usually 
given at a fixed time after drug administration. Following stimulation, the animal was 
observed for the entire duration of the seizure. The anticonvulsant activity of the test 
substance was graded upon the limb tonic extensor component. 
 In the s. c. Met/PTZ (subcutaneous metrazol/pentylenetetrazol) test, a 
convulsive dose of pentylenetetrazol was injected subcutaneously. The animals were 
placed in isolation cages and observed for presence or absence of an episode of clonic 
spasms. Absence of a clonic seizure suggested that the test substance have the ability 
to raise the seizure threshold. The two above-mentioned tests are able to predict the 
type of seizures that can be controlled. It is generally agreed that substances that 
obtund only the tonic extension of maximal seizures (in MES test) may be clinically 





minimal seizure threshold (in s. c. Met test) may be useful in generalized absence 
seizures. 
 The TTE test is a non-selective, electroconvulsive seizure model that identifies 
substances that block seizures induced in the MES and/or s. c. Met tests. However, this 
test will also identify a small number of compounds that are inactive in the MES and  s. 
c. Met tests. The TTE test is similar to the MES test except that the TTE test uses 
sufficient current to elicit threshold limb tonic extension, while the MES test uses a 
supra maximal current (four to five times threshold). The results from these 
identification tests can provide important preliminary information pertaining to oral 
bioavailability, species variation, duration of action, toxicity, efficacy, and overall 
potential of novel anticonvulsant substances. 
  Antinociceptive effects of compounds can be investigated using a plethora of 
methods, with the hot plate and tail-flick tests being the most common. In the hot plate 
test, mice were put on a hot plate that was heated, usually to 55° C. Response 
measured includes front and hind paw licking or jumping. For the tail-flick test, only 
the tail of a rat was immersed in either hot or cold water, and the time taken for the rat 
to flick its tail was the end-point. A commonly used visceral pain model test is the 
writhing syndrome test, where compounds to be tested can be injected into various 
sites for comparison. P34 P The number of writhes was then noted over 10 minutes periods 
for about 1 hour. 
 Neuroprotection is usually measured by the reduction in cell damage due to 
cerebral ischemia as compared to a negative control. The most common method used 
was the middle cerebral artery occlusion (MCAO) technique that can be performed in 




occluded for a short period of about 5 minutes. The animal was sacrificed several days 
later, and the area of infarct was examined through histological preparations.   
 
2.2.3 Sodium Channel Blockers as Anticonvulsants 
Epilepsy is a leading neurological disorder in man, characterized by recurrent 
seizures that have a sudden onset. Idiopathic epilepsies, which accounted for up to 
40% of all epilepsies, were mainly caused by genetic factors. P35P Recently, researchers 
found a link between mutation of the sodium channel and abnormal neuronal 
excitability that resulted in epilepsy. It was found that a clinical subset termed 
generalized epilepsy with febrile seizures plus (GEFSP+P) was associated with a mutation 
of the sodium channel β1 subunit SCN1B gene. P36P Similarly, GEFSP+P type 2 was 
associated with a mutation of the α subunit SCN1A gene. P37P 
 










Phenytoin and carbamazepine were established as anticonvulsants long before 
their mechanism of action was established. Phenytoin is most certainly the reference 
standard of anticonvulsants that act via sodium channel blockade. Many analogues of 
phenytoin were synthesized in order to achieve better activity and selectivity. The 
focuses of these syntheses were usually the hydantoin moiety or its bioisostere. For 
example, Brouilette et al designed a series of hydantoins containing conformationally 
constrained 5-phenyl substitutions, phenyl-substituted bicyclic 2,4-oxazolidinediones 
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and bicyclic hydantoins with a bridgehead nitrogen. 38-40 Scholl et al explored the 
lipophilicity of a representative number of hydantoins derivatives and used the results, 
combined with structure similarities, to propose a pharmacological model for binding 
the hydantoins derivatives along the sodium channel. 41 Solubility of phenytoin was 
improved by formulating the salt form, fosphenytoin (Cerebyx). 42 Brown et al 
synthesized a series of compounds with the hydantoin moiety and then used 
comparative molecular field analysis (CoMFA) to build a model of the binding site of 
this structure. 43 Further development of carbamazepine resulted in several derivatives, 
such as oxcarbazepine and SGB-017 (ADCI). Benes et al found the enantiomeric 
acetates of carbamazepine at the 10-position were more potent than both 
carbamazepine and oxcarbazepine. 44 SGB-017 produced its anticonvulsant activity by 
blocking both sodium- and NMDA-receptor. 45
                                                                                                





















    
More recently, lamotrigine, zonisamide and topiramate were marketed as 
Lamictal, Excegran and Topamax respectively. Lang et al showed that lamotrigine 
inhibited sodium channels in a manner that was similar to that produced by phenytoin 
and carbamazepine. 46 Another study reported that lamotrigine caused concentration 
dependent inhibition of 5-hydroxytryptamine (5-HT) uptake in both human platelets 
and rat brain synaptosomes, probably reflecting an affinity for biogenic amine 
transporters. 47 Zonisamide was demonstrated to block voltage-sensitive sodium 





electroshock seizure (MES) in animal models. P48P However, zonisamide was also shown 
to be a weak carbonic anhydrase inhibitor, and also a T-type calcium channel blocker. 
Taverna et al assessed the action of topiramate on sodium channels using whole-cell 
patch-clamp recordings. P49P The study reported that there was a slight but significant 
inhibition of the persistent fraction of the sodium current, obtained with the relatively 
low topiramate concentration. It was concluded that topiramate may contribute to its 
anticonvulsant effectiveness by modulating the near-threshold depolarizing events that 
were sustained by this small current fraction. McLean et al determined the ability of 
topiramate to limit depolarization-induced spontaneous repetitive firing in cultured 
mouse spinal neurons and compared the results with those of phenytoin and 
lamotrigine. P50P The study did not support the concept that sodium channel blockade is 
the primary mechanism responsible for the anticonvulsant activity of topiramate. 
Topiramate had been shown to modulate sodium channels, potentiate γ-aminobutyric 
acid (GABA) inhibition, block excitatory neurotransmission, and possibly modulate 
voltage- and receptor –gated calcium ion channels. P51P 
 


















Ralitoline (CI-446) and CI-953 were structurally similar and their profile of 
anticonvulsant activity was similar to those of phenytoin and carbamazepine. P52P These 
two compounds inhibited sustained repetitive action potentials from neuronal 
membrane depolarization and also inhibited the binding of BTX to rat synaptosomal 
membranes. U-54494A had potent and long-acting anticonvulsant activity without 
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antinociceptive or sedative effects on intact animals. 53 Two major metabolites of U-
554494A, U-83892E and U-83894A, were synthesized and tested for anticonvulsant 
activity. The two compounds displayed anticonvulsant activity against electrical shock 
in experimental animals and blocked voltage-gated sodium channel in the resting stage. 









                     
 Edafiogho et al synthesized a series of enaminones, with the most potent 
compound being methyl 4-[(p-chlorophenyl)amino]-6-methyl-2-oxo-cyclohex-3-ene-
1-oate. 54 Free-Wilson analysis was applied for structure-activity correlation. Scott et 
al further developed the aniline-substituted enaminones that has 4’-, 3’- and 2’- 
substitution and polysubstitution. 55 In vivo assays discovered that para-substituted 
compounds generally had good anticonvulsant activity, while the meta-substituted 
compounds were largely inactive, and the ortho-substituted compounds had no clear 
relationship with biological activity. 








Vincanol and vinpocetine are derivatives of vincamine, the major alkaloid of 





and vincanol also exhibit neuroprotective properties, like that of vinpocetine. Since 
vinpocetine was known to inhibit voltage-gated sodium channels, the compounds were 
tested for their effects on sodium channel. Vincamine, vincanol and vinpocetine 
reduced [P3 PH]-batrachotoxin binding with ICB50B values of 1.9, 10.7 and 0.34 µM, and 
have MES EDB50 B values of 15.4, 14.6 and 27mg/kg respectively. It was observed that 
vinpocetine, according to results from BTX assays, was the most potent sodium 
channel blocker reported in the literature. 











Clark et al developed amides having a primary amine in the 4-position of the 
benzamide moiety and an aromatic N-substitution of the 4-aminobenzamide 
pharmacophore, which resulted in the emersion of ameltolide; a potent anticonvulsant 
with structural similarities to lidocaine. P57P Vamecq et al synthesized 15 compounds 
related to ameltolide and tested them in both BTX and MES assays. P58 P The correlation 
between the two assays suggested that the anticonvulsant properties of most 
compounds tested could be a direct result of their interaction with the neuronal 
voltage-dependent sodium channel. The 4-aminobenzamide unit seem to be essential 
and was compared with thalidomide to develop 4-amino-N-(2,6-dimethylphenyl)- 
phthalimide and eventually the substituted N-phenyl derivatives of the phthalimide 
pharmacophore. P59 P Vamecq et al synthesized a series of compounds based on the 
phthalimide pharmacophore and found the 2-chloro-4-amino derivative to be the most 
potent compound of this series. It showed blockade of the neuronal voltage-dependent 
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sodium channels, potentiation of GABA-evoked current responses, and inhibition of 
kainite-evoked response. Therefore the 2-chloro-4-amino derivative may be of interest 
in a wide range of seizure models and neurological disorders due to its interaction with 
multiple ion channels. 
 Unverferth et al observed that there were numerous derivatives stemming from 
5-, 6-, and 7-membered heterocycles, and that only few representatives with 
remarkable activity come from the pyrrole group. 60 Based on these observations, the 
group developed a series of 3-aminopyrroles and tested them for anticonvulsant 
activity using a variety of test models, including the MES test. The essential structural 
features, which could be responsible for an interaction with an active site of the 
voltage-dependent sodium channel, were established within a suggested 
pharmacophoric model. 
 Structure-activity relationships of a series of N, N’-diarylguanidines were used 
to develop several simpler diphenylguanidines with improved in vitro and in vivo 
activity. 61 Results indicated that N, N’-diphenylguanidines substituted with flexible 
and moderate size lipophilic groups were preferred over aryl and/or hydrophilic groups 
for biological activity. Compounds of this series showed only weak N-methyl-D-
aspartate (NMDA) ion-channel blocking activity indicating that the anticonvulsant 
activity of these compounds are more likely to be via sodium channel blockade. 





3-Benzyl-3-ethyl-2-piperidinone (3-BEP) belongs to a family of compounds 





including 3-BEP, had been shown to exhibit potent in vivo anticonvulsant activity in 
mice. The study reported that 3-BEP also modulates sodium channels, and thus may 
prevent seizures by both enhancing inhibition and diminishing neuronal excitability. 
 Antagonists of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors and voltage-dependent sodium channels blockers both exhibited 
anticonvulsive and neuroprotective activity. BIIR 561 CL was identified in a screening 
campaign targeted to the identification of new structures active at AMPA receptors and 
voltage-gated sodium channels. P63P Weiser et al provided evidence that BIIR 561 CL 
was able to inhibit glutamate receptors of the AMPA subtype, as well as voltage-gated 
sodium channels. 







Diphenhydramine and many other HB1 B histamine receptor antagonists, such as 
chlorpheniramine, have long been known for their local anaesthetic effect. However, 
the underlying mechanism of such an effect was unknown. Kuo et al explored the 
inhibition of the neuronal sodium current by diphenhydramine and other diphenyl 
compounds and found that diphenhydramine bound to the inactivated sodium channel 
with a dissociation constant of 10µM. P64P The study suggested that the two phenyl 
groups were the key ligands interacting with the channel. 
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The pyridinotriazole BW534U87 had good activity in a variety of assays 
against seizures. 65 Preclinical evidence suggested that it would be free from side 
effects such as emesis and nausea, which had earlier cause the failure of the clinical 
development of its precessor, BW A78U. In a serendipitous approach to develop 
structurally novel central nervous system drugs, a series of two hundred 3-
aminopyrrols were synthesized and tested. 66 AWD 140-190 was selected from this 
series based on its strong anticonvulsant activity and absence of side effects in 
experimental models. It was concluded, via the patch-clamp technique, that AWD 140-
190 is a sodium channel blocker. PNU-151774E is a novel antiepileptic compound 
with potency comparable or superior to that of most classic anticonvulsant drugs, such 
as phenytoin and carbamazepine, in electrically and chemically induced seizure 
models. 67 PNU-151774E exerts its anticonvulsant activity, at least in part, through 
inhibition of sodium and calcium channels, stabilization neuronal membrane 
excitability and inhibition of transmitter release. Snell et al developed a novel series of 
N-substituted 4-ureido-5, 7-dichloro-quinolines (DUCKs) by combining parts of the 
structures of phenytoin, carbamazepine and dichlorokynurenate. 67 These compounds 
had combined actions: blockade of voltage-sensitive sodium channels and selective 






2.2.4 Sodium Channel Blockers as Neuroprotective Agents 
Stroke had been reported to be the third leading cause of death in industrialized 
countries and the major cause of serious long-term disability. 69 A transient or 
permanent obstruction of blood flow in a major cerebral artery, usually the middle 
cerebral artery, will cause ischemic stroke. A reduction in blood flow will cause failure 
of ionic, metabolic and electronic homeostasis and irreversible death of neurons. It was 
reported that the effects occurred within minutes in the immediate area of the 
occlusion of blood flow, or over hours or days in adjacent areas that were supported by 
anastomoses with surrounding collateral arteries. 70, 71
 The development of a model of the ischemic cascade had provided much 
insight into the complex sequence of the pathophysiological changes. 72 The 
neurochemical sequelae following cerebral ischemia was reported to involve excess 
release of excitatory amino acids, particularly glutamate, disruption of ionic 
homeostasis due to sodium and calcium influx and generation of toxic free radicals, 
ultimately leading to cell death by necrosis and apoptosis. The progression of such 
events had been shown to depend on the extent and duration of the arterial occlusion 
and differed in the immediate and adjacent regions of the occlusion. 70, 73
 TTX, and various sodium channel blockers had been shown to have 
neuroprotective effects in various in vitro and in vivo studies. 74 The possible 
mechanisms of sodium channel blockers as neuroprotective agents were summarized 
in a review paper. 75 It was postulated that since the excitability of hippocampal and 
cortical neurons was inherently reduced during hypoxia by the inhibition of transient 
sodium ion current, it was possible that there was an endogenous neuronal mechanism, 
which decreased excitability and sodium ion influx via the sodium channel. Thus 




and protect neurons from hypoxia-induced injury. Another mechanism of action 
revolved around the idea that the non-inactivating sodium ion current (persistent 
sodium ion current that resists inactivation during depolarization) was involved in the 
entry of sodium ion during acute hypoxia. It was discovered that the non-inactivating 
sodium ion current was sensitive to TTX and other sodium channel blockers. During 
hypoxia, high intracellular concentration of sodium ions will increase calcium ion 
influx through the Na+-Ca+ exchangers. Since an increase in intracellular concentration 
of calcium ions constitutes a major cause of hypoxia-induced neuronal damage, 
sodium channel blockers may contribute to neuroprotection by reducing the 
intracellular concentration of calcium ions.  










  In vivo tests of rodent models showed that riluzole significantly reduced the 
extent of infarct in both global and focal cerebral ischemia. 76 These effects were 
attributed to the inhibition of sodium channel activity, which in turn inhibited 
glutamate release. Studies on cloned rat brain neuronal sodium channels verified that 
riluzole was able to bind selectively to inactivated sodium channels and not the open 
channel, which suggested that the stabilization of the inactivation state contributed to 
riluzole’s neuroprotective properties. 77 Results had shown that riluzole, in addition to 
its ability to block sodium channels, was able to block glutamate release, reduce 
nonvesicular (calcium-independent) transmitter release, block potassium channels, 




pertussis toxin-sensitive manner. 24 Cell-viability assays that utilized veratridine as the 
noxious substance showed that riluzole had better neuroprotective ability than 
phenytoin or lamotrigine. 78 Riluzole had been used clinically as a neuroprotective 
agent in cases of amyotrophic lateral sclerosis. 











 Lubeluzole had been shown to be effective in animal models of stroke in rats. 
79,80 In vitro studies conducted on lubeluzole revealed that it inhibited nitric oxide 
synthesis, blocked sodium channels, and inhibited glutamate release, and these 
pharmacological actions were hypothesized to contributed to its neuroprotective 
effects. 81-83 Unfortunately, lubeluzole also blocked low-voltage and high-voltage 
calcium channel currents from both the extracellular and intracellular side, which is the 
cause of its side effects. In a review of all the randomized unconfounded trials 
comparing intravenous lubeluzole with placebo or open control in patients with 
clinical acute stroke, it was concluded that lubeluzole was not associated with a 
significant reduction of death or dependency at the end of scheduled follow-up period 
but seem to be associated with a significant increase of heart-conduction disorders (Q-
T prolonged > 450msec). 84 
 A few compounds were already in clinical trials for neuroprotection. 
Sipatrigine, or BW619C89, is a substituted pyrimidine derived from lamotrigine. 
Rodent models of global and focal ischemia showed that sipatrigine was effective as a 
neuroprotective agent by reducing cortical infarct. 85 In electrophysiological studies, 




types), with similar potencies (IC50 of 5-16mM). Ramacemide is a non-competitive, 
low-affinity NMDA receptor antagonist. Ramacemide and its active metabolite also 
interact with sodium channels. These two pharmacological actions contribute to their 
neuroprotective effects. 86 Lifarizine, a piperizine, had been shown to be a sodium 
channel blocker, an inhibitor of intracellular calcium ion concentration rises and a 
neuroprotective agent in animal models. 87-90 Its analogues, lomerizine and flunarizine 
also shown promise as neuroprotective agents. 91,92 BIII 890 Cl, a benzomorphan 
derivative, had an IC50 value of 49 nM in the BTX assay and were shown to protect 
brain tissue from ischemia. 93
 









                                   
 In recent years, researchers have recognized the need to provide 
neuroprotection in a multi-prong approach. It was found that compounds that have 
multiple mechanism of actions, such as zonisamide, topiramate, T-477 and AM-36, 
more effectively prevented ischemic injury. 64, 94-96 For example, AM-36 has been 
shown to inhibit binding to the polyamine site of glutamate receptors, blocked 
neuronal sodium channels and had potent anti-oxidant activity.  
 
2.2.5 Sodium Channel Blockers as Antinociceptive Agents 
Neuropathic pain was reported to be due to hyperexcitability in primary 
sensory neurons following injury. Waxman et al detailed the molecular 




been shown that in acute injury, activation of pre-existing sodium channels played an 
important role in the generation of the transient burst of impulses in primary sensory 
neurons. Subsequently, changes in gene expression resulted in down-regulation of 
some sodium channel subtypes, while some previously unexpressed sodium channel 
subtypes were up-regulated. There was also activity–related regulation of sodium 
channel expression in uninjured central neurons. In particular, there was a high 
proportion of TTX-insensitive (TTXi) sodium channels in hyperexcitable neurons. 
Phenytoin and carbamazepine were tested for differential inhibition of sodium 
currents in small cells from adult rat dorsal root ganglia using the patch-clamp 
technique. 98 The results showed that both fast TTX-sensitive and slow TTX-resistant 
currents were inhibited by 10-100 mM of the drugs. Another study investigated the 
responses of inflamed and non-inflamed neurons to noxious substances. 99 It was 
showed that carbamazepine was able to significantly reduce the responses of neurons 
which were under inflammatory conditions, but not in non-inflamed conditions. This 
observation led to the conclusion that there were changes to the type, or proportion of 
sodium channels underlying the transmission of noxious messages. Carbamazepine 
and phenytoin were the first anticonvulsants to be used in controlled clinical trials of 
neuropathic pain and showed abilities to relieve painful diabetic neuropathy and 
paroxysmal attacks in trigeminal neuralgia. 100 The amide functional group was often 
found in sodium channel blockers, such as in phenytoin and carbamazepine. Therefore 
it was not surprising to find substituted 2-benzylamino-2-phenylacetamides, 
substituted 2-aminoacetamides and aminocycloalkyl cinnamide compounds being 










Based on the hypothesis that a selective blockade of the relay of messages by 
C-fibers into the spinal cord will reduce nociceptive transmission, the effects of 
bupivacaine and lamotrigine on these fibers were investigated. 104 The results showed 
that although both compounds were sodium channel blockers, only bupivacaine 
reduced the C-fibers-evoked responses while lamotrigine had a tendency to facilitate 
the responses. Thus it was concluded that lamotrigine may not be an antinociceptive. 
However, in a study of short- and long-term neuropathic models of hyperalgesia in rats 
done by Klamt et. al., intrathecally administered lamotrigine produced a spinal, dose-
dependent, and long-lasting (24-48h) anti-hyperalgesic effect. 105 Lamotrigine was 
demonstrated to be effective in trigeminal neuralgia, painful peripheral neuropathy, 
and post-stroke pain in a controlled clinical trial. 100 Lamotrigine was subsequently 
used as a lead compound to develop GW4030W92. 106-108 
Plant extracts from the Aconitum species were used in traditional Chinese 
medication as anti-inflammatory and antinociceptive agents, and it was known that the 
active ingredients were aconitine and its derivatives. 109 In order to elucidate the mode 
of action of aconitine and its derivatives, a series of 10 aconitine-like derivatives were 
investigated. The first group of compounds, which consisted of aconitine, 3-
acetylaconitine and hypaconitine had high affinity for the neuronal sodium channels 
(Ki of about 1.2mM) and good antinociceptive effects (ED50 of approximately 0.06 
mg/kg). The second group of compounds, only consisting of lappaconitine, had lower 
affinity for the sodium channel (Ki of 11.5mM), and lesser antinociceptive effect (ED50 




significant pharmacological effects. A subsequent review paper characterized the 
aconitum alkaloids into three groups. 110 The first group of alkaloids activated voltage-
gated sodium channels at resting potential and inhibited noradrenaline uptake, and had 
antinociceptive properties due to the eventual inexcitability of the sodium channel. The 
second group consisted of sodium channel blockers which are monoesters. These 
compounds were less toxic than the first group, and had strong antinociceptive, 
antiarrhythmic and antiepileptiform properties. The last group of compounds lacked an 
ester side chain and were only reported to have antiarrhythmic activity. 
                                                                                 












Lidocaine, a well-known local anaesthetic, can be positively-charged in 
physiological conditions. Therefore QX-314, one of its positively-charged derivatives, 
was investigated in tandem with lidocaine in animal models of neuropathic pain.111 
Intravenously administered lidocaine inhibited ectopic nerve activity at the dorsal root 
ganglia, dorsal horn neurons and neromas (fine bundles of microfilaments) teased from 
the sciatic nerves in anesthetized and paralyzed rats. QX-314 induced dose-dependent 
inhibition of ectopic nerve activity at the dorsal root ganglia and neromas, but only a 
small inhibition of ectopic nerve activity at the dorsal horn neurons. The data 
suggested that intravenously administered QX-314 was able to acutely block sodium 
channels that contributed to the generation of ectopic nerve activity. Mexiletine, an 




1-methylethyl)]ethylamine, which exhibited antinociceptive effect against mechanical 
allodynia. 112 Ketamine, a general anaesthetic, was tested for its ability to block TTX-
sensitive and TTX-resistant sodium channels that were expressed in dorsal root 
ganglion neurons, using the patch-clamp technique. The results showed that ketamine 
was able to block both types of sodium channels, which suggested that high 
concentrations of ketamine might produce local anaesthetic action via this mechanism. 
 The extensive literature review showed that sodium channel blockers are 
chemically diverse, with the hydantoin moiety being the most prominent. Other 
chemical classes include amides, benzamide, and enaminones. Natural products, such 
as alkaloids from Vinca minor and the Aconitum species, were also used to develop 
sodium channel blockers. With so many different chemical classes that were tested for 
sodium channel blockade activity, the experimental data could be exploited to 
rationally design de novo compounds. One plausible approach to achieving this aim 
would be to use computer modelling methods, such as the search of a common 











3. RATIONALE AND OBJECTIVES 
3.1 The Need for New Sodium Channel Blockers  
The sodium channels play an important role in coordinating higher bodily 
functions, such as locomotive and cognitive processes, by transmitting electrical 
impulses rapidly throughout cells and cell networks. Excessive sodium channel 
activity may lead to disorders such as epilepsy, neurodegeneration, and extreme pain. 
Neuronal voltage-gated sodium channels blockers are therefore potential 
anticonvulsants, neuroprotectants and analgesics. Despite the large number of 
therapeutically useful sodium channel blockers, there are several reasons that justified 
the need for new therapeutic agents. It has been reported that most seizures can be 
treated to some extent, but with the existing anticonvulsants, either in monotherapy or 
in combination, complete or satisfactory seizure control can only be achieved in 
roughly 30% of all patients. 113 Furthermore, it is common to see manifestation of side 
effects despite the incomplete control of seizures. Thus there is a need to develop new 
anticonvulsants with higher therapeutic indexes and lesser side effects. In the field of 
pain management, there is a need for long-acting analgesic drugs because of the aging 
populations in the world, which will amplify the use of analgesics for treatment of 
neuropathic pain, rheumatoid arthritis, and cancer pain. 114 Such long-acting analgesic 
can also be used for post-operative pain, in place of morphine-like analgesics, or as 
pre-emptive analgesics. Treatment of stroke has been reported to be inefficient, as it is 
found that the neurochemical sequelae following cerebral ischemia are complex, and a 
single drug treatment is unlikely to be beneficial in its treatment. 69 Thus it is proposed 
to incorporate multiple neuroprotective mechanisms within one structure, such as 





inhibition of NMDA receptors. Therefore, the demand is high for effective and 
therapeutically distinct sodium channel blockers. 
 
3.2 Previous Studies on Sodium Channel Blockers 
A lot of information pertaining to the structure, function, and mechanism of 
action of the neuronal sodium channel receptors are available. However, the most 
prescribed sodium channel blockers are still phenytoin, carbamazepine and lamotrigine. 
Based on the vast amount of information that has been gathered over the years, new 
sodium channel blockers can be designed. Such information should be properly 
organized into forms which can facilitate novel drug design. The information gathered 
from the literature, clearly showed that there were several common structural moieties 
which were present in most sodium channel blockers, such as the amine and amide 
functional groups and aromatic rings. CADD is an effective tool for lowering the cost 
of drug discovery, both in terms of time and monetary expenses. It can be utilized to 
collate and process the data, into information that can be exploited for designing new 
compounds with potential sodium channel blocking activity. Ideally, these compounds 
will evolve into clinically useful therapeutic agents.  
 There have been several attempts to study the SARs of sodium channel 
blockers, such as the studies done on phenytoin, enaminones, ameltolides and their 
analogues. A CoMFA study on hydantoins carried out by Brown et. al., suggested that 
features that enhanced the binding of hydantoins to the sodium channel include the 
orientation of the phenyl ring at the position C5 and a C5-alkyl chain of suitable 
length.P43P The CoMFA model was then used to design a structurally novel α-hydroxy-
α-phenylamide, and the results showed that the actual and predicted biological activity 




hydantoin ring was not necessary for efficient binding to the sodium channels. 
However, since the compounds used to develop the CoMFA model were all 
hydantoins, the model had limited ability to predict the biological activity of 
compounds from other chemical classes. Although the α-hydroxy-α-phenylamides 
were structurally novel, they were actually analogues of the hydantoin moiety.  
Unverferth et. al. summarized the previous attempts to explore the 
pharmacophoric model of different anticonvulsant  classes , e.g., benzodiazepines, 
barbiturates, triazolines, enaminones and hydantoins, and also for structurally different 
compounds.P60P The group concluded that the various postulated pharmacophoric models 
showed no uniform picture. The previous studies were only concerned with 
pharmacophoric models for a single class of sodium channel blockers such as 
hydantoins. Since the compounds used had low structural diversity, the derived model 
can only be related to compounds in that particular class, and cannot be extended to 
other chemical classes acting at the sodium channel receptor. In view of the 
deficiencies in the pharmacophoric models available at that time, Unverferth et. al. 
used five well-known and structurally diverse sodium channel blockers with 
anticonvulsant activity, namely carbamazepine, phenytoin, lamotrigine, zonisamide 
and rufinamide to build a pharmacophoric model. The pharmacophoric model derived 
consisted of an electron donor, an aryl ring and a hydrogen bond acceptor/donor unit 
(HAD). However, the study did not choose the compounds based on their ability to 
block the neuronal sodium channel, but instead chose the compounds based on in vivo 
studies. In vivo studies were unable to estimate the binding affinity of the compounds 
to the sodium channel as it was confounded by pharmacokinetic parameters. Data on 
binding affinity of the compounds to the sodium channel receptor was necessary to 
estimate the ability of each compound to fit the receptor. When a set of compounds 
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with low binding affinities was used to create a pharmacophore model, the model 
developed would differ from the actual requirements needed to bind to the receptor-
binding site. Carbamazepine and lamotrigine are known to have low binding affinities 
for the sodium channel according to BTX radio-ligand binding assays. A possible 
limitation of this study is that without binding affinity data, it was difficult to validate 
the consistency of the model. Binding data reflect how well a compound binds to the 
receptor, and should be correlated to their abilities to fit the proposed model. A good 
model should have a good correlation between these two properties. Unverferth et. al. 
validated their model using vinpocetine, remacemide hydrochloride, dezinamide and 
compounds that they synthesized. The authors concluded that only the hydrogen bond 
donor part of the HAD unit, together with the two other essential structure elements R 
and D may be sufficient for activity as blocker of the voltage-dependent sodium 
channel. He also concluded that compounds having R and D, and only a hydrogen 
bond acceptor were inactive.  
 Tasso et. al. made use of similarity analysis to generate a pharmacophoric 
model for antiepileptic drugs that act via sodium channel blockade. 115 The compounds 
used included 15 antiepileptic drugs that were active against the MES test and able to 
block the neuronal sodium channels. An inactive compound was also utilized to help 
define the structural factors that were important for the activity. However, the choice 
of the training set of compounds and the validation of the pharmacophoric model was 
not based on in vitro biological activity. The proposed pharmacophoric model consists 
of a polar group comprising two negative atoms and one positive atom, and a 
hydrophobic group that should be no smaller than three atoms. It must be emphasized 
that the polar group stated in the model represented local density charges restricted to 





3.3 Hypotheses and Objectives 
3.3.1 Hypotheses 
Literature review shows that many compounds from diverse chemical classes 
bind to the neuronal sodium channels. In order for these compounds to bind to the 
sodium channel, they must have certain requisite pharmacophoric elements. Thus the 
current study hypothesizes is that all compounds that exhibit blockade activity against 
the neuronal (type II) sodium channel, as characterized by the BTX assay, share a 
common pharmacophore. In addition, it is hypothesized that the pharmacophore is able 
to discern good blockers from weaker blockers. As such, compounds that have the 
requisite pharmacophoric elements and fit well to the pharmacophore should have 
good binding affinity to the sodium channels in the BTX assay, and vice versa for 
compounds which do not possess the requisite pharmacophoric elements or do not fit 
well to the pharmacophore. 
 
3.3.2 Objectives 
 It is proposed that the hypotheses are to be tested by setting up experiments that 
will: 
• exploit existing information from the literature and use the active analogue 
approach to derive a pharmacophoric model for sodium channel blockers. 
• validate the pharmacophoric model using a larger population of blockers of the 
sodium channels that have a variety of pharmacological activities. 
• demonstrate that the pharmacophoric model can be used to discern good 
blockers from weaker blockers and therefore be recommended for use in a 




• use the model to identify potential sodium channel blockers and to optimise the 
blockade activity of the new compounds. 
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4. A NEW PHARMACOPHORIC MODEL FOR 
NEURONAL (TYPE II) SODIUM CHANNEL BLOCKERS. 
4.1 Choice of a CADD Strategy 
 CADD is an effective tool for lowering the cost of drug discovery, both in 
terms of time and monetary expenses. In order to utilize this tool effectively, there is a 
need to fully understand the field to which it is to be applied. Literature search has 
shown that a 3D X-ray crystallographic structure of the sodium channel receptor is not 
available, due to the difficulties in the isolation of membrane-bound receptors. In view 
of such a circumstance, CADD strategies based on docking cannot be utilized. 
 Genetic algorithms (GA) is a high throughput method due to its combinatorial 
approach. GA has a major advantage over other combinatorial approaches due to the 
ability of the computer program to direct the library of compounds to be synthesized, 
thus it is possible to screen a lot of compounds for sodium channel blocking activity in 
a rational manner. Other than being used to screen for sodium channel blocking 
activity, GA can also be utilized in computer modelling, such as for elucidation of a 
pharmacophoric model, conformational analysis and QSAR studies. The major 
drawback of GA is the resources needed for its application. At the basic level where 
GA is used for computer modelling, it requires special computer modules, such as the 
PKUDDS. 19 When GA is utilized for screening of compounds, the cost of operations 
is innately high due to its combinatorial approach. Other than the basic combinatorial 
apparatus, the computer program needed to direct the synthesis is also expensive. Such 
high costs associated with this strategy have limited its use to mainly drug companies 
or well-funded institutions.  
 Extensive research had been done in the field of sodium channel blockers ever 
since it was discovered that phenytoin and carbamazepine work via blockade of 
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sodium channel receptors, thus many sodium channel blockers from different chemical 
classes had been reported in the literature. Such a situation is favourable for the 
development of a pharmacophoric model using the active analogue approach. 12 In the 
active analogue approach, a set of compounds with good biological activity, usually 
called the training set, is first chosen to define the pharmacophoric model. In order to 
get a good pharmacophoric model, it is important to have structural diversity in the 
training set. Structural diversity allows the model to map out a bigger volume in the 
receptor. It also helps in refining the location in the receptor that is essential for good 
activity and differentiating the location, if occupied, that is detrimental to activity. The 
second reason for structural diversity is to reduce redundancy. The inclusion of 
structurally similar analogues does not add new information to the solution, but instead 
adds time to the search for possible pharmacophoric models.  
 CoMFA is a 3D QSAR technique that is favoured by many researchers in 
computer modelling. Many articles have been published using the CoMFA approach 
but they are usually based on a single chemical class of compounds. This is a critical 
concern, as the results obtained from a single class of compounds cannot be 
extrapolated to compounds from other chemical classes, even if they act via the same 
mechanism. The only exception would be to extrapolate the results to analogues of the 
same class of chemicals. Some examples of CoMFA models, which were based on a 
single chemical class of compounds, include the CoMFA model of hydantoins by 
Brown et. al., or more recently the CoMFA and CoMSIA models of phenothiazines by 
Tsakovska. 43, 16 This trend can be partly attributed to the basic concept of CoMFA, 
where a group of compounds is aligned to optimize the overlapping of their steric and 
electrostatic fields. It is easier to overlap compounds of the same chemical class as 
there are already a ‘backbone’ and common functional groups. Comparatively, it is 
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difficult, if not impossible, to optimize the overlapping of sodium channel blockers 
from various chemical classes. It is unlikely that a good CoMFA model can be derived 
using the sodium channel blockers reported in the literature, as they are from different 
chemical classes. 
 Upon consideration of the various pros and cons of the CADD strategies, 
pharmacophoric modelling using the active analogue approach was chosen for the 
project. GA is a powerful strategy, but the lack of resources prevented its use. 
Pharmacophoric modelling was chosen over CoMFA, as diverse sodium channel 
blockers from numerous chemical classes would be better utilized for computer 
modelling. 
 
4.2 Selection of a Training Set of Compounds 
4.2.1 Characteristics of the Compounds in the Training Set 
 In the active analogue approach, the training set of compounds is first 
superimposed based on their pharmacophoric elements to derive a pharmacophoric 
model. As such, the choice of a training set of compounds is very important as the 
theoretical soundness of the pharmacophoric model depends on it. Furthermore, it 
determines whether the pharmacophoric model can be extrapolated to estimate 
biological activity of other compounds that are not studied during pharmacophoric 
modelling. The hypothesis of the current study is that sodium channel blockers utilize 
the same pharmacophoric elements to bind to the sodium channel receptor, and their 
binding affinities were based on the spatial relationships of these pharmacophoric 
elements. In order to determine whether the pharmacophoric model was theoretically 
sound, it was necessary to evaluate the training set of compounds from the 
pharmacological viewpoint.  
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The researcher must first be very clear about the parameters that are to be 
utilized for modelling. In pharmacophoric modelling, the in silico parameter being 
modelled is the binding affinity of the compound to the proposed receptor site. The 
binding affinity is usually represented by parameters that can be easily calculated, such 
as goodness of fit of the compound to the receptor or change in entropy during binding. 
The choice of a training set of compounds should thus be based on biological data that 
reflects binding affinity, and usually the compounds with the highest binding affinities 
should be chosen. Such a requirement is imposed because high affinity compounds 
tend to satisfy well all receptor-binding requirements in terms of conformation, 
pharmacophoric groups and inter-pharmacophoric group distances. 
In vivo biological data gives information about the potency of the compound in 
a given clinical application, such as analgesia, but is unable to provide binding affinity 
data. The clinical effect measured in in vivo studies cannot be used to estimate binding 
affinity as its measurement can be confounded by pharmacokinetics of the compound. 
It should be noted that a pharmacophoric model does not model pharmacokinetic 
parameters of the compounds. For example, the researcher usually does not know the 
concentration of the compound at the site of action (e.g. brain) where the 
pharmacological effect is manifested. There are other confounding factors, such as 
whether the compound can cross the blood-brain-barrier to exert its pharmacological 
effect (e.g. anticonvulsants), active metabolites that may be present, or that the 
pharmacological effect may be missed because of rapid elimination. Another drawback 
of using in vivo biological data for choosing the training set of compounds is that they 
may have multiple mechanisms of action. For example, topiramate is an anticonvulsant 
that has been shown to modulate sodium channels, potentiate GABA inhibition, block 
excitatory neurotransmission, and possibly modulate voltage- and receptor-gated 
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calcium ion channels. 61 In such cases, the compound may be treated as having high 
binding affinity to the receptor due to its in vivo biological data, but the actual binding 
affinity to the receptor being evaluated (e.g. sodium channel receptor) is lower because 
the biological action is also mediated by another mechanism of action. In general, it is 
not suitable to choose a training set of compounds based on in vivo biological data, as 
the computer modelling data is not likely to correlate well with in vivo observations.  
In vitro biological data, on the other hand, is preferred when selecting the 
training set of compounds for pharmacophoric modelling. Due to the nature of the 
assays, it is possible to accurately control the concentration of the compound being 
tested at the site of action. This is in sharp contrast with the in vivo assay methods 
which can be confounded by pharmacokinetics. Another advantage of in vitro 
biological data is that the parameter measured is usually based on the surrogate 
measure of one mechanism of action. For example, radio-ligand binding assays can be 
done using radio-ligands that are specifically displaced by sodium channel blockers. In 
this example, the biological data only represents the ability of the compound to bind to 
one receptor, namely the sodium channel receptor. The advantage of the specificity of 
the assay can be seen when the test compound has several mechanisms of action. For 
example, in the case of topiramate, the many mechanisms of action did not interfere 
with the measurement of the sodium channel blocking activity in the BTX assay. In 
summary, in vitro biological data is more suitable than in vivo biological data for 
selection of the training set of compounds. A good pharmacophoric model is likely to 
correlate well with, and may even predict, in vitro biological data. 
The compounds in the training set should be from different chemical classes. 
Such a requirement allows the resultant pharmacophoric model to be extrapolated to 
other compounds acting at the same receptor site. As iterated above in the discussion 
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of the choice of CADD strategies, structural diversity in the training set of compounds 
will produce a pharmacophoric model which is more informative and representative. In 
contrast, if the training set of compounds is from a single chemical class, the 
conclusions gathered from the pharmacophoric model is limited to that particular 
chemical class and its analogues only, thus severely limiting the usefulness of the 
pharmacophoric model and lay to waste the immense amount of data available on 
sodium channel blockers.  
  
4.2.2 In Vitro Method for Assessment of Biological Activity of Compounds used 
for Modelling and Validating the Pharmacophoric Model  
When choosing an in vitro assay method for evaluating the training set of 
compounds and to eventually validate the pharmacophoric model, it is necessary to 
focus on the application of the pharmacophoric model. The pharmacophoric model is 
designed to discover more information about the receptor site, and thus aid in drug 
discovery of sodium channel blockers. Therefore the in vitro assay method chosen 
must be able to screen potential sodium channel blockers in a high-throughput manner. 
Among the in vitro assay methods available for sodium channel blockers, radioligand 
binding, radioligand flux and fluorescence based assays are considered to be high-
throughput assays. The BTX assay is a radio-ligand binding assay that is frequently 
used by researchers to ascertain the binding affinity of sodium channel blockers to the 
neuronal type II sodium channel receptors. A lot of information can be obtained from 
the literature with regard to the binding affinity of sodium channel blockers as 
measured by this assay method, thus it was preferential to choose the training set of 
compounds using data derived from BTX assays. Therefore the BTX assay was used in 
the current project to assess the biological activity of sodium channel blockers used for 
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computational work, and also for compounds discovered by the current study to be 
potential sodium channel blockers. As such, only neuronal sodium channel blockers 
that were tested using the BTX assay were used for pharmacophoric modelling. As 
iterated in chapter 2, the work done by McPhee et al and Linford et al suggested that 
the BTX binding site shares overlapping but not identical molecular determinants with 
the binding site of sodium channel blockers. 25, 26 Therefore the BTX assay is suitable 
for comparing binding affinity of sodium channel blockers. 
In order to standardize the potencies of the various sodium channel blockers for 
purpose of comparison, the relative blocking potential (RBP) was determined in the 
current study. The IC50 value of each selected sodium channel blocker was converted 
to the Ki value. The RBP was calculated as a ratio of the Ki value of phenytoin to the 
Ki value of the sodium channel blocker. Phenytoin was used as the reference in the 
calculation of RBP because it was a reference in most literatures. However in some 
studies, carbamazepine or veratridine were used as reference. In these situations, the 
relative RBP values (RBPcarbamazepine and RBPveretridine) of the compounds with respect to 
carbamazepine or veratridine were calculated. These values were then converted to 
RBP by correcting with a factor of 0.31 for carbamazepine, and 15.3 for veratridine. 
The factors used for correction are the RBP values of carbamazepine and veratridine 
respectively. A higher RBP value means that the test compound has higher binding 
affinity for the sodium channel receptor. Compounds of high RBP values were used to 
develop the pharmacophoric model because such compounds would tend to satisfy 
well all receptor-binding requirements in terms of conformation, pharmacophoric 
groups and inter-pharmacophoric group distances. Since BTX assay was used as a 
selection criterion, it would not matter if the compounds have multiple mechanisms of 
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action. This is because BTX assay is an objective measurement of the compounds’ 
abilities to block sodium channels.  
 
4.2.3 Compounds Selected as the Training Set 
As stated in the preceding sections, a training set should consist of potent 
sodium channel blockers, and be chosen based on their binding affinity to the sodium 
channels in the BTX assay. It must be emphasized that the compounds were chosen 
from literature articles that presented data derived from a BTX assay that used 
synaptoneurosomes obtained from the rat brain. These preparations are known to 
contain high levels of neuronal (type II) sodium channels. The training set of 
compounds (Figure 1) was used to develop plausible pharmacophoric models, and 
they consisted of the most potent and representative members of the class of sodium 
channel blockers to which they belong. The five compounds in the training set were 
vinpocetine, (1) 56 ; a 2-aminopropanamide analogue, (2) 116 ; dextromethorphan, (3) 116 
; BIIR561C1, (4) 63 ; and lubeluzole, (5) 117. It should be noted that the free acid of 
vinpocetine was used for computer modelling so as to reflect esterase activity in the 
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4.3 A Search for Pharmacophoric Models 
4.3.1 Methodology of Conformational Analysis  
 The great majority of drug molecules are able to assume a large number of 
conformations, through the rotations about bonds and/or inversions about atomic 
centres. Since the conformation of the drug molecule will dictate the spatial 
relationships between its pharmacophoric elements, it is necessary to find the 
particular conformation of each drug which has optimal complementarities to the 
receptor binding site during the search for a pharmacophoric model. It is well accepted 
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that any molecule will be in its GMEC most of the time as this conformation is more 
energetically favourable. Due to limitations in computation resources, GMECs instead 
of multiple conformations were used for the derivation of pharmacophoric models. 
 The choice of a conformational search methodology depends heavily on the 
drug molecules being investigated. As discussed in the first chapter, small molecules 
are best analysed using grid searches which can probably give the most complete 
number of conformations, even though it is more time consuming. On the other hand, 
molecular dynamics and Monte Carlo techniques are more suited for large molecules 
such as proteins. Most of the neuronal sodium channel blockers in the literature were 
small molecules, therefore the grid search approach was used. 
 Molecular mechanics or quantum mechanic can be used in the conformational 
analyses of small molecules. It was a matter of software availability that molecular 
mechanics was chosen for the current project. Since most of the compounds had either 
an amide or amine functional group, MMFF94s by Tripos was used for all the 
conformational analysis, because MMFF94s had its torsional and out-of-plane 
parameters modified to provide nearly planar structure for amide and unsaturated  
amine trigonal nitrogen.  
 
4.3.2 DISCO 
A systematic conformational search was performed for each compound in the 
training set in order to identify their low-energy conformations. The low energy 
conformers were then used in Distance Comparison (DISCO), a molecular 
superimposition program, to derive 3D-pharmacophores models. When a group of 
compounds with diverse chemical structures is used in DISCO, there is a tendency to 
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get multiple pharmacophoric models. Each of these models should then be tested and 
validated to identify the most credible one. 
During superimposition of the compounds in DISCO, a ‘template’ compound 
was needed, so that the rest of the compounds in the training set could be 
superimposed onto it. The compound that could bind to the sodium channel receptors 
most effectively was used as the ‘template’ as it should be most capable in satisfying 
all receptor-binding requirements in terms of conformation, pharmacophoric groups 
and inter-pharmacophoric distances. Judging from BTX studies, vinpocetine was 
chosen as the ‘template’. Pharmacophoric models could differ in tolerance. When 
compounds in the training set were fitted to vinpocetine, they were superimposed so 
that the distances between their respective pharmacophoric elements to the 
corresponding pharmacophoric elements of vinpocetine were minimal. Therefore 
tolerance would measure how large these distances were. In other words, a model with 
low tolerance would mean that the compounds in the training set had their 
pharmacophoric elements overlapped well with those of vinpocetine. 
 
4.4 Validation of Pharmacophoric Models 
The ultimate use of a pharmacophoric model is to design new compounds 
which have high binding affinity for the investigated receptor. The model should be 
validated with a set of compounds, from the literature, having a range of high to low 
binding affinities in biological assays, before being used to design new compounds. 
Conversely, if a pharmacophoric model, which was inaccurate or even invalid, was 
used indiscriminately for drug design, a lot of resources would be wasted. Validation 
can be done using molecular superimposition techniques. If a compound with low 
binding affinity in the BTX assay was found to have a poor fit to the model in any 
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conformation, or if it fitted the model well but in a high energy conformation, it would 
strengthen the credibility of the pharmacophoric model. However, if such a compound 
would fit the model well in its low energy conformation, then there would be three 
possibilities to rationalise this phenomenon. Firstly, the compound may be too 
voluminous in some parts of the molecule which may cause steric interactions with the 
receptor, thus causing low binding affinity. Secondly, the compound may have a very 
unfavourable free energy of solvation, and lastly, the electronic properties of the 
compound may not be complementary to the receptor site. If none of the three cases 
stated above are possible, then the pharmacophoric model would be deemed inaccurate 
or even invalid. On the other hand, a compound with high binding affinity in the BTX 
assay should be able to fit the model well. However, if such an active compound could 
not be fitted to the model, the pharmacophoric model would be considered invalid, 
unless it could be proven biologically to have a different binding mode. 
 Validation could be brought a step further by correlating in silico data with 
biological data. Ability of the compounds to fit the model could be quantified by the 
distances between each of the pharmacophoric elements of the compound to each of 
the corresponding pharmacophoric elements at the receptor site. This quantified 
parameter can then be correlated to binding affinity data using linear correlation. A 
good correlation between the two parameters would help to strengthen the 
pharmacophoric model’s validity and predictive ability. 
Validation of the models in the current study was carried out through the 
correlation of Total Difference (TD) with RBP. Each member of the training set was 
superimposed on the derived models and the TD was calculated. TD value is an 
arbitrary unit used to quantify the goodness of fit between the derived pharmacophoric 
model and each analyte. When the analyte was superimposed onto the pharmacophoric 
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model, the distance between each designated corresponding pharmacophoric element 
in the analyte and model was noted. TD is the sum of the three distances derived in the 
pharmacophoric triangle, and a low value would imply a better fit. Since higher RBP 
values equate to better binding affinity, RBP and TD values should therefore be 
inversely correlated. The compounds in the training set were correlated to ascertain the 
validity of the various pharmacophoric models.  
The models were subsequently challenged to see if they could discern between 
good blockers from the poor blockers. This was carried out by first determining the TD 
values of a larger group of chemically diverse compounds (Figure 2, validation set) 
that exhibited different extent of sodium channel blockade activity. This larger group 
of compounds was later subjected to the same correlation study between the TD and 
RBP values. Similar to the compounds in the training set, compounds in the validation 
set were chosen from literature articles that performed the BTX assay using 
synaptoneurosomes obtained from the rat brain, which contained high levels of 
neuronal (type II) sodium channels. 
The compounds in the validation set were lidocaine, (6) 118 ; lamotrigine, (7) 116 ; 
phenytoin, (8) 27 ; carbamazepine, (9) 27 ; a phenyl hydantoin, (10) 40 ; ameltolide, (11) 
58 ; an ameltolide analogue, (12) 58 ; a N-phenyl derivative of phthalimide, (13) 59 ; 
ralitoline, (14) 52 ; a ‘smissmanone’, (15) 39 ; a carboxamide, (16) 44 ; DCUKA-Ome, 
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          Figure 2. Validation set of compounds 
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4.5 Results and Discussion of Pharmacophoric Modelling 
 The use of vinpocetine as the ‘template’ in the DISCO study resulted in five 
pharmacophoric models, A to E. Each model was made up of one hydrogen-bond (H-bond) 
acceptor (A), one H-bond donor (D) and one hydrophobic group (H). The distances 
between each pharmacophoric element described the dimensions of each model. AH, AD 
and HD are distances between the H-bond acceptor and hydrophobic group; between H-
bond acceptor and H-bond donor; and between hydrophobic group and H-bond donor 
respectively. Inter-pharmacophoric distances and tolerance of the five models are listed in 
Table 1. Model A had the lowest tolerance, followed by model C and then model B. 
Model D and E had large tolerance values and were less likely to be the correct models. 
 
Table 1. Pharmacophoric models and inter-pharmacophoric distances (Å) 
 Model A Model B Model C Model D Model E 
AHa 4.02 3.60 4.31 5.39 5.42 
ADa 5.65 6.12 5.65 5.65 5.65 
HDa 3.27 2.61 5.33 1.41 1.46 
Tolerance 1.26 1.88 1.65 2.88 2.88 
aAH, AD and HD are distances between the H-bond acceptor and hydrophobic group; 
between H-bond acceptor and H-bond donor; and between hydrophobic group and H-bond 
donor respectively. 
 
 The proposed pharmacophoric models of drug-receptor interaction were validated 
by co-relationship study between RBP and the molecular modelling data (TD) using linear 
regression. This was done using both the compounds in the training set and validation set 
and goodness of correlations were represented with r2 values. TD values for every 
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compound was calculated for each model and listed together with RBP values in Table 2.  
If the pharmacophoric models were plausible, then RBP and TD values 
Table 2. TD and RBP values of the compounds 
Compounds TD values RBP 
 Model A Model B Model C Model D Model E  
1 0.00 0.00 0.00 0.00 0.00 122.0 
2 2.63 3.64 4.36 6.25 4.87 36.4 
3 3.34 4.09 4.02 5.15 4.27 30.8 
4 2.23 6.43 1.11 5.80 7.70 29.2 
5 1.67 2.10 2.07 3.59 3.72 98.6 
6 4.20 5.50 6.39 5.54 5.04 0.6 
7 3.11 4.01 2.65 5.22 4.95 0.2 
8 4.16 3.35 2.78 6.79 5.60 1.0 
9 7.19 8.54 6.14 6.82 8.27 0.3 
10 4.05 3.36 5.77 5.55 5.77 1.0 
11 2.54 2.23 5.34 4.21 4.26 0.9 
12 0.74 1.06 2.07 3.91 3.30 7.8 
13 2.04 1.42 3.24 3.94 3.45 6.2 
14 2.85 2.94 4.57 6.18 6.07 1.6 
15 NAa NAa NAa NAa NAa 0.3 
16 0.72 1.31 1.05 5.13 3.82 0.6 
17 1.69 1.13 2.43 3.75 3.14 0.5 
18 1.88 2.99 6.89 5.47 3.38 0.2 
19 3.35 1.83 4.70 4.36 4.25 1.2 
20 NAa NAa NAa NAa NAa 0.5 
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Table 3. Correlation of TD with RBP values 
Correlation of TD with RBP, r2 values Set of compounds  
Used 
Compounds 
used Model A Model B Model C Model D Model E
Training set 1-5 0.80 0.82 0.43 0.85 0.70 
All 1-14 0.34 0.18 0.41 0.55 0.39 
Charged nitrogen 1-7 0.83 0.73 0.46 0.73 0.55 
Uncharged nitrogen 8-14 0.56 0.41 0.57 0.55 0.59 
 
 
would be inversely correlated. TD values were correlated with their RBP values for each 
of the pharmacophoric models (Table 3). 
The first step was to validate using compounds in the training set. The r2 values of 
the five pharmacophoric models ranged from 0.43 to 0.85. Other than model C, the other 
models had good r2 values, which indicated that the pharmacophoric models were well 
correlated with the RBP values of compounds in the training set. This was expected as 
compounds in the training set have high affinity for the sodium channel receptor, and thus 
tend to satisfy well all receptor-binding requirements. In other words, the correlation was 
not confounded by interference from unfavourable parameters, such as steric hindrance of 
pharmacophoric groups. Model C had a low r2 value of 0.43 and was deemed not to be the 
correct model. It was difficult to isolate the best model from the others based on the 
correlation of the TD with RBP values of the training set.  
Compounds 15 to 20 were omitted from the correlations due to reasons such as 
steric hindrance, electron withdrawing effects, or lack of pharmacophoric elements. When 
a correlation study was carried out on compounds 1 to 14, the results yielded low r2 values 
of 0.18 to 0.55. Upon careful inspection of the 14 compounds, it was found that 7 of the 
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compounds (compounds 1-7) would be ionised with a positive charge at physiological pH 
while the rest of the compounds would not. It was also observed that compounds with a 
chargeable nitrogen atom as one of their pharmacophoric elements were usually more 
active than those without. When the 14 compounds were separated and correlation studies 
carried out independently, better r2 values for both the positively charged compounds and 
non-chargeable compounds were obtained. Correlation of the models using the charged 
nitrogen group of compounds yielded r2 values, for the five pharmacophoric models, of a 
range from 0.46 to 0.83. It became more obvious that models C and E were less credible. 
Further correlation of the models using the compounds having uncharged nitrogen group 
resulted in r2 values of 0.41 to 0.59. The poorer correlations with compounds having the 
uncharged nitrogen group were expected as these compounds were of low to moderate 
binding affinity to the receptor, and the correlations were confounded by interference from 
unfavourable parameters, such as steric hindrance of pharmacophoric groups. The results 
of the correlation studies in the group of compounds having uncharged nitrogen suggested 
that model B would not be a good model, due to the lowest r2 value obtained. From the 
correlation studies of both groups of compounds, that has or do not have the charged 
nitrogen group, the three models: B, C and E were eliminated from the list of possible 
pharmacophoric models. The choice was left between model A and model D, as the r2 
values of the correlation in these two models were similar.  
When the tolerance values (Table 1) of these two models were compared, it 
seemed that model A was the better pharmacophoric model. A high tolerance value in the 
model meant that the compounds in the training set fitted onto vinpocetine with a large 
margin of error. In other words, the ranges of inter-pharmacophoric distances in model D 
were larger, and it was thus a less precise model. The tolerance in the model was expected 
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to be low because the compounds used in the training set had high binding affinities to the 
receptor and should be similar in their inter-pharmacophoric distances. Furthermore, 
model A had better r2 values in the correlation studies of both groups of compounds that 
have or do not have the charged nitrogen group (Figure 3 to 5). 
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Figure 4. Correlation plot of RBP vs. TD (from model A) using compounds 1 to 7 
(compounds with a charged nitrogen at physiological pH) 
 
Figure 5. Correlation plot of RBP vs. TD (from model A) using compounds 8 to 14 
(compounds that do not have a charged nitrogen at physiological pH) 
RBP = -1.1 TD + 6.4 
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From the above observations that compounds having the charged nitrogen group 
have higher RBP values than those having the uncharged nitrogen group, it was therefore 
inferred that charged nitrogen in the pharmacophoric elements of the compound is good 
for activity, but is not essential for its binding to the receptor. A possible situation would 
be that compounds in the charged nitrogen group are able to participate in long distance 
ion-ion interactions with negatively charged groups at the receptor site and/or along the 
channel leading to the receptor site. Another explanation is that the receptor site has a 
negatively charge group as its H-bond acceptor, which binds more tightly with a charged 
H-bond donor (e.g. a charged nitrogen).  
Compounds 15 to 20, from the uncharged nitrogen group were not included for 
correlation of TD and RBP. Corey-Pauling-Koltun  (CPK) view of compound 17 (Figure 
6) showed that the two phenyl rings sterically hinder the H-bond donor atom (the 
secondary amide in the ureido functional group). It was not possible to find an unhindered 
pharmacophoric triangle; thus the interaction between the receptor and compound 17 was 
weak despite having a good TD value. Similarly in compound 18, its ester group sterically 
hinders the hydrophobic group, thus its RBP is low despite its low TD. Riluzole (19) has a 
trifluoro-methyl group attached to its oxygen atom (H-bond acceptor), which withdraws 
electrons from the oxygen atom inductively, thus its activity was lower than what was 
suggested by its TD value. Compound 15 and Kavain (20) only have two of the three 
pharmacophoric groups, thus they do not have TD values and cannot be correlated to RBP 
values. Compound 16 is a derivative of carbamazepine (9), with compounds 9 and 16 
having RBP values of 0.31 and 0.58, respectively, while their TD values were very 
different in the model. There was insignificant difference between their RBP values 
whereas there was a very sharp contrast between the TD values of the two compounds. 
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The difference in TD values could be attributed to the additional H-bond acceptor in 
compound 16. However, observation from the RBP values suggested that the two 
compounds would bind to the receptor site in a similar fashion, as their structures and 
binding affinities were very similar. It was thus suggested that compound 16 did not 
utilise its acetyl group as an H-bond acceptor. Therefore its TD value should not be 




Figure 6. Compound (17 ) is shown with an arrow indicating the H-bond donor atom. It 
can be seen that the two phenyl rings sterically hinder the interaction of the H-
bond donor atom with the receptor site. 
 
  
All the conformations used for analysis in DISCO were in their GMECs, except 
for lidocaine (6). For lidocaine, the two ethyl groups attached on the nitrogen atom 
sterically hindered the charged nitrogen. In the GMEC of lidocaine, neither the charged 
nitrogen nor the uncharged nitrogen was able to present an unhindered pharmacophore in 
the CPK view. In other words, the GMEC was not likely to be the active conformation in 
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which lidocaine would adopt when interacting with the receptor site. The LMEC of 
lidocaine did not utilize its charged nitrogen to bind to the receptor site, but instead used 
its uncharged nitrogen to form a pharmacophoric triangle. 
  
4.6 Proposed Pharmacophoric Model for Neuronal (Type II) Sodium Channels 
This study generated a new pharmacophoric model (Figure 7) for blockers of the 
sodium channel receptor, as represented by model A. The proposed pharmacophoric 
model A is a triangle formed by three pharmacophoric elements: 1 hydrogen bond donor 
atom (H-bond donor), 1 hydrogen bond acceptor atom (H-bond acceptor) and 1 
hydrophobic group. The dimensions of the pharmacophoric triangle are as follows. The H-
bond acceptor to hydrophobic group distance (A-H distance) is 4.02±1.26Å, H-bond 
acceptor to donor distance (A-D distance) is 5.65±1.26Å, and the H-bond donor to 
hydrophobic group distance (D-H distance) is 3.27±1.26Å. It was observed that 
compounds with a charged nitrogen at physiological pH will have better binding affinity 
to the sodium channels. Correlation studies of the seven compounds having a charged 
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Figure 7. Proposed pharmacophoric model 
 
The model proposed by the current study was derived from structurally diverse 
compounds and could be related to compounds from other chemical classes acting at the 
rat brain neuronal sodium channel receptors. Unverferth et. al. P10P also used five 
structurally diverse compounds to generate a pharmacophoric model for anticonvulsants 
that are sodium channel blockers. Their model had different pharmacophoric elements 
from the current study, which consist of an electron donor, an aryl ring and a hydrogen 
bond acceptor/donor unit. However, the author concluded that the model had three 
essential pharmacophoric elements, which were a hydrogen bond donor, and two other 
essential structural elements, namely the aryl ring and the electron donor. Their essential 
pharmacophoric elements are similar to those proposed by the current study. The current 
study’s H-bond acceptor, H-bond donor and hydrophobic group are similar to their 
model’s electron donor, hydrogen bond donor part of the HAD unit and aryl ring 
respectively. The similarity of pharmacophoric elements in the two models suggest that 




4.02 ± 1.26 Å 3.27  ± 1.26 Å 
5.65 ± 1.26 Å 
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However the dimensions of the pharmacophoric triangles in the two models are different, 
as the compounds used for the two models were selected based on different criteria. In 
addition, the current study also considered the ionisation of compounds in physiological 
pH, and was thus able to show that compounds with a charged nitrogen as the H-bond 
donor were more active as sodium channel blockers than those which were uncharged. 
Thus it was suggested that a possible lead for sodium channel blockers should fit the 
proposed pharmacophoric model and should preferably have a charged nitrogen as its H-
bond donor.  
The proposed model had pharmacophoric elements which differed from those 
proposed by Tasso et. al. 115 Tasso’s group proposed that the pharmacophoric model 
includes a polar group comprising of two negative atoms and one positive atom, and a 
hydrophobic group that should be no smaller than three atoms. The two negative atoms 
and one positive atom in the polar group are local density charges and not formal charges. 
The pharmacophoric model in the current study is inherently different from that of Tasso’s 
model, because the model in the current study is based on formal charges.  
The proposed pharmacophoric model was derived from a training set of 
compounds that were selected based on their binding affinity to the sodium channels, as 
measured in the BTX assay. Thus the pharmacophoric model in the current study is 
different from the models proposed by Unverferth and Tasso, as their models were derived 
using anticonvulsants that act via sodium channel blockade. In other words, the focus of 
the current pharmacophoric model is to find a common pharmacophore for neuronal 
sodium channel blockers, and not only for anticonvulsants. The main advantage of the 
current study is that it can be useful for predicting the binding affinity of potential sodium 
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channel blockers in the BTX assay due to the derived linear correlations between RBP and 
TD values. The model can be used to predict the sodium channel blockade activity of new 
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5. ADAPTATION OF THE PHARMACOPHORIC MODEL 
FOR IDENTIFYING POTENTIAL SODIUM CHANNEL 
BLOCKERS 
The current study has derived a pharmacophoric model for neuronal (type II) 
sodium channels, based on 3D conformations and binding affinity profiles of known 
sodium channel blockers. It must be emphasized that the binding affinity profiles of the 
compounds have been measured using the BTX assay, thus the pharmacophoric model can 
be viewed as a computational model that can be used to predict the binding affinity of 
compounds in the BTX assay. In other words, the pharmacophoric model can be adapted 
to identify ligands that have high binding affinity to the neuronal (type II) sodium channel 
receptors. Such a screening process is advantageous as the displacement of tritiated BTX 
has been widely used as a rapid in vitro assay for the screening of potential sodium 
channel blockers. As a high throughput and non wet lab-based screening procedure, it can 
reduce screening time and save costs during lead identification. 
 
5.1 Criteria of a Screening Process for Potential Sodium Channel Blockers 
The pharmacophoric model suggested that a good sodium channel blocker should 
ideally have the three stipulated pharmacophoric elements, a charged nitrogen at 
physiological pH and a good fit to the pharmacophoric model. The first and second 
criteria can be fulfilled by the requisite functional groups, but a range needs to be defined 
for the goodness of fit of compounds to the model in order to use it to screen for potential 
sodium channel blockers. The objective of the screening process is to identify compounds 
with good binding affinity, as such; the compounds in the training set can be used as a 
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guide to determine the range of TD values that a potential sodium channel blocker should 
possess. The training set of compounds had a range of TD values from 0.00 to 3.34, 
therefore a TD value of less than 3.50 was chosen as the range of TD values for the 
screening process. The equation, RBP = -31.7 TD + 123.2, which was derived from the 
correlation study of the seven compounds having a charged nitrogen at physiological pH, 
will be used to predict the RBP of the potential sodium channel blocker. 
 In summary, active sodium channel blockers should have the three stipulated 
pharmacophoric elements, a TD value less than 3.50, and a charged nitrogen at 
physiological pH. The equation, RBP = -31.7 TD + 123.2, will be used to predict the RBP 
values of compounds that satisfy the three criteria. A potential ligand can be identified 
using a flowchart (Figure 8).  
 
Figure 8. Flowchart for the screening process. 
Presence of the three 
pharmacophoric elements
 
TD < 3.50 Rejected 
Yes No
Presence of a charged nitrogen 





Potential sodium channel 
blocker 
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5.2 Limitations of the Screening Process 
Other than the three criteria outlined above, the binding affinity of a sodium 
channel blocker is also governed by another major factor that was not incorporated into 
the pharmacophoric model. Compounds that are charged and possess low TD values need 
not necessarily have good binding affinity to the sodium channels, as their ability to 
interact with the receptor is not solely based on its pharmacophoric elements, but is also 
dependent on other parts of the molecule. In other words, non-pharmacophoric elements 
will modulate the binding affinity of a compound. For example, if a compound has a very 
bulky substitution next to its H-bond donor that hinders receptor-ligand interaction, then 
its RBP value would be much lower than predicted. As mentioned, only the most potent 
compound in each chemical class was chosen for computer modelling, so as to reduce 
confounding factors such as steric hindrance from interfering with the analysis of the 
pharmacophoric model. In such situations, it means that the compounds already have 
‘optimized’ non-pharmacophoric elements present in their structure. For example, 
compound 2 had the best binding affinity in a series of 2-aminopropanamides, that had 
ICB50B values ranging from 1.1 to 150.8 µM. P116 PThis series of compounds had the same 
prerequisites (charge and TD value) when assessed by the screening process, but their 
binding affinity to the sodium channel receptors differed up to 150 times. Such 
observations suggest that although both charge and TD value are important parameters, 
the substitutions that do not form part of the pharmacophoric elements can significantly 
alter the binding affinity of the compound. The screening process has a limitation as it is 
based on distances between pharmacophoric elements, and cannot detect whether 
compounds possess ‘optimized’ non-pharmacophoric elements. 
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In view of the limitation of the screening process, a lead compound that is 
predicted to be a good sodium channel blocker should not be discarded if it is 
subsequently found to possess only weak binding affinity in the BTX assay. Instead, 
structural modifications to the lead compound should be attempted in order to find the 
compound with the elusive ‘optimised’ non-pharmacophoric elements. The rationale 
behind this approach is that a lead compound that had been predicted to possess good 
binding affinity possesses the basic chemical structure for good affinity, and thus should 
be explored further to optimise the binding affinity of the compounds from the same 
chemical class. 
Another limitation of the screening process is that it cannot be used for compounds 
that do not have a charged nitrogen. A separate screening process for such compounds was 
not derived because compounds that do not possess a charged nitrogen in their structure 
are inherently weaker and thus not desirable as lead compounds. Another reason was that 
the correlation study involving compounds that do not have a charged nitrogen yielded a r2 
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6. VERIFICATION OF PREDICTIONS THROUGH 
CHEMICAL SYNTHESIS AND IN VITRO TESTING 
6.1 Identification of Potential Sodium Channel Blockers 
Compounds from two chemical classes were selected to verify the ability of the 
pharmacophoric model to discern good sodium channel blockers from the poor blockers. 
The compounds in one of the chemical classes possess a charged nitrogen at physiological 
pH and have low TD values, while the compounds in the other chemical class do not 
possess a charged nitrogen and have high TD values. The former chemical class was 
chosen to show that the screening process would be able to identify compounds that 
possess good binding affinity for the neuronal sodium channels. The latter chemical class 
was used to show that the screening process was able to differentiate the poor sodium 
channel blockers from the good ones. 
 








Compound 21  
 
Intuitively, it can be rationalised that 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-
phenyl-1,3,5-triazine (compound 21), possesses the 3 pharmacophoric elements delineated 
in the derived pharmacophoric model, and its structure closely resembles the sodium 
channel blocker, lamotrigine. In addition, compound 21 possesses a charged nitrogen at 
physiological pH. Compound 21 was identified for further investigation, and was 
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subsequently modelled using the computer software and superimposed onto the 
pharmacophoric model, yielding a TD value of 1.87. In short, compound 21 satisfied the 
two parameters set by the screening process and was predicted to have good binding 
affinity to the sodium channels. 





Compound 22  
 
4’-Fluoro benzyloxime (compound 22) possesses the three pharmacophoric 
elements that were stipulated in the pharmacophoric model. However, compound 22 does 
not have a charged nitrogen at physiological pH and has a high TD value of 7.9, and is 
therefore expected to have low binding affinity to the neuronal sodium channels. 
 
6.2 Chemical Synthesis and In Vitro Testing of Compounds 
6.2.1 Chemistry 
Compound 21 was synthesized using a general synthetic pathway for the 
phenyldihydro-1,3,5-triazines, which involves the condensation of molecular equivalents 
of the arylammonium chloride salt, cyanoguanidine, and acetone or cyclohexanone, with 
loss of one molecule of water (Figure 9). One equivalent of HCl was used and the 
reaction was carried out in 96% ethanol, with heating at reflux. The reaction mixture 
becomes a clear solution, from which the product crystallizes directly in pure form. The 
crystals were then re-crystallized with ethanol/water mixture. 
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Figure 9. Chemistry of phenyldihydro-1,3,5-triazines. (R1=H, Cl, CH3 or CH3O and 


















substituted aniline cyanoguanidine ketone phenyldihydro-1,3,5-triazines
conc. HCl
 
 Compound 22 was synthesized by a general procedure for benzyloximes, in which 
a Schiff-base reaction was carried out between the corresponding aldehyde/ketone and 
hydroxylamine hydrochloride, with sodium acetate as a base catalyst (Figure 10). The 
reaction was carried out in aqueous ethanol with stirring at room temperature. 
 
Figure 10. Chemistry of benzyloximes (R1= 4-F, 4-CF3, 4-OCH3, 2, 3-di-OCH3, 4-OC4H9, 















6.2.2 BTX Radioligand Binding Assay 
The BTX assay is a well established radio-ligand binding assay used for screening 
neuronal (type II) sodium channel blockers pioneered mainly by William A. Catterall and 
his co-workers. 27 The current study made use of an assay method modified from that 
reported by Brown et. al. 43 Synaptosomes has been used in the assay because they have 
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the same properties as those in neuroblastoma cells with respect to neurotoxin binding and 
action. P120P Furthermore the number of sodium channels per milligram of protein is much 
greater in synaptosomes, thus making it suitable for high throughput sodium channel 
binding assay. Synaptosomes are obtained from rat cerebral cortex because 
autoradiographic localization of the BTX binding sites shows that the highest density of 
the receptors are concentrated in the grey matter and lower in the white matter. P121P In the 
preparation of the receptors for the study, the brain tissue was first disrupted by 
homogenization to increase access of the radio-ligand to the receptor population. A series 
of manipulations with centrifugation and filtration were carried out to obtain the desired 
fraction of protein that contained the sodium channel receptors. This fraction was 
subsequently stored frozen in isotonic sucrose solution and thawed before use.  
Since the BTX assay is a competitive binding assay, the isolated receptors were 
incubated with increasing concentrations of the drug being tested, together with a fixed 
concentration of tritiated BTX. Scorpion venom was used to increase the specific binding 
of tritiated BTX by approximately 15 fold. P27P At equilibrium, the proportion of unbound 
and bound tritiated BTX depended on the ability of the drug to displace BTX from its 
binding site. As most of the tritiated BTX remained unbound at the end of the binding 
reaction, an efficient method for its removal, without the loss or dissociation of the 
receptor-ligand complex, was necessary to accurately quantify the amount of bound 
tritiated BTX. Separation was carried out at 0°C in order to reduce the ligand dissociation 
rate. Filtration was employed as it was an efficient and convenient method of separating 
free from bound tritiated BTX, because it required less handling and manipulation of 
samples compared to the centrifugation method.  
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In radio-ligand binding assays, there will always be a certain amount of 
nonspecific binding, which is not saturated by radio-ligand and therefore continues to 
increase as a function of radio-ligand. Thus, non specific binding must be quantitated at 
every concentration of receptor and radio-ligand by including assay tubes that had high 
concentration of veratridine. Since veratridine was present in such a concentration which 
was sufficient to occupy more than 99% of the receptors, it prevented the tritiated BTX 
from binding to the receptors; therefore the remaining bound radioactivity that was 
measured represented the nonspecific binding. The specific binding of the tritiated BTX 
can therefore be calculated by subtracting nonspecific binding from the total binding. 
 
6.3 Results of CADD and In Vitro Testing of 4,6-Diamino-1,2-dihydro-2,2-
substituted-1-phenyl-1,3,5-triazines (Phenyldihydro-1,3,5-triazines) 
6.3.1 In Vitro Testing of 4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-
triazines (Series (I)) 
In order to verify the prediction of the pharmacophoric model, compound 21 was 
synthesized and tested for its binding affinity for the neuronal sodium channels using the 
BTX assay, and was found to have a ICB50B value of 195.1 ±10.8 µM. The screening process 
predicted, through equation RBP = -31.7 TD + 123.2, that compound 21 should have a 
RBP value of 63.9. However, on comparing the KBi B values of compound 21 and phenytoin, 
compound 21 was found to have a RBP value of 0.8. 
As iterated in the limitations of the screening process, if a potential lead compound 
was found to have weak in vitro activity, it should not be discarded immediately. Different 
substitution to the basic chemical structure should be attempted in order to improve its 
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binding affinity, as it is believed that a lead compound that satisfies the screening 
process’s criteria should possess the prerequisites that are needed to bind strongly to the 
receptor. Thus a series of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazines, 
series (I), was synthesized and tested in the BTX assay (Figure 11). This series of 
compounds explored the effects of phenyl substitutions. Attempts to use more electron-
withdrawing substituents (such as para-nitro) were not successful. 
Figure 11. Binding affinity of compounds in series (I) in the BTX assay 










Compound R BTX 
ICB50 B (µM) 
 
SEM RBP 
21 H 195.1 10.8 0.8 
23 o-Cl 123.4 4.7 1.3 
24 m-Cl 44.0 3.6 3.6 
25 p-Cl 48.3 7.4 3.3 
26 o-CHB3 B 81.2 9.7 2.0 
27 m-CHB3 B 38.7 1.7 4.1 
28 p-CHB3 B 48.3 5.2 3.3 
29 o-OCHB3 B 180.7 15.9 0.9 
30 m-OCHB3 B 71.5 11.8 2.2 
31 p-OCHB3 B 97.6 10.8 1.6 
Phenytoin 159.5 7.8 1.0 
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All the compounds in series (I) showed moderate binding affinity to the neuronal 
sodium channels, with compound 27 having the lowest ICB50B value of 38.7 ± 1.7 µM, 
which translated to an RBP value of 4.1. In other words, the meta-methyl substitution 
(compound 27) improved the binding affinity of the unsubstituted compound (compound 
21) by about 5 times. 
The results showed that, the presence of a substituent on the phenyl ring, has a 
positive effect on the binding of the compounds in the phenyldihydro-1,3,5-triazines series 
with the receptor site on the sodium channel. This is inferred from the significantly lower 
ICB50 Bvalues of the compounds with substitutions introduced at the meta and para position 
compared to the unsubstituted compound.  
The ortho-substituted compounds have similar ICB50 Bvalues to the unsubstituted 
compound. The lower binding affinities of these compounds are likely to be due to the 
steric interaction between the ortho-substitution and the heterocyclic ring. The electron 
donating or electron withdrawing characteristics of the phenyl-substitutions does not have 
significant impact on the BTX activity of the compounds, as can be seen from the similar 
results between the chloro-substituted and methyl substituted compounds. 
 
6.3.2 In Vitro Testing of 4,6-Diamino-1,2-dihydro-2,2-cyclohexyl-1-phenyl-1,3,5-
triazines (Series (II)) 
Although the in vitro testing of the compounds in series (I) showed that compound 
27 had a RBP value of 4.1, its binding affinity was still considered too weak compared to 
the predicted RBP value of 63.9 by the screening process. Therefore further modifications 
RESULTS AND DISCUSSION 
________________________________________________________________________ 
had to be made in order to unearth the potential of the phenyldihydro-1,3,5-triazines. A 
further attempt to improve compound 21 as a sodium channel blocker was made by the 
Computer-aided Drug Refinement (CADR) approach.  
 
Figure 12. Compound 21 overlapped onto the pharmacophoric triangle                                               
 
Compound 21 was superimposed on the pharmacophoric model and examined in 
detail (Figure 12). For compound 21, DISCO assigned the 4-NH2 group as D (H-bond 
donor), its 6-NH2 group as A (H-bond acceptor) and its heterocyclic ring as H 
(hydrophobic site). It can be seen from the figure that the ‘epicentre’ of the hydrophobic 
group, as depicted by the pharmacophoric model, is near to the 2-position. Thus the 
dimethyl group at the 2-position has an important contribution to the hydrophobic 
pharmacophoric element of the compound. An increase in hydrophobicity at the 2-position 
should theoretically increase the binding affinity of compound 21, and it was proposed to 
 78
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change the dimethyl group at the 2-position to a cyclohexyl group. With this information, 
compound 32 was synthesized and tested in the BTX assay, and was found to have an ICB50B 
value of 14.7 ± 1.3 µM. Compound 32 has a RBP value of 10.9 and is approximately 13 
times more active than compound 21 in the BTX assay. In other words, the CADR 
approach was accurate in predicting, that increasing the hydrophobicity at the 2-position, 
will improve binding affinity.  
As it was observed that phenyl substitutions in series (I) improved binding 
affinities of the compounds, the same phenyl substitutions were used to form series (II) 
(Figure 13). The phenyldihydro-1,3,5-triazine compounds in series (II) generally 
exhibited good sodium channel inhibitory activity based on the ICB50B values obtained from 
the BTX binding assay. In particular compound 34 (ICB50B of 4.0 ± 0.5 µM) has a RBP value 
of 39.9. The high binding affinity of compound 34 suggested that the screening process 
was able to identify potential sodium channel blockers that have high affinity to the 
neuronal sodium channels. Emphasis must be placed on the fact that 4,6-diamino-1,2-
dihydro-2,2-substituted-1-(substituted)-phenyl-1,3,5-triazines were never before reported 
as sodium channel blockers. The trend in the binding affinities of the compounds in series 
(II) is similar to that of series (I), as it was observed that compounds with substitutions 
introduced at the meta and para positions have significantly lower ICB50 Bvalues compared 
to the unsubstituted compound. The ortho-substituted compounds in series (II) have 
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Figure 13. Binding affinity of compounds in series (II) in the BTX assay 












32 H 14.7 1.3 10.9 
33 o-Cl 13.0 0.6 12.3 
34 m-Cl 4.0 0.5 39.9 
35 p-Cl 4.4 0.3 36.3 
36 o-CHB3 B 9.1 1.2 17.5 
37 m-CHB3 B 4.7 0.1 33.9 
38 p-CHB3 B 4.2 0.6 38.0 
39 o-OCHB3 B 12.3 2.1 13.0 
40 m-OCHB3 B 5.1 0.3 31.3 
41 p-OCHB3 B 7.8 0.8 20.4 
                               
 
Although compound 21 had a RBP value of only 0.8, the phenyldihydro-1,3,5-
triazines were explored further based on the belief that this chemical class of compounds 
possess the prerequisites required for good binding affinity to the neuronal sodium 
channel receptors. The use of the CADR approach and variation of the phenyl 
substitutions had improved the RBP value to 39.9 in compound 34. It must be emphasized 
that the TD values of compound 21 and 34 are the same, thus reinforcing the belief that a 
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compound with a good TD value need not necessarily possess good binding affinity to the 
sodium channels, but with structural modifications and functional group substitutions 
(without changing the TD value), it is possible to improve its activity. The RBP of 
compound 34 is 39.9, still lower than the predicted RBP value of 63.9. A margin of error 
is expected in the prediction of the TD value of compound 34, especially since only seven 
compounds were used for formulating the equation. Furthermore, it is possible that the 
RBP values of phenyldihydro-1,3,5-triazines can still be increased through further 
structural changes. 
The screening process had been shown to be able to identify a potential sodium 
channel blocker, based on the criteria set for the process and through the use of the 
flowchart in figure 8. Future experiments can be done using the derived screening process 
to identify new compounds with potential sodium channel blockade activities. The 
activities of existing compounds can be improved using the pharmacophoric model, 
through the application of the CADR approach, where subtle modifications can be 
performed on existing compounds in the literature, to generate derivative compounds with 
improved binding affinity. Since only small changes are being made, the resulting 
compounds are more likely to have favourable activity in the BTX assay. The best 
compounds can then be synthesized and tested in the BTX assay to verify the accuracy of 
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6.3.3 Structural Activity Relationships of Phenyldihydro-1,3,5-triazines and PLS 
Analysis 
In order to get a better understanding of the factors that are important for binding 
of the compounds to the receptor, a partial least squares (PLS) analysis, using SIMCA 
version 8.0, of the BTX activity (as the y variable) and physical parameters (8 x variables) 
of the phenyldihydro-1,3,5-triazines compounds in series (I) and (II) was performed 
(Table 4). The x variables selected were Log P, molecular refractivity (MR), solvent 
accessibility surface (SAS), dipole moment, lowest unoccupied molecular orbital (LUMO) 
energy, highest occupied molecular orbital (HOMO) energy, electron affinity and 
dielectric energy. A 3-component principal component analysis (PCA) of the x variables 
gave a r2 of 0.973. The scores scatter plot (Figure 14) showed a good scatter of the 
observations in all the four quadrants, with no outliers as seen by the Hotelling’s t2 eclipse 
on the same plot.  
With this information, a partial least squares (PLS) analysis was carried out, 
yielding a 2-component model, with r2 of 0.749 and validated r2 (q2) of 0.528. The scores 
scatter plot (Figure 15), showed two prominent clusters, namely the 2,2-dimethyl series in 
the upper right quadrant, and the 2,2-cyclohexyl series in the lower left quadrant. In other 
words, the PLS model was able to differentiate, based on the physicochemical properties 
of the compounds, the active and less active compounds into two different clusters. It was 
noted that BTX IC50 values were used for the analysis, thus the smaller the value, the more 
active the compound. Therefore the active compounds are in the lower left quadrant of the 
scores scatter plot while the BTX variable is in the upper right quadrant of the loadings 
scatter plot (Figure 16).  
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Together, the loadings scatter plot and the variable importance plot (VIP, Figure 
17) clearly identified Log P, MR and SAS as the most important parameters that 
contributed significantly to the binding affinity of the compounds. This is consistent with 
major forces that are important in biochemical ligand binding are hydrophobic, dispersive 
and electrostatic interactions. Log P and MR are related respectively to hydrophobicity 
and dispersive forces, while SAS is related to electrostatic interactions. SAS was 
measured in silico by conductor-like screening model (COSMO), a dielectric continuum 
model.26 The solute molecule was embedded in a dielectric continuum of permittivity and 
formed a cavity within the dielectric. The interface between the cavity and the dielectric is 
called the SAS. The importance of hydrophobicity, as shown in the PLS analysis, further 
supports the CADR approach’s deduction on the improvement of compound 21’s activity. 
The PLS model also suggested that dipole moment, LUMO energy, HOMO energy, 
electron affinity and dielectric energy are of less importance to BTX activity. This 
conclusion was in agreement with the observation of this study that electronic factor was 
less important, because the activities of chloro-substituted and methyl substituted 
compounds were similar.  
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21 2.320        -12.508 -4.575 63.958 233.225 8.640 -3.075 4.575
22 3.349        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
-12.408 -4.509 75.694 264.981 8.812 -3.021 4.509
23 2.838 -12.402 -4.580 68.762 244.683 8.886 -3.092 4.580
24 2.838 -12.226 -4.641 68.762 251.358 12.198 -3.167 4.641
25 2.838 -12.156 -4.643 68.762 251.362 13.410 -3.187 4.643
26 2.787 -12.195 -4.548 68.999 243.317 9.034 -3.049 4.548
27 2.787 -12.117 -4.543 68.999 250.038 9.387 -3.052 4.543
28 2.787 -12.064 -4.532 68.999 250.589 9.501 -3.053 4.532
29 2.067 -11.905 -4.425 70.421 253.568 8.187 -3.071 4.425
30 2.067 -11.700 -4.535 70.421 260.353 9.741 -3.199 4.535
31 2.067 -11.660 -4.539 70.421 261.500 11.226 -3.239 4.539
32 3.867 -12.360 -4.509 80.499 275.682 8.320 -3.014 4.509
33 3.867 -12.196 -4.573 80.499 283.089 11.724 -3.098 4.573
34 3.867 -12.120 -4.576 80.499 283.623 12.774 -3.147 4.576
25 3.816 -12.161 -4.483 80.735 275.187 9.075 -2.995 4.483
36 3.816 -12.086 -4.478 80.735 283.487 9.298 -3.001 4.478
37 3.816 -12.026 -4.468 80.735 283.492 9.349 -2.994 4.468
38 3.096 -11.873 -4.365 82.157 286.087 8.183 -3.026 4.365
39 3.096 -11.674 -4.469 82.157 292.771 9.409 -3.141 4.469
40 3.096 -11.629 -4.475 82.157 293.132 10.718 -3.182 4.475
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Figure 16. PLS loadings plot 
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6.4 Results of CADD and In Vitro Testing of Benzyloximes 
In a separate study, benzyloximes were used as the investigative molecules. Upon 
analysis of the oxime functional group, it was noted that benzyloximes possessed the three 
pharmacophoric elements needed for binding to the sodium channel receptor. Compound 
22, 4’-fluoro benzyloxime, was modeled in silico and superimposed onto the 
pharmacophoric model, and it was found to have a TD value of 7.9. The high TD value, 
and the absence of a charged nitrogen at physiological pH, suggested that compound 22 
was likely to be a weak sodium channel blocker. Therefore a series of benzyloximes was 
synthesized and tested in the BTX assay to verify this prediction.  
All the 11 compounds in the series were screened for biological activity at 
concentrations of 100 and 1000 µM, and only six were further investigated to obtain ICB50 B 
values (Figure 18) based on the preliminary screening. The five compounds that were not 
tested further consisted of three compounds which were found to be insufficiently soluble, 
and two others that had low binding affinity for the receptor. In general, all the 11 
benzyloximes synthesized exhibited poor sodium channel blockade activity, which 
suggested that the pharmacophoric model’s prediction, that the benzyloximes being weak 
sodium channel blockers, was accurate and the model is able to discern between good 
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Figure 18. Binding affinity of compounds in the benzyloximes series 
 







Compound RB1 B RB2 B Percentage  
Inhibition (%) 
ICB50 B (mM) RBP 
   100 µM  
 
1000 µM   
22 4-F H 3.2 (6.0)  43.1 (3.2) 1.45 (0.24) 0.11 
42 4-CFB3 B H 16.8 (1.3) NS  NS NA 
43 4-OCHB3 B H 1.9 (2.8) 32.2 (5.7) 2.67 (0.59) 0.06 
44 2,3-di-OCHB3 B H 0.0 30.4 (0.8) 2.60 (0.03) 0.06 
45 4-OCB4 BHB9 B H 24.9 (4.0) NS NS NA 
46 4-CN H 1.2(1.3) NS NS NA 
47 4-NOB2 B H 3.9 (1.8) 44.2 (2.2) 1.43 (0.13) 0.11 
48 3-NHB2 B CHB3 B 0.6 (3.0) 16.5 (1.1) ND NA 
49 4-NHB2 B CHB3 B 2.7 (5.9) 15.0 (5.0) ND NA 
50 4-NHB2 B CB2 BHB5 B 3.8 (1.5) 31.3 (1.9) 2.36 (0.23) 0.07 
51 H CB2 BHB5 B 10.1 (0.7) 80.1 (1.1) 0.44 (0.02) 0.36 
Values in parentheses are SEM values; NS areP Pcompounds not tested as it was insoluble in 
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Of the six compounds that were tested further for ICB50B values, compound 51 had 
the best binding affinity with an ICB50 B value of 0.44 ± 0.02 mM (RBP = 0.36), which was 
approximately three times weaker than phenytoin. The results showed that electron-
donating substitution on the benzene ring decreased binding affinity for the receptor, as 
observed from the comparison of compounds 50 and 51. An increase in hydrophobicity of 
the substitution at RB2 Bincreased binding affinity, which was reflected in the percentage 
inhibition values of compounds 49 and 50. The results of compounds 43 and 45 also 
suggested that an increase in hydrophobicity of the substitution at RB1 Bwill improve binding 
affinity. Compounds 42 and 45 were not sufficiently soluble in the incubation buffer, thus 
they were only screened in the BTX assay at a concentration of 100 µM. From these 
preliminary results, it would be expected that these two compounds had the best binding 
affinity in the benzyloxime series of compounds for the sodium channel receptors. 
 In summary, electron-withdrawing substitution at RB1 B and hydrophobic 
substitutions at RB1B and RB2 B showed better binding affinity of the benzyloximes. It was 
postulated that electron-withdrawing substitution at RB1B can improve binding affinity by 
increasing the overall electron-withdrawing effects on the oxime group, thus facilitating 
the formation of a partially charged nitrogen atom, through mesomeric interactions 
between the oxime and benzene functional groups. This observation agreed with the 
results of the pharmacophoric model, which suggested that a charged nitrogen in the 
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7. POTENTIAL PHARMACOLOGICAL ACTIONS 
RELATED TO SODIUM CHANNEL BLOCKADE 
The ultimate aim of CADD is to develop new lead compounds with specific 
pharmacological actions that have clinical utility. Blockers of the neuronal (type II) 
sodium channels are known to be anticonvulsants, analgesics and neuroprotective agents. 
The most logical path to assume after the compounds have been shown to be active 
sodium channel blockers in the BTX assay was to carry out in vivo screening of these 
compounds.  
 
7.1 Choice of Pharmacological Assays 
 Anticonvulsant screening can be done using the MES, s. c. Met (PTZ) and TTE 
tests. The MES and TTE tests are based on electrically-induced convulsions, while the s.c. 
Met test utilizes chemically-induced convulsions. Although it has been claimed that the 
different assay methods can be used to differentiate the compounds’ potential clinical use, 
it has been observed that most articles in the literature only reported MES test results. As a 
preliminary screening test for protection against convulsion, only the MES test was 
performed. 
 Antinociceptive screening can be performed using the hot-plate, tail-flick and 
writhing syndrome tests. The hot-plate and writhing syndrome tests are behavioural tests, 
while the tail-flick test is mainly a test of pain reflex. The most commonly performed tests 
were the hot-plate and tail-flick tests. Both tests were equally easy to perform, and the hot-
plate test was chosen as the screening assay for antinociceptives. 
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 Cerebral ischemia involves very complex neurochemical sequelae, and it is 
eneral
ss 
chanisms of action. 24, 69 Furthermore, the MCAO assay is technically difficult 
 carry  the 




g ly agreed that neuroprotection requires a multi-prong approach in order to be 
effective. Thus it is not feasible to target cerebral ischemia with a drug that has a single 
mechanism of action, as stopping a single mechanism will only mean that the effects of 
ischemia will emerge through another pathway. This view is supported by the fact that 
riluzole, a clinically used neuroprotectant for amyotrophic lateral sclerosis, and many 
compounds that are still in clinical trials, such as AM-36, had been reported to posse
multiple me
to  out, as it requires a lot of skill to perform the surgery. In view of the point that
compounds were not expected to be effective neuroprotective agents, coupled with the 
difficulty in operations, this screening assay was not attempted. 
 Phenyldihydro-1,3,5-triazines are known to be dihydrofolate reductase (DHFR) 
inhibitors, and some of them are used as antineoplastic, antimalari
a  122 As such, DHFR inhibition is considered a potential side effect of the 
compounds if they are to be used as sodium channel blockers. Therefore, the abilities 
the phenyldihydro-1,3,5-triazines in inhibiting DHFR were explored. It was postulated 
that the phenyldihydro-1,3,5-triazines with rigid and bulky substitutions at the 2-position
of the triazine ring would have weak inhibitory activity on DHFR. 122 In addition to 
compounds in series (I) and (II), another series of compounds, with 2,2-cyclopentyl 
substitution, was included for DHFR inhibitory assays to better ascertain the change in 
inhibitory activity with respect to the increase in the rigidity and bulkiness of the 
substitution at the 2-position. 
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7 Anticonvulsant and Sedative Effects of the Phenyldihydro-1,3,5-triazines an
Benzyloximes  in the MES and Rotarod Assays  
The MES test was carried out to screen and evaluate the anticonvulsant a
the compounds. Chemical entities that abolished the tonic extension of maximal seizures 
in the MES test would most likely show clinical efficacy in the treatment of generalized
tonic-clonic seizures. The MES test used a supra maximal current (four to five times 
threshold) to elicit threshold limb tonic extension, and the anticonvulsant activity of 
test compound was graded upon the limb tonic extensor component. In other words, 
arbitrary grades were given based on the ability to abolish the extension of either hind 
limbs, or both forelimbs and hind limbs extension. The higher the MES score, the 






ds against electrically-induced seizures.  
The mice were subjected to rotarod screening, which was basically an assay to 






 resulted in 
toxicity for compounds 33 to 37, and compound 39. When the mice were injected with 
assess the sedative and CNS impairment effects of the compounds on the mice. The mice 
bjected to the rotarod test before injecting the test c
to stay on the rotarod for 300 seconds were rejected and not used for the assay. 
This pre-screening of the mice ensured that the inability to stay on the rotarod after 
injection of the test compounds could be attributed to the sedative effects of the 
compounds. Mice injected with test compounds that had lower CNS impairment effec
would stay longer on the rotarod. 
The MES scores and rotarod values for the phenyldihydro-1,3,5-triazines are l
in Figure 19. MES scores for all of the phenyldihydro-1,3,5-triazines at both 25 mg/Kg
and 50 mg/Kg were 1.00. Hence it was apparent that none of the compounds exhibited an
anticonvulsant activity. Increasing the dose from 25 mg/kg to 50 mg/kg
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brain barrier to exert their effects on the sodium 
channe
 
st compounds at the dose of 50 mg/Kg, some, if not all, of the mice died shortly
after drug administration. All the phenyldihydro-1,3,5-triazines tested were lethal at 100 
mg/Kg. The lack of anticonvulsant activity in the phenyldihydro-1,3,5-triazines in the 
MES test could be partly attributed to the high toxicity of the compounds, which 
prevented testing at higher doses. The results in Figure 20 showed that compound 5
most potent of the benzyloximes tested, was also not active in the MES assay at t
of 50 mg/Kg. Another possibility was that the phenyldihydro-1,3,5-triazines were unable
to adequately transverse the blood 
l receptors in the brain. The average rotarod values (Figure 19) at the dose of 25 
mg/kg were generally at the maximum of 300 seconds whilst there was reduction in the 
values when the dose was doubled to 50 mg/kg. However, compounds 38 and 41 only 
exhibited slight sedative effects at 50 mg/kg. The sedative effect of the compounds 
therefore manifested at higher doses but at 25 mg/kg it was absent, except for compound
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Figure 19. MES scores and Rotarod values of phenyldihydro-1,3,5-triazines 
 









Compound R 50 mg/Kg 25 mg/Kg 








32 H 1.00(0.00) 39.0 1.00(0.00) 300(0) 
33 o-Cl 1.00(0.00)b 168.5b 1.00(0.00) 300(0) 
34 m-Cl -- -- 1.00(0.00) 300(0) 
35 p-Cl 1.00c 29.0c 1.00(0.00) 300(0) 
36 o-CH3 -- -- 1.00(0.00) 25 
37 m-CH3 1.00c 110.3c 1.00(0.00) 300(0) 
38 p-CH3 1.00(0.00) 231.0 
(38.0) 
1.00(0.00) 300(0) 
39 o-OCH3 1.00c 134.0c 1.00(0.00) 300(0) 
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e toxicity pr e of th mes was better than the phenyldihydro-1,3,5-
triazines, thus they were tested at doses up to 200  Only pounds, which 
had their IC50 values ined in the BTX assay, w  tested and r
all the mice di r dr ion; b 1 mou dministratio
ed ug ; value entheses a  value
Th ofil e benzyloxi
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tests. T ost poten pound o enzyloxim es was 51, which had 
a MES re of 4 at /Kg. It w noted that co ound 51 e most potent 
compo  of benzy assay mpar ata fr
Figure 18 and Figure 20, it was observed that the pounds with better affinity for 
the receptor in the BTX assay generally had better ores, with compound 47 as the 
only exception. The results suggested that in a single chemical class of compoun
compounds with better binding affinity for the el the B y 
are more likely to have better anticonvulsant effects in the MES assay.  
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sodium chann receptors in TX assa
The results showed that an electron-donating substituent on the benzene ring 
nzyloximes ranged from non-sedative to absolute sedation at the dose of 100 
mg/Kg in the rotarod test. The rotarod test results (Figure 20) seemed to suggest that 
electron-withdrawing groups in the phenyl ring tend to cause sedation, as can be seen in
compounds 22, 43 and 47. On the other hand, compound 50, with an electron-donating 
group in the phenyl ring, had low sedative effects. Compound 44 (2’,3’-dimethoxy) was 
non-sedative, while mice injected with compound 43 (para-methoxy) were too sedate
be put on the rotarod apparatus. It was interesting to note that these two compounds had 
similar substitutions, thus it was suggested that electron-withdrawing effects was not the 
only factor in determining the sedative effects of the compounds, and that an ortho 
substitution may abolish sedative effects completely. 
 
95 
RESULTS AND DISCUSSION 
 
96 
Figure 20. MES scores and Rotarod values of benzyloximes 
 







Compound R1 R2 200 mg/Kg 150 mg/Kg 100 mg/Kg m  50 g/Kg















22 4-F H   2.75(0.25) 0a 1 0
Ro arod
(sec) 
.50( .34) 60(28)   
43 4-OCH3 H ----- -----   1 0 0  
44 2,3-di-
OCH3
H 1.25(0.25) 154(79)   1 0
47 4NO2 H   ----- ----- 1 (0
50 4-NH2 CH2 CH3 2.00(0.00) 101(15)   (
51 H CH2 CH3   4.00(0.00) 0 3.00(0 117(29) ( ) 7
.25( .25)  
.00( .00) 300(0)   
.00 .00) 110(55)   
1.5(0.29) 222 46)   
.00) 1.00 0.00 17 (71) 
a mice too sedated to be put on rotarod apparatus; ----- mice too sick; values in parenthe
 
ses are SEM values. 
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7.3 Antinociceptive Effects of the Phenyldihydro-1,3,5-triazines and 
Benzyloximes in the Hot-plate Assay 
The hot-plate assay is a behavioural test that measures the response of the mouse 
to heat as a noxious stimulus. Each mouse was placed on a heated surface maintained at a 
temperature which cause in to  felt at the paws of the anim y time, the 
interval between the placement ouse on  h la
recorded. Reaction to heat can  j in om late 
surface. Hind paw-lickin as s ac
performed a long time after the m
measures a behavioural reaction to heat, and thus cannot be performed on mice which are 
sedated. Therefore, for the phenyldi pounds 38 and 41 were 
tested in the hot-plate as as they lowest sedative effe  th series of 
compounds. In order reduce the num ice used, compound 
pound from the benzyloxime series that was tested, as it had the best binding affinity 
m channel recepto T s
From the results lis  Table 5, it can be seen that the two phenyldihydro-1,3,5-
wed insignif t
tive effects at 50 mg/kg. Due to the toxicity of the phenyldihydro-1,3,5-
g ated that 
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5.  Mean hot-plate latency values of seleTable cted phenyldihydro-1,3,5-triazines and 
benzyloxime 
 
Compound Mean hot-plate latency (sec) and amount of drug injected 
 0 mg/Kg 5 mg/Kg 25 mg/Kg 50 mg/Kg 100 mg/Kg 
Control 6.5     
Morphine  13.9  
(2.9 X 10-5)a
   
38   8.4 
(0.12) 
13.6 
(3.9 X 10-5) 
 
41   8.5 
(0.04) 
13.1 
(6.8 X 10-6) 
 
51    7.0 
(0.52) 
9.3 
(5.5 X 10-3) 
a p value from ANOVA (single factor) analysis. 
und 
had to be placed on the fact that antinociceptive effects measured in the 
hot-plate assay did not necessarily mean that the compounds gained access to the brain 
through the blood brain barrier. Antinociceptive can either work by binding to the 
neuronal sodium channel receptors in the brain or by binding to the neuronal sodium 
 
 
The benzyloxime, compound 51, had insignificant antinociceptive effects at the 
dose of 50 mg/Kg, but had slight antinociceptive effects at 100 mg/Kg. Since compo
51 displayed weak antinociceptive activity, further hot-plate tests were not performed on 
the other benzyloximes in order to reduce the number of mice used. 
Emphasis 
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channel receptors in the peripheral nerves. The preliminary screening of the compounds in 
 
ork need to be done to ascertain their site of action. 
 
7.4 Inhibitory Activity of the Phenyldihydro-1,3,5-triazines against DHFR 
As iterated above, the phenyldihydro-1,3,5-triazines had been known to be DHFR 
inhibitors, thus the DHFR inhibitory activity of three series of phenyldihydro-1,3,5-
triazines was explored. In view of the need to increase bulkiness at the 2-position to 
reduce DHFR inhibitory activity, cyclopentyl and cyclohexyl substitutions were utilized. 
Although a tertiary-butyl substitution at the 2-position could further increase bulkiness, it 
was not attempted as the synthesis of such compounds was of low yield due to steric 
hindrance of the ketones. 123
The DHFR enzyme assay is an Ultra Violet (UV) spectrophotometric assay which 
measures the change in UV absorbance over time. DHFR catalyzes the NADPH-
ependent reduction of dihydrofolate (DHF) to tetrahydrofolate (THF). NADPH is 





the hot-plate assay only served to highlight their potential as antinociceptives, and more
w
d
+ does not. Therefore, the rate of decrease in absorbance at 340 nm over time is an
indication of the rate of enzyme reaction. In the presence of a DHFR inhibitor, this 
decrease in absorbance will occur at a slower rate and if there is 100% inhibition of DHFR
activity, no reduction in absorbance will be observed. 
During the enzyme assay, DHFR was allowed to equilibrate with NADPH in 
phosphate buffer at 37oC. A fixed amount of DHF was then added and the UV absorban
at 340 nm was monitored automatically by the spectrophotometer to generate the 
absorbance versus time graph and the gradient of the slope was calculated. If an inhibi
99 
RESULTS AND DISCUSSION 
________________________________________________________________________ 
100 
was present, the enzyme would be allowed to incubate with the inhibitor at 37 Po PC before 
the addition of DHF. Different concentrations of the inhibitor were used and the 
percentage of DHFR inhibition at each concentration was calculated. A graph of the 
percentage of inhibition against the logarithmic concentrations of the inhibitor was then 
plotted using Prism 3.0. The concentration of the inhibitor which inhibited 50% of DHFR 
activity (ICB50 B) was found from the graph. 4,6-Diamino-1-(4’-chloro-3’-nitrophenyl)-1,2-
dihydro-2,2-dimethyl-s-triazine was used as a positive control (ICB50B = 0.083 µM). 
There was a trend of decreasing DHFR inhibitory activity  with increasing 
bulkiness of the substitution at the 2-position, which was evident in the meta-methyl 
(compounds 27, 37 and 57), para-methyl (compounds 28, 38 and 58) and para-methoxy 
(compounds 31, 41 and 61) substitutions in the three series of compounds (Figure 21). 
However, it was observed that some compounds in the cyclopentyl series, such as 
compounds 54, 55 and 57, had good DHFR inhibitory activity. On comparison, the 
compounds in the cyclohexyl series were at least a thousand fold weaker in their 
inhibitory activity than the positive control; 4,6-diamino-1-(4’-chloro-3’-nitrophenyl)-1,2-
dihydro-2,2-dimethyl-s-triazine (ICB50B = 0.083 µM). From these results, it was suggested 
that only the compounds in the cyclohexyl series should be considered for further 
pharmacological exploration, as the low DHFR inhibitory activity in this series means 
lesser side effects. 
It should be highlighted that the compounds with the ortho substituted phenyl rings had 
markedly higher ICB50 B values than the meta and para substituted compounds in all the three 
series of compounds.  It was initially proposed by Modest et. al. that the reduced activity 
in triazines with ortho substitutions in the phenyl ring was due to the steric interference of 
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the substitution that manifests in certain conformational changes of the molecule. It was 
suggested that tendency towards coplanarity between the phenyl ring and the triazine ring 
led to an increase in biological activity of the phenyldihydro-1,3,5-triazines. P122 PMatthews 
et. al., however, found that the two rings were out of plane with respect to each other in 
the active conformation. P127P Hence, the low activity of the ortho substituted compounds 
could be due to the inability of the molecule to fit the receptor pocket as a consequence of 
the sterically-induced restrained freedom of rotation of the phenyl ring by the ortho 
substitution. On the other hand, the meta and para substituted compounds in all the three 
series generally had similar DHFR inhibitory activity.  
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Figure 21. DHFR inhibitory activity of phenyldihydro-1,3,5-triazines 
 
























(I)  (II)  (III) 
Compound R DHFR ICB50 B 
(µM) Pa P 
 Compound R DHFR ICB50 B 
(µM) 
 Compound R DHFR ICB50 B 
(µM) 
21 H 0.18  32 H 146.20  52 H ND 
23 o-Cl 6.46  33 o-Cl > 1000 PbP  53 o-Cl > 1000 PbP 
24 m-Cl 0.08  34 m-Cl 7.95  54 m-Cl 0.08 
25 p-Cl NA  35 p-Cl 73.78  55 p-Cl 1.06 
26 o-CHB3 B 5.89  36 o-CHB3 B > 500 PbP  56 o-CHB3 B 1009.00 
27 m-CHB3 B 0.08  37 m-CHB3 B 15.54  57 m-CHB3 B 0.71 
28 p-CHB3 B 0.09  38 p-CHB3 B 12.99  58 p-CHB3 B 3.75 
29 o-OCHB3 B 91.20  39 o-OCHB3 B > 500 PbP  59 o-OCHB3 B > 1000 PbP 
30 m-OCHB3 B 0.29  40 m-OCHB3 B 217.10  60 m-OCHB3 B ND 
31 p-OCHB3 B 0.13  41 p-OCHB3 B 252.10  61 p-OCHB3 B 14.15 
P
a
P data from references P124-126P; Pb P exact ICB50 B not determined due to solubility problems. 
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7.5 Pharmacological Profile of Phenyldihydro-1,3,5-triazines and 
Benzyloximes 
The phenyldihydro-1,3,5-triazines in series (I) and (II) had good binding 
affinity for the sodium channel receptor in the BTX assay. The compounds in the 
cyclohexyl series had higher binding affinity, with compound 34 being approximately 
40 times more potent than phenytoin. However, on screening for in vivo 
pharmacological actions, none of the phenyldihydro-1,3,5-triazines have 
anticonvulsant activity in the MES test, but instead were found to be toxic in mice; all 
the compounds were lethal at 100 mg/Kg. Compounds 38 and 41, with the lowest 
sedative effects as measured in the rotarod test were further tested in the hot-plate test. 
The results showed that both the compounds displayed antinociceptive effects at 50 
mg/Kg, and were both approximately 10 times weaker than morphine as an 
antinociceptive. As these two compounds exhibited antinociceptive potential, it was 
interesting to find out whether they also exhibit DHFR inhibitory activity as 
phenyldihydro-1,3,5-triazines are traditionally recognized as DHFR inhibitors. An 
additional series of phenyldihydro-1,3,5-triazines, the cyclopentyl series of compounds, 
were synthesized and the DHFR inhibitory activity of the phenyldihydro-1,3,5-
triazines were elucidated. The results showed that an increase in bulkiness of the 
substitution at the 2-position decreased DHFR inhibitory activity. However, compound 
37 still possessed considerable DHFR inhibitory activity, with an ICB50B value of 13.0 
µM. On the other hand, compound 41 had much weaker DHFR inhibitory activity, 
with an ICB50 B value of 252.1 µM. Therefore it was proposed that compound 41 was the 
most suitable candidate to be developed as a potential antinociceptive which acts at the 
sodium channel receptors. 
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The benzyloximes had weak binding affinity to the sodium channel receptors, 
and were synthesized mainly to provide data for the validation of the screening process. 
One of the compounds in the benzyloxime series, compound 51, had moderate binding 
affinity for the sodium channel receptor, with an ICB50B value of 0.44 ± 0.02 mM and 
was approximately 3 times weaker than phenytoin. MES scores of compound 51 
showed that it had excellent and good anticonvulsant activity at 150 mg/Kg and 
100mg/Kg, respectively. However, this compound only displayed weak 
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8. CONCLUSIONS AND FUTURE WORK 
8.1 CADD and its Application in the Development of a Pharmacophoric model 
for Sodium Channel Blockers  
Lead compound identification for neuronal (type II) sodium channel blockers 
has been mainly focused on analogues and derivatives of hydantoins or other first 
generation sodium channel blockers such as carbamazepine and lidocaine. Furthermore, 
the traditional method of screening compounds for sodium channel blockade activity is 
tedious and costly. The use of CADD, a rational drug design approach, will potentially 
save both time and cost of discovering new lead compounds.  
The current study focused on the derivation of a pharmacological model for 
sodium channel blockers. Five structurally diverse compounds having good blocking 
activity against the sodium channel receptor were selected for DISCO study, and a new 
pharmacophoric model for neuronal (type II) sodium channel blockers was derived. 
The dimensions of the pharmacophoric triangle are as follows. The H-bond acceptor to 
hydrophobic group distance (A-H distance) is 4.02±1.26Å, H-bond acceptor to donor 
distance (A-D distance) is 5.65±1.26Å, and the H-bond donor to hydrophobic group 
distance (D-H distance) is 3.27±1.26Å. 
The pharmacophoric model was subsequently validated with 20 compounds 
from the literature, by correlating TD against RBP. Through correlation studies, the 
pharmacophoric model was found to have rP2 P values of 0.83 and 0.56 for the charged 
nitrogen set and uncharged nitrogen set of compounds respectively. The current study 
took into account the charge status of the compounds at physiological pH and the 
observations of the RBP of the charged nitrogen set and the uncharged nitrogen set of 
compounds suggested that in addition to the pharmacophoric triangle, a positively 
charged nitrogen would give better blocking effect. 
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The major strength of the pharmacophoric model in the current study is the 
selection of compounds from different chemical classes for derivation of the model. 
Due to the diversity of the compounds used for its derivation, the model is robust 
enough to be used to analyse compounds from different chemical classes. If a single 
chemical class of compounds was used, then the resulting pharmacophoric model can 
only be used for analyzing that particular class of compounds.  
Another advantage of the current study is the use of in vitro binding affinity 
data of the compounds, both for the selection of the training set of compounds and for 
the validation of the pharmacophoric model. The use of in vitro data allows the 
selection of compounds that has the highest binding affinity to the receptor for use as 
the training set. If the training set consists of compounds, with weak to moderate 
binding affinity to the receptor, the resulting pharmacophoric model will be inaccurate. 
Choosing compounds for the training set using in vivo data is not advisable, because in 
vivo data cannot give accurate information regarding the abilities of the compounds to 
bind to the receptor, due to confounding factors such as pharmacokinetic profiles of 
the compounds. The use of in vitro data for validation of the pharmacophoric model is 
also preferred over in vivo data. 
 
8.2 Adaptation of the Pharmacophoric Model into a Screening Process for 
Potential Neuronal Sodium Channel Blockers 
 The pharmacophoric model was adapted into a high throughput screening 
process for the identification of potential neuronal sodium channel blockers. The 
screening process is based on three criteria; the presence of the three pharmacophoric 
elements, the presence of a charge nitrogen at physiological pH, and a TD value of less 
than 3.50. The equation, RBP = -31.7 TD + 123.2, is used to predict the RBP values of 
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compounds that satisfy the three criteria. Compounds that do not satisfy the three 
criteria are not recommended for further investigation. 
The screening process was carried out using two series of compounds, which 
have not been tested in the BTX assay before. The two series of compounds, the 
phenyldihydro-1,3,5-triazines and the benzyloximes, were selected because of their in-
silico ability, and inability respectively, to fulfil the criteria of the screening process. 
The screening process predicted that the phenyldihydro-1,3,5-triazines will have good 
binding affinity to the neuronal sodium channels, while the benzyloximes will have 
poor binding affinity. As expected from the prediction of the screening process, the 
phenyldihydro-1,3,5-triazines generally have good binding affinity, as measured by the 
BTX assay, with the most potent phenyldihydro-1,3,5-triazine (compound 34) having 
an ICB50B value of 4.0 ± 0.5 µM. The benzyloximes tested generally have poor binding 
affinity, with the most potent compound (compound 51), having an ICB50 B value of 0.44 
± 0.02 mM.  
A screening process capable of identifying potent neuronal sodium channel 
blockers had been derived in the current study. Since the displacement of tritiated BTX 
has been widely used as a rapid in vitro assay for screening potential blockers of 
neuronal sodium channels, such an in silico screening process can potentially reduce 
costs of lead identification. However, the screening process does not have an equation 
for predicting the RBP values of compounds without a charged nitrogen at 
physiological pH as the linear correlation studies done on these compounds yielded a 
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8.3 Screening of Pharmacological Activities 
Since the ultimate purpose of developing a pharmacophoric model is to use it 
to identify new lead compounds with pharmacological properties that have therapeutic 
interests, the compounds synthesized were screened for their pharmacological 
activities. Knowing that neuronal sodium channel blockers were potential 
anticonvulsants, antinociceptives and neuroprotective agents, these compounds were 
screened in the MES and hot-plate assays. The rotarod assay was conducted in tandem 
with the MES assay to assess the sedative effects of the compounds. Neuroprotective 
potential of the compounds was not explored as it was deemed that neuroprotective 
agents would be more likely to be active if they possessed multiple mechanisms of 
actions.  
The animal studies showed that the phenyldihydro-1,3,5-triazines did not 
possess any anticonvulsant activity in the MES assay at 50 mg/Kg and were lethal at 
100 mg/Kg. Since rotarod assay results showed that only compounds 38 and 41 from 
this series of compounds had low sedative effects, these two compounds were further 
tested in the hot-plate assay. Compounds 38 and 41 displayed antinociceptive effects at 
a dose of 50 mg/Kg and were approximately ten times weaker than morphine as an 
antinociceptive in the hot-plate assay. Since the phenyldihydro-1,3,5-triazines had 
been known traditionally as DHFR inhibitors, the compounds were tested in the DHFR 
inhibition assay. An additional series of compounds, the cyclopentyl series of 
phenyldihydro-1,3,5-triazines, was also synthesized and tested in this assay to help 
determine how an increase in bulkiness of the substitution at the 2-position of the 
molecule would affect its DHFR inhibitory activity. From the results, it was observed 
that an increase in bulkiness in the substitution at the 2-position decreased the DHFR 
inhibitory activity of the compounds. However, it was noted that the extent of decrease 
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ant in the cyclopentyl series of compounds. Compound 38 had been found to 
possess significant DHFR inhibitory activity, while compound 41 was much weaker as 
a DHFR inhibitor. The current study identified a suitable candidate, compound 
future exploration as a potential antinociceptive.  
 MES assay results showed that the benzyloximes had varied potency as 
anticonvulsants, and that the MES scores were generally higher in those compounds 
that had better binding affinity in the BTX assay. For example, of the compounds in 
the benzyloxime series, compound 51 had the highest binding affinity in the BTX 
assay and the highest anticonvulsive potential in the MES assay. Compound 51 was
tested in t
, and since compound 51 did not display potential as an antinociceptive, the
benzyloximes were not tested further in this assay.  
 The current study identified a potential lead compound for the treatment of pai
(compound 41). However, the major contribution of the current study, to the discovery
of new sodium channel blockers, lies in the development of a general procedure; for 
the in silico screening of potential sodium channel blockers, verification of the bindi
affinity of the compounds to the neuronal sodium channels and the in vivo screening
the compounds for anticonvulsant and antinociceptive effects. 
 
8.4 Future Work 
Future experiments can be done using the derived screening process to iden
new compounds with potential sodium channel blockade. Compounds predicted to 
have good binding affinity in the screening processes can be synthesized and tested in 
the BTX assay. Compounds with good binding affinity in the BTX assay can then be 
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put through in vivo pharmacological screening assays. Another alternative is to use 
Unity, a module in the Sybyl program, which allows a three-dimensional search of 
databases for compounds that fit the pharmacophoric model. The pharmacophoric 
model can also be used to improve the activities of existing compounds using CADR. 




 for its potential to block sodium 
 
an be developed. Then 
ompounds can be screened to determine whether they are likely to act via N-methyl-
reening compounds using pharmacophoric models for 
differen
on the pharmacophoric model, to generate derivative compounds with improved
binding affinity. Since only small changes are being made, the resulting compounds 
are more likely to have favourable activity in the BTX assay. The best compounds ca
then be synthesized and tested in the BTX assay to verify the accuracy of the 
modifications.  
The pharmacophoric model can be used to predict the mechanism of actions o
antinociceptives and anticonvulsants. For example, a novel compound with an 
unknown mechanism of action can be tested in silico
channel receptors, and if the compound fits the model well, it is highly likely that the 
compound acts via sodium channel blockade. Then the mechanism of action can be 
further elucidated by either the BTX assay or patch-clamp technique. This idea can be
taken a step further by introducing screening processes for therapeutic compounds that 
have different mechanisms of action. For example, a pharmacophoric model for 
anticonvulsants that act via N-methyl-D-aspartate antagonism c
c
D-aspartate antagonism. Sc
t mechanisms can determine whether the compounds have multiple 
mechanisms of action.  
The structural similarities between the sodium, potassium and calcium voltage-
gated ion channels meant that selectivity of the compounds between the receptors of 
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these channels would determine the extent of side effects. Many compounds that blo
sodium channels are also calcium channel blockers. For example, lubeluzole’s abilit
to block sodium channels contributed to its neuroprotective effects, but its ability to










84 Therefore, it was suggested to
derive pharmacophoric models of the potassium and calcium channel, and the results 
can be analyzed in order to find the area of the pharmacophoric models which are
overlapping. The overlapped area can be avoided when designing new compounds in
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9 MATERIALS AND METHODS 
9.1 Computer-aided Drug Design  
9.1.1 Systematic Conformational Search  
The structures of the compounds were modelled using Sybyl6.6 by Tripos. The 
computer system used was Indigo 2 from Silicon Graphics. Structures were then built 
according to their net charge status at physiological pH and minimized to their global 
minimum energy conformation (GMEC) using grid search, at rotatable single bonds 
with steps of 30° or 60°. The conjugate-gradient optimization and MMFF94s force 
field were utilized. The global minimum energy conformation (GMEC) of each 
compound, which is the conformation with the lowest energy value, was then selected 
for further work in DISCO. Ideally, all the conformations near the GMEC should be 
used to derive possible pharmacophoric models, however the GMEC of each 
compound was used due to limited computational resources. 
 
9.1.2 Distance Comparison (DISCO) 
 DISCO is a molecular superimposition program (Sybyl6.6 from Tripos), which 
used the least-squares superimposition of pharmacophore elements represented as 
ligand points or site points. The DISCO program was set to overlap the compounds 
according to 3 main ‘functional classes’. The functional class can be an H-bond 
acceptor, an H-bond donor or a hydrophobic group. The three functional classes had 
been used in various combinations, and only the combination with one H-bond 
acceptor, one H-bond donor and one hydrophobic group gave a viable pharmacophore. 
All the other combinations did not result in any pharmacophore. When using DISCO, a 
reference compound had to be chosen as a template for the rest of the compounds to 
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superimpose upon. Vinpocetine was chosen as the reference compound as it is the 
most potent sodium channel blocker, according to BTX radio-ligand binding assays. 
 
9.1.3 Quantitative Structure-Activity Relationship (QSAR) 
 QSAR of the 4,6-diamino-1,2-dihydro-1-phenyl-1,3,5-triazines were carried 
out using Principal Component Analysis (PCA) and  Partial Least Squares (PLS) 
modelling in SIMCA version 8.0. All physical parameters were calculated with 
BioMedCaChe version 5.1 by the CAChe Group, Fujitsu. All compounds were first 
minimized using gridsearch for single bonds, at 30° steps, employing PM5 geometry 
minimization. Log P and molecular refractivity (MR) was done using the program’s 
atom typing parameters. Solvent accessibility surface (SAS) and dielectric energy was 
done using COSMO in PM5 geometry. Dipole moment, LUMO energy, HOMO 
energy, dielectric energy and electron affinity were measured in PM5 geometry. 
 
9.2 Chemical Synthesis 
9.2.1 Materials and Equipments 
The chemicals used in the synthesis were obtained from Aldrich Chemical 
Company (USA) and Tokyo Kasei Organic Chemicals (TCI, Japan). Melting points 
were determined using a Gallenkamp Melting Point Apparatus without correction. 
Maximum UV absorption wavelengths of the compounds were determined by a 
Shimadzu UV-160A UV-visible Recording Spectrophotometer. Infrared (IR) spectra 
were recorded using KBr discs via a Jasco FT/IR-430 Fourier Transform Infrared 
Spectrophotometer. P1 PH NMR spectra were recorded on a Bruker ACF 300MHz NMR 
Spectrometer. Chemical shifts (δ) were expressed in parts per million (ppm) relative to 
tetramethylsilane (TMS), the internal standard. 
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9.2.2 General Three-component Synthesis of 4,6-Diamino-1-(substituted)phenyl-
1,2-dihydro-2,2-substituted-1,3,5-triazine HCl.P 
 Compound 21, compounds 23 to 41 and compounds 52 to 61 were synthesized 
by the three-component synthesis developed by Modest et al. P123P A mixture of the 
substituted aniline (0.05 mole), cyanoguanidine (0.055 mole), concentrated 
hydrochloric acid (0.05 mole), ketone (0.05 mole) and 96% ethanol (15 ml) was 
refluxed with stirring for 3 to 24 hours, depending on the type of aniline used. The 
reaction mixture became clear within 10 to 20 minutes, followed by the precipitation 
of the product during reflux. Progress of the reaction was monitored by TLC. The 
absence of arylbiguanide in the reaction mixture was ascertained by carrying out the 
biguanide test. For all of the compounds, precipitation of the product occurred during 
the reaction process.  Upon completion of the reaction, the reaction mixture was 
vacuum filtered and washed with cold ethanol. The product obtained was then oven 
dried and purification was achieved by recrystallisation using admixtures of ethanol 
and water. The filtrate was kept in the refrigerator for a few days and the crystalline 
products harvested by vacuum filtration. The final product was dried in a vacuum oven 
at 50Po PC for at least 24 hours before further characterization. 
 
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-1,3,5-triazine HCl (21) 
Yield 32.9 %; mp 198-200 Po PC (200-203 PoPC) P123 P; λBmax B (methanol) = 240.6 nm; IR (KBr 
disc) 3304 (νBN-H B); 3133 (νBC-H, aromaticB); 2991 (νBC-H, aliphatic B); 1648 (νBC=NB); 1546 (νBC BU···UBC B, 
BaromaticB) cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 9.25 (2H, br s, NHB2 B, ex) 7.55-7.54 (3H, m, ArH) 
7.38-7.36 (2H, m, ArH) 6.26 (2H, br s, NHB2 B, ex) 1.34 (6H, s, CHB3 B) ppm. 
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1-(o-Chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine HCl (23) 
Yield 35.4 %; mp 217 Po PC (222-225 Po PC) P128 P; λBmax B (methanol) = 239.8 nm; IR (KBr disc) 
3262 (νBN-H B); 3125 (νBC-H, aromatic B); 2968 (νBC-H, aliphatic B); 1645 (νBC=NB); 1589 (νBC BU···UBC B, BaromaticB) 
cmP-1 P; P1 PH NMR (DMSO-dB6B) δ 9.11 (2H, br s, NHB2 B, ex) 7.72-7.69 (1H, m, Ar-H) 7.60-
7.50 (3H, m, Ar-H) 6.64 (2H, br S, NHB2 B) 1.56 (3H, s, CHB3 B) 1.20 (3H, s, CHB3 B)  ppm. 
 
1-(m-Chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine HCl (24) 
Yield 27.7 %; mp 190-193 Po PC (196.5-197.5 PoPC) P129 P; λBmax B (methanol) = 241.0 nm; IR 
(KBr disc) 3294 (νBN-H B); 3142 (νBC-H, aromaticB); 2967 (νBC-H, aliphatic B); 1645 (νBC=NB); 1591 (νBCBU···UBCB, 
BaromaticB) cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 9.08 (2H, br s, NHB2 B, ex) 7.62-7.53 (3H, m, ArH) 
7.38-7.36 (1H, m, ArH) 6.51 (2H, br s, NHB2 B, ex) 1.36 (6H, s, CHB3 B) ppm. 
 
1-(p-Chlorophenyl)-4,6-diamino-1,2-dihydro-2,2-dimethyl-1,3,5-triazine HCl (25) 
Yield 35.7 %; mp 205-207 Po PC (210-215 PoPC) P123 P; λBmax B (methanol) = 240.8 nm; IR (KBr 
disc) 3303 (νBN-H B); 3141 (νBC-H, aromaticB); 2979 (νBC-H, aliphatic B); 1646 (νBC=NB); 1598 (νBC BU···UBC B, 
BaromaticB) cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 9.20 (2H, br s, NHB2 B, ex) 7.60(2H, d, J = 8.7, ArH) 
7.42 (2H, d, J = 8.3 ArH) 6.47 (2H, br s, NHB2 B, ex) 1.35 (6H, s, CHB3 B) ppm. 
 
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(o-methylphenyl)-1,3,5-triazine HCl (26) 
Yield 33.7 %; mp 211-214 Po PC (223-224 PoPC) P128 P; λBmax B (methanol) = 244.0 nm; IR (KBr 
disc) 3300 (νBN-H B); 3132 (νBC-H, aromaticB); 2970 (νBC-H aliphatic B); 1643 (νBC=NB); 1590 (νBC BU···UBC B, 
BaromaticB) cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 8.90 (2H, br s, NHB2 B, ex) 7.33-7.43 (4H, m, ArH) 
6.35 (2H, br s, NHB2 B, ex) 2.17 (3H, s, Ar-CHB3 B) 1.55 (3H, s, CHB3 B) 1.12 (3H, s, CHB3 B) ppm. 
 
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(m-methylphenyl)-1,3,5-triazine HCl (27) 
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Yield 45.0 %; mp 196-198 Po PC (204.5-205.5 PoPC) P129 P; λBmax B (methanol) = 246.8 nm; IR 
(KBr disc) 3305 (νBN-H B); 3142 (νBC-H, aromaticB); 2975 (νBC-H, aliphatic B); 1644 (νBC=NB); 1591 (νBCBU···UBCB, 
BaromaticB) cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 8.76 (2H, br s, NHB2 B, ex) 7.45-7.32 (2H, m, ArH) 
7.18-7.14 (2H, m, ArH) 6.25 (2H, br s, NH B2 B, ex) 2.37 (3H, s, Ar-CHB3 B) 1.35 (6H, s, CHB3 B) 
ppm. 
 
4,6-Diamino-1,2-dihydro-2,2-dimethyl-1-(p-methylphenyl)-1,3,5-triazine HCl (28) 
Yield 39.1 %; mp 199-201 Po PC (206-208 PoPC) P123 P; λBmax B (methanol) = 245.2 nm; IR (KBr 
disc) 3314 (νBN-H B); 3147 (νBC-H, aromaticB); 2977 (νBC-H, aliphatic B); 1643 (νBC=NB); 1593 (νBC BU···UBC B, 
BaromaticB) cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 8.99 (2H, br s, NHB2 B, ex) 7.30 (4H, q, J = 7.9, ArH) 




Yield 33.1 %; mp 193-195 Po PC (198-201 PoPC) P128 P; λBmax B (methanol) = 243.2 nm; IR (KBr 
disc) 3314 (νBN-H B); 3138 (νBC-H, aromaticB); 2973 (νBC-H, aliphatic B); 1646 (νBC=NB); 1591 (νBC BU···UBC B, 
BaromaticB); 1278 (νBC-OB)  cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 8.98 (2H, br s, NHB2 B, ex) 7.52-7.46 
(1H, t, J = 7.9, ArH) 7.31-7.22 (2H, q, J = 7.9, ArH) 7.09-7.04 (1H, t, J = 7.6, ArH) 











Yield 55.6 %; mp 192-194 Po PC (200-203 PoPC) P129 P; λBmax B (methanol) = 244.6 nm; IR (KBr 
disc) 3375 (νBN-H B); 3172 (νBC-H, aromaticB); 2920 (νBC-H, aliphatic B); 1630 (νBC=NB); 1568 (νBC BU···UBC B, 
BaromaticB); 1327 (νBC-OB)  cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 8.93 (2H, br s, NHB2 B, ex) 7.47-7.42 
(1H, t, J = 8.3, ArH) 7.10 (1H, d, J = 9.1, ArH) 6.91 (2H, s, ArH) 6.32 (2H, br s, NHB2 B, 




Yield 35.6 %; mp 200-203 Po PC (210 Po PC) P130 P; λBmax B (methanol) = 242.6 nm; IR (KBr disc) 
3399 (νBN-H B); 3162 (νBC-H, aromatic B); 2948 (νBC-H, aliphatic B); 1632 (νBC=NB); 1592 (νBC BU···UBC B, BaromaticB); 
1250 (νBC-OB)  cmP-1 P; P1 PH NMR (DMSO-dB6B) δ 8.84 (2H, br s, NHB2 B, ex) 7.17 (4H, q, J = 8.7, 
ArH) 6.27 (2H, br s, NHB2 B, ex) 3.81 (3H, s, Ar-OCHB3 B) 1.33 (6H, s, CHB3 B) ppm. 
 
2,2-Cyclohexyl-4,6-diamino-1,2-dihydro-1-phenyl-1,3,5-triazine HCl (32) 
Yield 56.4 %; mp 217-219 Po PC ; λBmax B (methanol) = 245.2 nm; IR (KBr disc) 3297 (νBN-H B); 
3132 (νBC-H, aromatic B); 2945 (νBC-H, aliphatic B); 1637 (νBC=NB); 1591 (νBC BU···UBC B, BaromaticB) cmP-1 P; P1PH NMR 
(DMSO-dB6 B) δ 9.18 (2H, br s, NHB2 B, ex) 7.57-7.53(3H, m, ArH) 7.37-7.33 (1H, m, ArH) 
6.22 (2H, br s, NHB2 B, ex) 1.89-0.82 (m, 10H, (CHB2 B) B5B) ppm; CB14 BHB19BNB5 B.HCl, (Found C, 
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1-(o-Chlorophenyl)-2,2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine  HCl 
(33) 
Yield 25.7%; mp 217-219 Po PC; λBmax B (methanol) = 244.8 nm; IR (KBr disc) 3296 (νBN-H B); 
3136 (νBC-H, aromatic B); 2928 (νBC-H, aliphatic B); 1643 (νBC=NB); 1590 (νBC BU···UBC B, BaromaticB) cmP-P1; P1 PH NMR 
(DMSO-dB6 B) δ 9.16 (2H, br s, NHB2 B, ex) 7.72-7.52 (4H, m, Ar-H) 6.57 (2H, br s, NHB2 B) 
1.77-1.04 (10H, m, (CHB2 B) B5B) ppm; CB14 BHB18 BNB5 BCl.HCl, (Found C, 51.17; H, 6.01; N, 
20.89); M-HP+P 291.9 [293.8] (3:1). 
 
1-(m-Chlorophenyl)-2,2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine  HCl 
(34) 
Yield 25.9 %; mp 234-237 Po PC; λBmax B (methanol) = 245.2 nm; IR (KBr disc) 3220 (νBN-H B); 
3130 (νBC-H, aromatic B); 2947 (νBC-H aliphatic B); 1647 (νBC=NB); 1607 (νBCBU···UBC B, BaromaticB) cmP-1 P; P1PH NMR 
(DMSO-dB6 B) δ 9.22 (2H, br s, NHB2 B, ex) 7.64-7.51 (3H, m, ArH) 7.37-7.27 (1H, m, ArH) 
6.45 (2H, br s, NHB2 B, ex) 1.89-0.93 (m, 10H, (CHB2 B) B5B) ppm; CB14 BHB18BNB5 BCl.HCl, (Found C, 
51.24; H, 5.82; N, 20.99); M-HP+P 291.9 [293.8] (3:1). 
 
1-(p-Chlorophenyl)-2,2-cyclohexyl-4,6-diamino-1,2-dihydro-1,3,5-triazine HCl (35) 
Yield 28.0 %; mp 242-244 Po PC; λBmax B (methanol) = 244.8 nm; IR (KBr disc) 3300 (νBN-H B); 
3134 (νBC-H, aromatic B); 2936 (νBC-H, aliphatic B); 1666 (νBC=NB); 1601 (νBC BU···UBC B, BaromaticB) cmP-1 P; P1PH NMR 
(DMSO-dB6 B) δ 9.23 (2H, br s, NHB2 B, ex) 7.68-7.57 (2H, m, ArH) 7.40 (2H, d, J = 8.7, 
ArH) 6.41 (2H, br s, NHB2 B, ex) 1.89-0.91 (m, 10H, (CHB2 B) B5 B) ppm; 
CB14 BHB18BNB5 BCl.HCl.(HB2 BO) B0.5 B, (Found C, 45.22; H, 5.23; N, 18.31); M-HP+P 291.9 [293.8] 
(3:1). 
 





Yield 26.1 %; mp 250-252.5 Po PC; λBmax B (methanol) = 244.4 nm; IR (KBr disc) 3298 (νBN-
HB); 3133 (νBC-H, aromatic B); 2928 (νBC-H, aliphatic B); 1667 (νBC=NB); 1590 (νBC BU···UBC B, BaromaticB) cmP-1 P; P1 PH 
NMR (DMSO-dB6 B) δ 9.05 (2H, br s, NHB2 B, ex) 7.68-7.35 (4H, m, ArH) 6.40 (2H, br s, 
NHB2 B, ex) 2.17 (3H, s, CHB3 B) 1.72-1.03 (m, 10H, (CHB2 B) B5B) ppm; CB15 BHB21BNB5 B.HCl, (Found C, 




Yield 20.6 %; mp 234-235 Po PC; λBmax B (methanol) = 245.0 nm; IR (KBr disc) 3304 (νBN-H B); 
3136 (νBC-H, aromatic B); 2925 (νBC-H, aliphatic B); 1664 (νBC=NB); 1599 (νBC BU···UBC B, BaromaticB) cmP-1 P; P1PH NMR 
(DMSO-dB6 B) δ 9.10 (2H, br s, NHB2 B, ex) 7.45-7.39 (1H, t, J = 7.5, ArH) 7.33 (1H, d, J = 
7.5, ArH) 7.16-7.11 (2H, t, J = 6.4,  ArH) 6.16 (2H, br s, NHB2 B, ex) 2.37 (3H, s, CHB3 B) 





Yield 25.0 %; mp 234-235 Po PC; λBmax B (methanol) = 244.8 nm; IR (KBr disc) 3296 (νBN-H B); 
3135 (νBC-H, aromatic B); 2936 (νBC-H, aliphatic B); 1646 (νBC=NB); 1593 (νBC BU···UBC B, BaromaticB) cmP-1 P; P1PH NMR 
(DMSO-dB6 B) δ 9.14 (2H, br s, NHB2 B, ex) 7.37 (2H, d, J = 7.9, ArH) 7.21 (2H, d, J = 8.3, 
ArH) 6.16 (2H, br s, NHB2 B, ex) 2.37 (3H, s, CHB3 B) 1.88-0.88 (m, 10H, (CHB2 B) B5B) ppm; 
CB15 BHB21BNB5 B.HCl, (Found C, 57.59; H, 7.00; N, 22.01); M-HP+P 271.9. 
 





Yield 30.6 %; mp 248.250 Po PC; λBmax B (methanol) = 243.4 nm; IR (KBr disc) 3298 (νBN-H B); 
3140 (νBC-H, aromatic B); 2932 (νBC-H, aliphatic B); 1640 (νBC=NB); 1555 (νBC BU···UBC B, BaromaticB);1278 (νBC-OB) cmP-
P1; 1H NMR (DMSO-dB6 B) δ 9.00 (2H, br s, NHB2 B, ex) 7.53-7.49 (1H, t, J = 8.6, ArH) 7.26 
(2H, q, J = 7.9, ArH) 7.11-7.09 (1H, t, J = 7.5, ArH) 6.29 (2H, br s, NHB2 B, ex) 3.80 (3H, 
s, Ar-OCHB3 B) 1.99-0.95 (m, 10H, (CHB2 B) B5B) ppm; CB15 BHB21BNB5 BO.HCl, (Found C, 55.71; H, 




Yield 31.6 %; mp 231-233 Po PC; λBmax B (methanol) = 244.6 nm; IR (KBr disc) 3312 (νBN-H B); 
3141 (νBC-H, aromatic B); 2826 (νBC-H, aliphatic B); 1665 (νBC=NB); 1553 (νBC BU···UBC B, BaromaticB); 1270 (νBC-OB) 
cmP-1 P; P1 PH NMR (DMSO-dB6B) δ 9.22 (2H, br s, NHB2 B, ex) 7.47-7.42 (1H, t, J = 8.7, ArH) 
7.10 (1H, d, J = 9.0, ArH) 6.86 (2H, d, J = 7.2, ArH) 6.25 (2H, br s, NHB2 B, ex) 3.80 (3H, 
s, Ar-OCHB3 B) 1.92-0.91 (m, 10H, (CHB2 B) B5B) ppm; CB15 BHB21BNB5 BO.HCl, (Found C, 54.99; H, 




Yield 45.5 %; mp 288-289 Po PC; λBmax B (methanol) = 244.4 nm; IR (KBr disc) 3293 (νBN-H B); 
3144 (νBC-H, aromatic B); 2938 (νBC-H, aliphatic B); 1640 (νBC=NB); 1557 (νBC BU···UBC B, BaromaticB); 1249 (νBC-OB) 
cmP-1 P; P1 PH NMR (DMSO-dB6B) δ 9.14 (2H, br s, NHB2 B, ex) 7.25 (2H, d, J = 8.6, ArH) 7.06 
(2H, d, J = 8.3, ArH) 6.21 (2H, br s, NHB2 B, ex) 3.80 (3H, s, Ar-OCHB3 B) 1.88-1.24 (m, 
10H, (CHB2 B) B5 B) ppm; CB15 BHB21BNB5 BO.HCl, (Found C, 55.75; H, 6.61; N, 21.14); M-HP+P 288.3. 





Yield: 25.1%; mp: 219–220.8 °C; λ Bmax B (methanol): 243.8 nm; IR (KBr disc): 3298  
(νBN–HB), 3139 (νBC–H, aromatic B), 2970 (νBC–H, cyclopentaneB), 1645 (νBC=NB), 1600 (νBC BU···UBC, aromaticB) cmP-1P; 
P
1
PH NMR (DMSO-d B6 B): δ 9.36 (2H, br s, NHB2 B), 7.80–7.33 (4H, m, ArH), 6.64 (2H, br s, 
NHB2 B), 2.01–1.24 (8H, m, Cyclopentyl) ppm; CB13 BHB16 BNB5 BCl.HCl, (Found C, 49.74; H, 




Yield: 5.6%; mp: 201.2–203.1 °C; λ Bmax B (methanol): 245.2 nm; IR (KBr disc): 3301 
(νBN–HB), 3143 (νBC–H, aromatic B), 2967 (νBC–H, cyclopentaneB), 1647 (νBC=NB), 1604(ν BC BU···UBC, aromaticB) cmP-1 P; 
P
1
PH NMR (DMSO-d B6 B): δ 9.39 (2H, br s, NHB2 B), 7.61–7.07 (4H, m, ArH), 6.57 (2H, br s, 
NHB2 B), 1.83–1.49 (8H, m, Cyclopentyl) ppm; CB13 BHB16 BNB5 BCl.HCl.(HB2BO) B0.5 B, (Found C, 




Yield: 34.7%; mp: 222.8–224.3 °C; λ Bmax B (methanol): 245.2 nm; IR (KBr disc): 3293 
(νBN–HB), 3131 (νBC–H, aromatic B), 2972 (νBC–H, cyclopentaneB), 1640 (νBC=NB), 1599 (νBC BU···UBC, aromaticB) cmP-1P; 
P
1
PH NMR (DMSO-d B6 B): δ 9.39 (2H, br s, NHB2 B), 7.61–7.41 (4H, m, ArH), 6.53 (2H, br s, 
NHB2 B), 1.82–1.48 (8H, m, Cyclopentyl) ppm; CB13 BHB16 BNB5 BCl.HCl, (Found C, 49.88; H, 
6.06; N, 22.07); M-HP+P 278.3 [280.1] (3:1). 
 
 





Yield: 27.4%; mp: 221.7–223.5 °C; λ Bmax B (methanol): 244.0 nm; IR (KBr disc): 3297 
(νBN–HB), 3135 (νBC–H, aromatic B), 2968 (νBC–H, cyclopentaneB), 1644 (νBC=NB), 1596 (νBC BU···UBC, aromaticB) cmP-1P; 
P
1
PH NMR (DMSO-d B6 B): δ 9.28 (2H, br s, NHB2 B), 7.46–7.32 (4H, m, ArH), 6.34 (2H, br s, 
NHB2 B), 2.22 (s, 3H, CHB3 B), 1.67–1.28 (8H, m, Cyclopentyl) ppm; CB14 BHB19 BNB5 B.HCl, (Found 




Yield: 8.6%; mp: 213.3–213.9 °C; λ Bmax B (methanol): 245.0 nm; IR (KBr disc): 3301 
(νBN–HB), 3138 (νBC–H, aromatic B), 2975 (νBC–H, cyclopentaneB), 1643 (νBC=NB), 1597 (νBC BU···UBC, aromaticB) cmP-1P; 
P
1
PH NMR (DMSO-d B6 B): δ 9.34 (2H, br s, NHB2 B), 7.45–7.13 (4H, m, ArH), 6.28 (2H, br s, 
NHB2 B), 2.37 (s, 3H, CHB3 B), 1.83–1.50 (8H, m, Cyclopentyl) ppm; CB14 BHB19 BNB5 B.HCl, (Found 




Yield: 19.0%; mp: 208.9–211.0 °C; λ Bmax B (methanol): 245.2 nm; IR (KBr disc): 3292 
(νBN–HB), 3134 (νBC–H, aromatic B), 2971 (νBC–H, cyclopentaneB), 1638 (νBC=NB), 1593 (νBC BU···UBC, aromaticB) cmP-1P; 
P
1
PH NMR (DMSO-d B6 B): δ 9.21 (2H, br s, NHB2 B), 7.66–7.23 (4H, m, ArH), 6.29 (2H, br s, 
NHB2 B), 2.37 (s, 3H, CHB3 B), 1.81–1.47 (8H, m, Cyclopentyl) ppm; CB14 BHB19 BNB5 B.HCl, (Found 
C, 57.25; H, 6.34; N, 23.48); M-HP+P 258.3. 
 
 





Yield: 14.5%; mp: 221.1–222.3 °C; λ Bmax B (methanol): 243.2 nm; IR (KBr disc): 3292 
(νBN–HB), 3162 (νBC–H, aromatic B), 2962 (νBC–H, cyclopentaneB), 1637 (νBC=NB), 1586 (ν BC BU···UBC, aromaticB), 
1236 (νBC-OB) cmP-1 P; P1 PH NMR (DMSO-dB6B): δ 9.31 (2H, br s, NHB2 B), 7.52–7.04 (4H, m, 
ArH), 6.39 (2H, br s, NHB2 B), 3.84 (3H, s, OCHB3 B), 1.86–1.49 (8H, m, Cyclopentyl) ppm; 




Yield: 16.5%; mp: 215.4–216.7 °C; λ Bmax B (methanol): 242.2 nm; IR (KBr disc): 3293 
(νBN–HB), 3135 (νBC–H, aromatic B), 2968 (νBC–H, cyclopentaneB), 1639 (νBC=NB), 1595 (ν BC BU···UBC, aromaticB), 
1255 (νBC-OB) cmP-1 P; P1 PH NMR (DMSO-dB6B): δ 9.33 (2H, br s, NHB2 B), 7.67–7.05 (4H, m, 
ArH), 6.30 (2H, br s, NHB2 B), 3.81 (3H, s, OCHB3 B), 1.80 – 1.46 (8H, m, Cyclopentyl) ppm 
CB14 BHB19BNB5 BO.HCl, (Found C, 54.17; H, 6.16; N, 22.09); M-HP+P 274.3. 
 
9.2.3 General Synthesis of Benzyloximes. P131 
 Compound 22 and compounds 42 to 51 were synthesized from the 
corresponding aryl aldehydes/ketones using modified standard procedure for preparing 
oximes. 0.02 moles of the aryl aldehyde/ketone was reacted with two equivalents of 
hydroxylamine hydrochloride in the presence of 4 equivalents of sodium acetate in 
alcoholic solution at room temperature with stirring. The carbonyl compound was first 
dissolved in 96% ethanol while hydroxylamine hydrochloride and sodium acetate were 
dissolved in water and ethanol solution (2:1). The hydroxylamine hydrochloride 
solution was then added drop wise to the solution of aryl aldehyde/ketone with 
MATERIALS AND METHODS 
_____________________________________________________________________ 
 124
continued stirring, and the reaction was monitored using Thin Layer Chromatography 
(TLC).Except for compounds 46, 48, 49 and 50,where the products precipitated out 
from the reaction mixture, the products were extracted with ether. Anhydrous sodium 
sulphate was used to dry the combined ether layers. The products remained as liquid 
after evaporation of ether under vacuum and solidified after being kept in the fridge for 
at least one day. Recrystallisation was carried out using 96% ethanol and/or distilled 
water. All crystals were collected by suction filtration, washed with ice-cold 
ethanol/water (1:9) solution and dried in the vacuum oven. Compound 45 was purified 
by passing through a flash column.  
 
4’-Fluoro benzyloxime (22) 
Yield  41.1%; mp 88-90 Po PC (88.5 PoPC) P132 P; λBmax B (methanol) = 251.8 nm; IR (KBr disc) 
3263 (νBOH B, str); 1596 (νBC=NB, str)  cmP-1 P; P1PH NMR (DMSO-d B6 B) δ 11.24 (1H, s, NOH, ex) 
8.15 (1H, s, C(NOH)H) 7.68-7.20 (4H, m, ArH) ppm; M-HP+P 140.1. 
 
4’-Trifluoromethyl benzyloxime (42) 
Yield 60.2 %; mp 103-104 Po PC (100-101.5 PoPC) P133 P; λBmax B (methanol) = 256.2 nm; IR 
(KBr disc) 3295 (νBOH B, str); 1618 (νBC=NB, str)  cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 11.62 (1H, s, 
NOH, ex) 8.26 (1H, s, C(NOH)H) 7.82 (2H, d, J = 8.3, ArH) 7.76 (2H, d, J = 8.3, ArH) 
ppm; M-HP+P 174.1. 
 
4’-Methoxy benzyloxime (43) 
Yield 43.5 %; mp 62-64 Po PC (63-64 Po PC) P134 P; λBmax B (methanol) = 267.0 nm; IR (KBr disc) 
3212 (νBOH B, str); 1608 (νBC=NB, str)  cmP-1 P; P1PH NMR (DMSO-d B6 B) δ 10.95 (1H, s, NOH, ex) 
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8.06 (1H, s, C(NOH)H) 7.52 (2H, d, J = 9.0, ArH) 6.96 (2H, d, J = 8.7, ArH) 3.78 (3H, 
s, OCHB3 B) ppm; M-HP+P 152.1. 
 
2’,3’-Dimethoxy benzyloxime (44) 
Yield 80.1 %; mp 97-99 Po PC (98-99 Po PC) P132 P; λBmax B (methanol) = 300 nm; IR (KBr disc) 
3219 (νBOH B, str); 1577 (νBC=NB, str)  cmP-1 P; P1PH NMR (CDCl B3 B) δ 8.65 (1H, s, NOH, ex) 8.5 
(1H, s, C(NOH)H) 7.35-6.92 (3H, m, ArH) 3.86 (6H, s, OCHB3 B) ppm; M-HP+P 182.1. 
 
4’-Buthoxy benzyloxime (45) 
Yield 32.4 %; mp 57-60 Po PC; λBmax B (methanol) = 267.0 nm; IR (KBr disc) 3256 (νBOH B, str); 
1605 (νBC=NB, str)  cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 10.94 (1H, s, NOH, ex) 8.05 (1H, s, 
C(NOH)H) 7.50 (2H, d, J = 8.7, ArH) 6.94 (2H, d, J = 8.7, ArH)  4.00-3.96 (2H, t, CHB2 B) 
1.74-1.65 (2H, m, CHB2 B) 1.49-1.37 (2H, m, CHB2 B) 0.96-0.91 (3H, t, CHB3 B) ppm; 
CB11 BHB15BNOB2 B, (Found C, 68.51; H, 7.97; N, 7.26); M-HP+P 194.1. 
 
4’-Cyano benzyloxime (46) 
Yield 41.2 %; mp 162-164 Po PC; λBmax B (methanol) = 272.0 nm; IR (KBr disc) 3249 (νBOH B, 
str); 1605 (νBC=NB, str)  cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 11.73 (1H, s, NOH, ex) 8.24 (1H, s, 
C(NOH)H) 7.86 (2H, d, J = 8.3, ArH) 7.72 (2H, d, J = 8.3, ArH) ppm; CB8 BHB6 BNB2 BO, 
(Found C, 65.75; H, 4.05; N, 19.21); M-HP+P 131.1. 
 
4’-Nitro benzyloxime (47) 
Yield 56.4 %; mp 128-131Po PC (133 Po PC) P132 P; λBmax B (methanol) = 304.0 nm; IR (KBr disc) 
3304 (νBOH B, str); 1538 (νBC=NB, str)  cmP-1 P; P1PH NMR (DMSO-d B6 B) δ 11.85 (1H, s, NOH, ex) 
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8.31 (1H, s, C(NOH)H) 8.26 (2H, d, J = 7.1, ArH) 7.86 (2H, d, J = 7.2, ArH) ppm; M-
HP+P 165.1. 
 
3’-Aminophenyl-methyl ketoxime (48) 
Yield 75.6 %; mp 148-151 Po PC (149-151 PoPC) P135 P; λBmax B (methanol) = 305.6 nm; IR (KBr 
disc) 3361 (νBOH B, str); 1580 (νBC=NB, str)  cmP-1 P; P1 PH NMR (DMSO-dB6 B) δ 10.97 (1H, s, NOH, 
ex) 7.03-6.53 (4H, m, ArH) 5.08 (2H, br, NHB2 B, ex) 2.07 (3H, s, CHB3 B) ppm; M-HP+P 151.1. 
 
4’-Aminophenyl-methyl ketoxime (49) 
Yield 81.6 %; mp 144-147 Po PC (150-152 PoPC) P136 P; λBmax B (methanol) = 277.4 nm; IR (KBr 
disc) 3350 (νBOH B, str); 1605 (νBC=NB, str)  cmP-1 P; P1 PH NMR (DMSO-dB6 B) δ 10.60 (1H, s, NOH, 
ex) 7.32 (2H, d, J = 8.7, ArH) 6.53 (2H, d, J = 8.6, ArH) 5.26 (2H, br, NHB2 B, ex) 2.04 
(3H, s, CHB3 B) ppm; M-HP+P 151.1. 
 
4’-Aminophenyl-ethyl ketoxime (50) 
Yield 78.2 %; mp 83-86 Po PC; λBmax B (methanol) = 278.4 nm; IR (KBr disc) 3396 (νBOH B, str); 
1604 (νBC=NB, str)  cmP-1 P; P1 PH NMR (DMSO-d B6 B) δ 10.54 (1H, s, NOH, ex) 7.32 (2H, d, J = 
8.6, ArH) 6.53 (2H, d, J = 8.7, ArH)   5.26 (2H, br, NHB2 B, ex) 2.64-2.59 (2H, q, J=7.53, 
CHB2 B) 1.03-0.98 (3H, t, CHB3 B) (2H, t, CHB2 B)  (3H, d, CHB2 B) ppm; CB9 BHB12 BNB2 BO, (Found C, 
65.81; H, 7.48; N, 17.35); M-HP+P 165.1. 
 
Phenylethyl ketoxime (51) 
Yield 46.0 %; mp 53-55 Po PC (53 PoPC) P137 P; λBmax B (methanol) = 244.5 nm; IR (KBr disc) 
3204 (νBOH B, str); 1466 (νBC=NB, str)  cmP-1 P; P1PH NMR (DMSO-d B6 B) δ 11.11 (1H, s, NOH, ex) 
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7.65-7.37 (5H, m, ArH) 2.75-2.68 (2H, q, J=7.53, CHB2 B) 1.07-1.02 (3H, t, CHB3 B) ppm; 
M-HP+P 150.1. 
 
9.3 Pharmacological Assays 
9.3.1 Sodium Channel Binding Assay   
The assay method was modified from that reported by Brown et. al.P43P 
Synaptoneurosomes for the assay were obtained from Sprague-Dawley rat cerebral 
cortex. These experiments were carried out within the appropriate institutional 
guidelines for animal experiments. The cerebral cortex (grey matter) was extracted 
from the rat brain by separating the white matter and other subcortical structures. The 
tissue (about 1 g) was then homogenized in 2 ml of incubation buffer using 10 full 
strokes of a low-speed Teflon-glass homogeniser. The incubation buffer was made up 
of 130 mM choline chloride, 50 mM HEPES, 5.5 mM glucose, 0.8 mM MgSOB4 B and 
5.4 mM KCl adjusted to pH 7.4 using Tris base. The tissue preparation was then 
centrifuged at 1000 g for 30 minutes at 4 Po PC. The pellet was resuspended in a total 
volume of 20 ml of the incubation buffer and homogenised. The suspension was gently 
filtered through a 160 µm stainless steel mesh and then through a Whatman #4 filter 
paper using house vacuum. The filtrate was centrifuged at 1000 g for 30 minutes at 4 
P
o
PC. The pellet was then resuspended with 2 ml of isotonic sucrose solution, which 
contained 10 mM NaHB2 BPOB4 B and 0.32 mM sucrose at pH 7.4 (Tris base). The isotonic 
solution was stored in a freezer at -70P o PC until the assay was performed. Prior to the 
binding assay, the tissue was thawed, the suspension centrifuged at 1000 g for 30 
minutes at 4P o PC and the pellet resuspended in the incubation buffer. The compounds 
were tested at 5 different concentrations to obtain the ICB50 B value. The appropriate 
amount of test drug was dissolved in DMSO and topped up with incubation buffer. 50 
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µl of this drug solution contained 45 µl of buffer. The incubation mixture consisted of 
10 nM [P3 PH] BTX, 50 µg /ml scorpion venom, 100 µl of synaptoneurosomes from rat 
cerebral cortex (approximately 1 mg of protein), 5 µl of DMSO, and top up with 
incubation buffer to 300 µl. 
The mixture was incubated for 30 minutes at 37 Po PC. The incubation was 
terminated by dilution with 3 ml of ice-cold wash buffer, which contained 130 mM 
choline chloride, 1.8 mM CaCl B2 B, 0.8mM MgSOB4 B, 1 mg/mL of bovine serum albumin, 
and 5 mM of HEPES at pH 7.4 (using Tris base). The mixture was then filtered 
through Whatman GF/B filter paper and the filters washed 2 times with ice-cold wash 
buffer (2 x 3 ml). The filters were left to stand overnight with liquid scintillant 
(NBCS104 from BCS) and were counted in a Beckman scintillation counter. Specific 
binding was determined by subtracting the nonspecific binding, which was measured 
in the presence of 300 µM veratridine, from the total binding of [P3 PH]-BTX. The ICB50B 
values were determined from Prism 3, using one-site competition non-linear regression. 
 
9.3.2 MES and Rotarod Test 
 The MES test was carried out using the UGO BASILE ECT Unit 7801. 
Neurotoxicity was assessed using the UGO BASILE Accelerating Rota-Rod (Jones 
and Roberts) 7650. Animals used in the test were adult male and female Swiss albino 
mice (20-28 g). These experiments were carried out within the appropriate institutional 
guidelines for animal experiments. 
 The mice were subjected to rotarod screening before the tests were commenced. 
They were placed on the accelerating rotarod treadmill, which was accelerated from 4 
to 40 rpm over 5 minutes. Mice which were able to stay on the rotating rod for at least 
5 minutes passed the screening test and were subsequently used for the MES test. 
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 Since most of the compounds were sparingly soluble in water, 
dimethylsulphoxide (DMSO) was used as solvent. The drug solutions were injected 
intraperitoneally (IP) at 5 ml/kg body weight of the mice. The phenyldihydro-1,3,5-
triazines were tested at dose levels of 25 mg/kg and 50 mg/kg, while the benzyloximes 
were tested from 50 mg/Kg to 200mg/Kg. 
 The mice were subjected to the rotarod test to assess the neurotoxicity of the 
drugs 15 minutes after injection. Measurements were reported as the time (in seconds) 
at which the mice fell from the rotating rod with 300 seconds (5 minutes) as the cut-off 
time. 15 minutes after the rotarod test (i.e. 30 minutes after drug administration), the 
mice were shocked with auricle electrodes using a 100 Hz alternating current at 45 mA, 
0.2 ms in width, delivered for 0.4 s. The anticonvulsant protection was evaluated by an 
arbitrary scoring system of 1 to 4, where 1 = no protection; 2 = tonic extension of the 
hind limbs was abolished; 3 = both hind limbs extension and tonic flexor stage were 
abolished; 4 = full protection with no apparent seizure activity. For each drug 
substance at each dose level, 4 mice were used for the animal testing.  
 
9.3.3 Hot-plate assay P138 
Adult, male Swiss albino mice (20-28 g) were used for this study. These 
experiments were carried out within the appropriate institutional guidelines for animal 
experiments. The mice were randomly divided into groups of eight animals each. One 
group of mice was used as a control, and was injected (via the i.p. route) with the drug 
vehicle (DMSO), while the other groups were injected (via the i.p. route) with the test 
compounds at a specified dose. Each animal was placed on a heated surface that was 
maintained at 55 ± 0.5 °C, and monitored until it either licked it front paws or jumped. 
Latency time, the time interval between the placement of the animal on the hotplate 
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and the reaction to heat, was recorded. Tissue damage was prevented by setting the 
cut-off time of 45 seconds for the test duration. Data analysis was performed using 
one-way analysis of variance (ANOVA). 
 
9.3.4 DHFR Inhibition Assay 
 Phosphate buffer (0.15 M, pH 7) was used for all of the DHFR assays and was 
prepared by dissolving potassium dihydrogen orthophosphate (10.21 g) in distilled 
water (ca 300 ml) adjusting the solution to pH 7 with potassium hydroxide (2 M) and 
diluting to 500 ml with distilled water. The buffer was kept at 4 Po PC and discarded after 
3 days. 2- Mercaptoethanol solution (0.25 M) was prepared by dissolving 2-
mercaptoethanol (1.75 ml) in distilled water to 100 ml. The solution was stored in a 
tinted bottle at 4P o PC prior to use. An aqueous solution of NADPH (2 mg/ml, 2 mM) 
was prepared immediately prior to use by dissolving 2 mg in 1 ml of the phosphate 
buffer. A solution of dihydrofolate (DHF) (1mg/ml, 2 mM) was also prepared 
immediately before use by suspending 1 mg of DHF in about 0.8 ml of the 2-
mercaptoethanol solution and adding 0.2 ml of sodium hydroxide (2 M) solution drop 
wise until dissolution had occurred. The solution was protected from light and 
maintained at 0Po PC. 
  The assay was performed in the Shimadzu UV-160A UV-visible Recording 
Spectrophotometer using the kinetics mode. The assay was conducted by mixing the 
appropriate volumes of phosphate buffer, NADPH, DHF, bovine liver DHFR and 
inhibitor in the quartz cuvette (Table 6). The temperature of the phosphate buffer was 
maintained at 37P o PC using a water bath. Rate of consumption of NADPH at 340 nm 
during the conversion of dihydrofolic acid to tetrahydrofolic acid was monitored by the 
reduction in the absorbance of the reaction mixture. The kinetics mode of the 
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spectrophotometer automatically generates the absorbance versus time graph and 
calculates the gradient of the slope (a measure of enzyme activity). Each run time w
4 minutes and the absorbance was recorde
as 
d at 10 second intervals by the software. 
otal inhibition of DHFR was indicated by an insignificant change in the rate of 
hibition would be seen when the rate of 
T
consumption of NADPH and no in
consumption of NADPH was equal to that of the uninhibited enzyme. The percentage 
activity of each inhibitor was calculated by the following formulae:- 
(i) Activity =  Slope of inhibited enzyme      x 100 % 
 
-2
                              Slope of uninhibited enzyme 
(ii) Inhibition = 100 % - % Activity 
 
For each inhibitor, the assay was first carried out at an inhibitor concentration 
of 1000 µM. A 30 mM solution of the inhibitor was prepared by dissolving 3 x 10  
moles of the inhibitor in 1 ml of distilled water. 0.1 ml of this solution was used for the 
assay. Thus the inhibitor concentration in the assay mixture was 1000 µM. Subsequent 
assays were carried out with serial dilution (10-100x dilution) of the inhibitor solution 
until an inhibition of less than 40% was achieved. 3 to 4 different inhibitor 
concentrations were tested to provide sufficient data points for the percentage 
inhibition against logarithmic concentration graph. IC50 values for the different 













MATERIALS AND METHODS 
_____________________________________________________________________ 



















0.1 0.1 0.1 2.7 - 3.0 
Inhibited 
enzyme 
















1. DiMasi, J. A.; Hansen, R. W.; Grabowski, H. G. The price of innovation: new 
estimate
Musta
s o elo sts. J. Health Ec 3, 8
2. ta, G. I gs, J. M tructure-based design approach for the 
tion vel inhibitors: application to an alanine racema . J. Com
ol. Des.  2003, 16(12), 935-953. 
3 .; Ch P.; Path . P.; Mo mery, J. A. Structure-based design of 
rs of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines. J. Med. 
Chem. 1994, 37, 2477-2480. 
4. Tantillo, C.; Ding, J. P.; Jacobo-Molina, A.; Nanni, R. G.; Boyer, P. L.; Hughes, S. 
H.; Pauwels, R. Andries, K.; Janssen, P. A.; Arnold, E. Locations of anti-AIDS 
drug binding sites and resistance mutations in the three-dimensional structure of 
HIV-1 reverse transcriptase-implications for mechanisms of drug inhibition and 
resistance. J. Mol. Biol. 1994, 243, 369-387. 
5. Tollinger, M.; Eichmuller, C.; Konrat, R.; Huhta, M. S.; Marsh, E. N. G.; Krautler, 
B. The B12-Binding Subunit of Glutamate Mutase from Clostridium 
Tetanomorphum Traps the Nucleotide Moiety of Coenzyme B12. J.Mol.Biol. 2001, 
309, 777-791. 
 Spadola, L.; Novellino, E.; Folkers, G.; Scapozza, L. Homology modelling and 
docking studies on Varicella Zoster Virus Thymidine kinase. Eur. J. Med. Chem. 
2003, 38(4), 413-419.    
. Lewis, D. F. V.; Lake, B. G.; Bird, M. G.; Loizou, G. D.; Dickins, M.; Goldfarb, P. 
S. Homology modelling of human CYP2E1 based on the CYP2C5 crystal 
structure: investigation of enzyme-substrate and enzyme-inhibitor interactions. 





on. 200 35, 1-35. 
identifica
Aided M
of no se put. 
. Niwas, S
inhibito






8. Shoichet, B. K.; Bodian, D. L.; Kuntz, I. D. Molecular docking using shape 
descriptors. J. Comp. Chem. 1992, 13(4), 505-524. 
9. Oshiro, C. M.; Kuntz, I. D.; Dixon, J. S. Flexible ligand docking using a
algorithm. J. Comput. Aided. Mol. Des. 1995, 9(2), 113-130. 
 Jones, G.; Willet, P. Glen, R. C. Molecula
 genetic 
10. r recognition of receptor sites using a 
11. . 
 inhibitors by Monte Carlo ligand generation. J. Med. 
12. 7, 
13. . 
r antagonists. Eur. J. Med. Chem. 
14. e ensemble 
(6), 899-906. 
del 
 Mol. Des. 2002, 16(4), 273-286. 
99. 
17.
lase catalysed oxirane ring opening: a 3D 
QSAR Study. J. Comput. Aided Mol. Des. 2003, 17(1), 1-11. 
genetic algorithm with a description of solvation. J. Mol. Biol. 1995, 245, 43-53. 
 Gehlhaar, D. K.; Moerder, K. E.; Zichi, D.; Sherman, C. J.; Ogden, R. C.; Freer, S
T. De novo design of enzyme
Chem. 1995, 38, 466-472. 
 Marshall, G. R. Computer-aided drug design. Ann. Rev. Pharmacol. Toxicol. 198
27, 193-213. 
 Naruto, S.; Motoc, I., Marshall, G. R. Computer-assisted analysis of bioactivity. I
Active conformation of histamine H1 recepto
1985, 20(6), 529-532. 
 Sheridan, R. P.; Nilakantan, R.; Dixon, J. S.; Venkataraghavan, R. Th
approach to distance geometry: application to the nicotinic pharmacophore. J. Med. 
Chem. 1986, 29
15. Poulsen, A.; Liljefors, T.; Gundertofte, K.; Bjornholm, B. A pharmacophore mo
for NK2 antagonist comprising compounds from several structurally diverse 
classes. J. Comput. Aided
16. Tsakovska, I. M. QSAR and 3D-QSAR of phenothiazine type multidrug resistance 
modulators in P388/ADR cells. Bioorg. Med. Chem. 2003, 11(13), 2889-28
 Paier, J.; Stockner, T.; Steinreiber, A.; Faber, K.; Fabian, W. M. F. 





18. Parrill, A. L. Evolutionary algorithms in computer-aided molecular design. Drug 
Discovery Today. 1996, 1(12), 514-521. 
19. Hou, T.; Xu, X. A new molecular simulation software package - Peking University 
Drug Design System (PKUDDS) for structure-based drug design. J. Mol. Graphics 
Modell. 2001, 19(5), 455-465. 
20. Gogonea, V. The QM/MM method. An overview. Internet Electron. J. Mol. Des. 
2002, 1, 173-184, HTUhttp://www.biochempress.comUTH. 
21. Morgan, K.; Stevens, E. B.; Shah, B.; Cox, P. J.; Dixon, A. K.; Lee, K.; Pinnock, 
R. D.; Hughes, J.; Richardson, P. J.; Mizuguchi, K.; Jackson, A. P. β3: An 
additional  auxiliary subunit of the voltage-sensitive sodium channel that 
modulates channel gating with distinct kinetics. Proc. Natl. Acad. Sci. U. S. A. 
2000, 97, 2308-2313. 
22. Wann, K. T. Neuronal sodium and potassium channels: structure and function. Br. 
J. Anaesth. 1993, 71(1), 2-14. 
23. Catterall, W. A. Structure and function of voltage-gated ion channels. Annu. Rev. 
Biochem. 1995, 64, 493-531. 
24. Anger, T.; Madge, D. J.; Mulla, M.; Riddall, D. Medicinal chemistry of neuronal 
voltage-gated sodium channel blockers. J. Med. Chem. 2001, 44(2), 115-137. 
25. McPhee, J. C.; Ragsdale, D. S.; Scheuer, T.; Catterall, W. A. A mutation in 
segment IVS6 disrupts fast inactivation of sodium channels. Proc. Natl. Acad. Sci. 
U.S.A. 1994, 91, 12346-12350. 
26. Linford, N. J.; Catterall, A. R.; Qu, Y. S.; Scheuer, T.; Catterall, W. A. Interaction 
of batrachotoxin with the local anesthetic receptor site in transmembrane segment 





27. Willow, M.; Catterall, W. A. Inhibition of binding of [P3 PH]batrachotoxinin A 20-α-
benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and 
carbamazepine. Mol. Pharmacol. 1982, 22, 627-635. 
28. Maillard, M. C.; Perlman, M. E.; Amitay, O.; Baxter, D.; Berlove, D.; 
Connaughton, S.; Fischer, J. B.; Guo, J. Q.; Hu, L.; McBurney, R. N.; Nagy, P. I.; 
Subbarao, K.; Yost, E. A.; Zhang, L.; Durant, G. J. Design, Synthesis, and 
Pharmacological evaluation of conformationally constrained analogs of N,N'-
Diaryl- and N-Aryl-N-aralkylguanidines as potent inhibitors of neuronal Na+ 
channels. J. Med. Chem. 1998, 41(16), 3048-3061. 
29. Leong, D.; Bloomquist, J. R.; Bempong, J.; Dybas, J. A.; Kinne, L. P.; Lyga, J. W.; 
Marek, F. L.; Nicholson, R. A. Insecticidal arylalkylbenzhydrolpiperidines: novel 
inhibitors of voltage-sensitive sodium and calcium channels in mammalian brain. 
Pest Manag. Sci. 2001, 57(10), 889-895. 
30. Deffois, A.; Fage, D.; Carter, C. Inhibition of synaptosomal veratridine-induced 
sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci. 
Lett. 1996, 220(2), 117-120. 
31. Haeseler, G.; Tetzlaff, D.; Bufler, J.; Dengler, R.; Munte, S.; Hecker, H.; Leuwer, 
M. Blockade of voltage-operated neuronal and skeletal muscle sodium channels by 
S(+)- and R(-)-ketamine. Anesth. Analg. 2003, 96(4), 1019-26, 
32. Grolleau, F; Gamelin, L; Boisdron-Celle, M; Lapied, B; Pelhate, M; Gamelin, E. A 
possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on 
neuronal voltage-gated sodium channels. J. Neurophysiol. 2001, 85(5), 2293-7. 
33. White, H. S.; Woodhead, J. H.; Franklin, M. R.; Swinyard, E. A.; Wolf, H. H. In 
Antiepileptic Drugs, 4Pth P ed.; Levy, R. H., Mattson, R. H., Meldrum, B. S., Eds; 




34. Porreca, F.; Mosberg, H. I.; Omnaas, J. R.; Burks, T. F.; Cowan, A. Supraspinal 
and spinal potency of selective opioid agonists in the mouse writhing test. J. 
Pharmacol. Exp. Ther. 1987, 240(3), 890-4. 
35. Steinlein, O. K. Channelopathies can cause epilepsy in man. Eur. J. Pain. 2002, 6 
Suppl, A27-34. 
36. Wallace, R. H.; Wang, D. W.; Singh, R.; Scheffer, I. E.; George, A. L.; Phillips, H. 
A.; Saar, K.; Reis, A.; Johnson, E. W.; Sutherland, G. R.; Berkovic, S. F.; Mulley, 
J. C. Febrile seizures and generalised epilepsy associated with a mutation in the 
Na+ channel‚1 subunit gene SCN1B. Nat. Genet. 1998, 19, 366-370. 
37. Escayg, A.; Macdonald, B. T.; Meisler, M. H.; Baulac, S.; Huberfeld, G.; An-
Gourfinkel, I.; Brice, A.; LeGuern, E.; Moulard, B.; Chaigne, D.; Buresi, C.; 
Malafosse, A. Mutations of SCN1A, encoding a neuronal sodium channel, in two 
families with GEFS+. Nat. Genet. 2000, 24, 343-345. 
38. Brouilette, W. J.; Brown, G. B.; DeLorey, T. M.; Liang, G. Sodium channel 
binding and anticonvulsant activities of hydantoins containing conformationally 
constrained 5-phenyl substituents. J. Pharm. Sciences 1990, 79(10), 871-874. 
39. Brouilette, W. J.; Brown, G. B.; DeLorey, T. M.; Shirali, S. S.; Grunewald, G. L. 
Anticonvulsant activities of phenyl-substituted bicyclic 2,4-oxazolidinediones and 
monocyclic models. Comparison with binding to the neuronal voltage-dependent 
sodium channel. J. Med. Chem. 1988, 31, 2218-2221. 
40. Brouillette, W. J.; Jestkov, V. P.; Brown, M. L.; Akhtar, M. S.; DeLorey, T. M.; 
Brown, G. B. Bicyclic hydantoins with a bridgehead nitrogen. Comparison of 
anticonvulsant activities with binding to the neuronal voltage-dependent sodium 
channel. J. Med. Chem. 1994. 37, 3289-3293. 
BIBLIOGRAPHY 
_____________________________________________________________________ 
41. Scholl, S.; Koch, A.; Henning, D; Kempter, G.; Kleinpeter, E. The influence of 
structure and lipophilicity of hydantoins derivatives on anticonvulsant activity
Struct. Chem. 1999, 10(5), 355-366. 
. 
44. earmonth, D. 




yptamine uptake in rats. Eur. 
48.
42. Boucher, B. A. Fosphenytoin: a novel phenytoin prodrug. Pharmacotherapy 1996, 
16(5), 777-91. 
43. Brown, M. L.; Zha, C. C.; Van Dyke, C. C.; Brown, G. B.; Brouillette, W. J. 
Comparative Molecular Field Analysis of hydantoins Binding to the neuronal 
voltage-dependent sodium channel. J. Med. Chem. 1999, 42, 1537-1545. 
 Benes, J.; Parada, A.; Figueiredo, A. A.; Alves, P. C.; Freitas, A.P.; L
A.; Cunha, R. A.; Garrett, J.; Soares-da-Silva, P. Anticonvulsant and sodium 
channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-
carboxamide derivative. J. Med. Chem. 1999, 42, 2582-2587. 
 Sun, L.; Lin, S. S. The anticonvulsant SGB-017 (ADC
sodium channels in rat and human neurons: comparison with carbamazepine.
Epilepsia 2000, 41(3), 263-270. 
 Lang, D. G.; Wang, C. M.; Cooper, B. R. Lamotrigine, Phenytoin and 
carbamazepine interactions on the sodium current present in N4TG1 mouse 
neuroblastoma cells. J. Pharmacol. Exp. Ther. 1993, 266(2), 829-835. 
 Southam, E.; Kirkby, D.; Higgins, G. A.; Hagan, R. M. Lamotrigine inhibits 
monoamine uptake in vitro and modulates 5-hydroxytr
J. Pharmacol. 1998, 358, 19-24. 
 Oommen, K. J.; Mathews, S. Zonisamide: a new antiepileptic drug. Clin. 





49. Taverna, S.; Sancini, G.; Mantegazza, M.; Franceschetti, S.; Avanzini, G. 
Inhibition of transient and persistent NaP+P current fractions by the new 
anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 1999, 288(3), 960-968. 
50. McLean, M. J.; Bukhari, A. A.; Wamil, A. W. Effects of topiramate on sodium-
dependent action-potential firing by mouse spinal cord neurons in cell culture. 
Epilepsia, 2000, 41(suppl. 1), S21-S24. 
51. Patsalos, P. N. The mechanism of topiramate. Rev. Contemp. Pharmaco. 1999, 
10(3), 147-153. 
52. Rock, D. M.; McLean, M. J.; Macdonald, R. L.; Catterall, W. A.; Taylor, C. P. 
Ralitoline (CI-946) and CI-953 block sustained repetitive sodium action potentials 
in cultured mouse spinal cord neurons and displace batrachotoxin A 20-α-benzoate 
binding in vitro. Epilepsy Res. 1991, 8, 197-203. 
53. Zhu, Y.; Im, W.; Lewis, R. A.; Althaus, J. S.; Cazers, A. R.; Nielsen, J. W.; Palmer, 
J. R.; VonVoigtlander, P. F. Two metabolites of U-54494A: their anticonvulsant 
activity and interaction with sodium channel. Brain Res. 1993, 606, 50-55. 
54. Edafiogho, I. O.; Hinko, C. N.; Chang, H.; Moore, J. A.; Mulsac, D.; Nicholson, J. 
M.; Scott, K. R. Synthesis and anticonvulsant activity of enaminones. J. Med. 
Chem. 1992, 35(15), 2798-2805. 
55. Scott, K. R.; Rankin, G. O.; Stables, J. P.; Alexander, M. S.; Edafiogho, I. O.; 
Farrar, V. A.; Kolen, K. R.; Moore, J. A.; Sims, L. D.; Tonnu, A. D. Synthesis and 
anticonvulsant activity of enaminones. 3. Investigations on 4’-, 3’-, and 2’-
substituted and polysubstituted anilino compounds, sodium channel binding studies, 




56. Erdõ, S. L.; Molnár, P.; Lakics, V.; Bence, J. Z.; Tömösközi, Z. Vincamime and 
vincanol are potent blockers of voltage-gated Na P+P channels. Eur. J. Pharmacol. 
1997. 314, 69-73. 
57. Clark, C. R.; Davenport, T. W. Synthesis and anticonvulsant activity of analogs of 
4-amino-N-(1-phenylethyl)benzamide. J. Med. Chem. 1987, 30(7), 1214-18. 
58. Vamecq, J.; Lambert, D.; Poupaert, J. H.; Masereel, B.; Stables, J. P. 
Anticonvulsant activity and interactions with neuronal voltage-dependent sodium 
channel of analogues of ameltolide. J. Med. Chem.1998, 41(18), 3307-3313. 
59. Vamecq, J.; Bac, P.; Herrenknecht, C.; Maurois, P.; Delcourt, P.; Stables, J. P. 
Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl 
derivatives of the phthalimide pharmacophore. J. Med. Chem. 2000, 43(7), 1311-
1319. 
60. Unverferth, K.; Engel, J.; Höfgen, N.; Rostock, A.; Günther, R.;Lankau, H.; 
Menzer, M.; Rolfs, A.; Liebscher, J.; Müller, B.; Hofmann, H. Synthesis, 
anticonvulsant activity, and structure-activity relationships of sodium channel 
blocking 3-aminopyrroles. J. Med. Chem. 1998, 41(1), 63-73. 
61. Reddy, N. L.; Fan, W.; Magar, S. S.; Perlman, M. E.; Yost, E.; Zhang, L.; Berlove, 
D.; Fischer, J. B.; Burke-Howie, K.; Wolcott, T.; Durant, G. J. Synthesis and 
pharmacological evaluation of N, N’-diarylguanidines as potent sodium channel 
blockers and anticonvulsant agents. J. Med. Chem. 1998, 41(17), 3298-3302. 
62. Hill, M. W.; Reddy, P. A.; Covey, D. F.; Rothman, S. M. Inhibition of voltage-
dependent sodium channels by the anticonvulsant γ-Aminobutyric acid type A 





63. Weiser, T.; Brenner, M.; Palluk, R.; Bechtel, W. D.; Ceci, A.; Brambilla, A.; 
Ensinger, H. A.; Sagrada, A.; Weinrich, M. BIIR 561 CL: A novel combined 
antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors 
and voltage-dependent sodium channels with anticonvulsive and neuroprotective 
properties. J. Pharmacol. Exp. Ther. 1999, 289(3), 1343-1349. 
64. Kuo, C.; Huang, R.; Lou, B. Inhibition of NaP+P current by diphenhydramine and 
other diphenyl compounds: molecular determinants of selective binding to the 
inactivated channels. Am. Soc. Pharmacol. Exp. Ther. 2000, 57, 135-143. 
65. Kelly, J. L.; Koble, C. S.; Davis, R. G.; McLean, E. W.; Soroko, F. E.; Cooper, B. 
R. 1-(Fluorobenzyl)-4-amino-1H-1, 2, 3-triazolo-[4, 5-c]pyridines: Synthesis and 
anticonvulsant activity. J. Med Chem. 1995, 38, 4131-4134. 
66. Rundfeldt, C. The novel anticonvulsant AWD 140-190 acts as a highly use-
dependent sodium channel blocker in neuronal cell preparations. Epilepsy Res. 
1999, 34, 57-64. 
67. Salvati, P.; Maj. R.; Caccia, C.; Cervini, M. A.; Fornaretto, M. G.; Lamberti, E.; 
Pevarello, P.; Skeen, G. A.; White, H. S.; Wolf, H. H.; Faravelli, L.; Mazzanti, M.; 
Mancinelli, E.; Varasi, M.; Fariello, R. G. Biochemical and electrophysiological 
studies on the mechanism of action of PNU-151774E, a novel antiepileptic 
compound. J. Pharmacol. Exp. Ther. 1999, 288(3), 1151-1159. 
68. Snell, L. D.; Claffey, D. J.; Ruth, J. A.; Valenzuela, C. F.; Cardoso, R.; Wang, Z.; 
Levinson, S. R.; Sather, W. A.; Williamson, A. V.; Ingersoll, N. C.; Ovchinnikova, 
L.; Bhave, S. V.; Hoffman, P. L.; Tabakoff, B. Novel structure having antagonist 
actions at both the glycine site of the N-methyl-D-aspartate receptor and neuronal 
voltage-sensitive sodium channels: biochemical, electrophysiological, and 




69. Callaway, J. K. Investigation of AM-36: a novel neuroprotective agent. Clin. Exp. 
Pharmacol. Physiol. 2001, 28(11), 913-918. 
70. Dirnagl, U.; Iadecola, C; Moskowitz, M. A. Pathobiology of ischemic stroke: an 
integrated view. Trends Neurosci. 1999, 22, 391-397. 
71. Fisher, M.; Garcia, J. H. Evolving stroke and the ischemic penumbra. Neurology. 
1996, 47, 884-888. 
72. Niedergaard, M.; Hansen, A. J. Characterization of cortical depolarizations evoked 
in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 1993, 13, 568-574. 
73. Lipton, P. Ischemic cell death in brain neurons. Physiol. Rev. 1999, 79, 1431-1568. 
74. Taylor, C. P.; Narasimhan, L. S. Sodium Channels and Therapy of Central Nervous 
System Diseases. Adv. Pharmacol. 1997, 39, 447-98. 
75. Fung, M. Role of voltage-gated Na+ channels in hypoxia-induced neuronal 
injuries. Clin. Exp. Pharmacol. Physiol. 2000, 27(8), 569-574. 
76. Pratt, J.; Rataud, J.; Bardot, F.; Roux, M.; Blanchard, J. C.; Laduron, P. M.; 
Stutzmann, J. M. Neuroprotective actions of riluzole in rodent models of global 
and focal cerebral ischemia. Neurosci. Lett. 1992, 140(2), 225-230. 
77. Hebert, T.; Drapeau, P.; Pradier, L.; Dunn, R. J. Block of the rat brain IIA sodium 
channel α subunit by the neuroprotective drug riluzole. Mol. Pharmacol. 1994, 
45(5), 1055-1060. 
78. Ashton, D.; Willems, R.; Wynants, J.; Van Reempts, J.; Marrannes, R.; Clincke, G. 
Altered Na+-channel function as an in vitro model of the ischemic penumbra: 
action of lubeluzole and other neuroprotective drugs. Brain Res. 1997, 745(1,2), 
210-221.  
79. De Ryck, M.; Keersmaekers, R.; Duytschaever, H.; Claes, C.; Clincke, G.; Janssen, 




size in a photochemical stroke model in rats. J. Pharmacol. Exp. Thera. 1996, 
279(2), 748-58.   
80. Aronowski, J.; Strong, R.; Grotta, J. C. Treatment of experimental focal ischemia 
in rats with lubeluzole. Neuropharmacology 1996, 35(6), 689-693.  
81. Maiese, K.; TenBroeke, M.; Kue, I. Neuroprotection of lubeluzole is mediated 
through the signal transduction pathways of nitric oxide. J. Neurochem. 1997, 
68(2), 710-4.  
82. Ashton, D.; Willems, R.; Wynants, J.; Van Reempts, J.; Marrannes, R.; Clincke, G. 
Altered Na+-channel function as an in vitro model of the ischemic penumbra: 
action of lubeluzole and other neuroprotective drugs. Brain Res. 1997, 745(1,2), 
210-221. 
83. Koinig, H.; Vornik, V.; Rueda, C.; Zornow, M. H. Lubeluzole inhibits 
accumulation of extracellular glutamate in the hippocampus during transient global 
cerebral ischemia. Brain Res. 2001, 898(2), 297-302. 
84. Gandolfo, C.; Sandercock, P.; Conti, M. Lubeluzole for acute ischaemic stroke. 
Cochrane Database Syst. Rev. 2002, 1, CD001924. 
85. Hainsworth, A. H.; Stefani, A.; Calabresi, P.; Smith, T. W.; Leach, M. J. 
Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and 
calcium channel inhibitor. CNS Drug Rev. 2000, 6(2), 111-134. 
86. Schachter, S. C.; Tarsy, D. Remacemide: current status and clinical applications. 
Expert Opin. Invest. Drugs. 2000, 9(4), 871-83. 
87. McGivern, J. G.; Patmore, L.; Sheridan, R. D.  Actions of the novel 
neuroprotective agent, lifarizine (RS-87476-190), on voltage-dependent sodium 
currents in the neuroblastoma cell line, N1E-115. Br. J. Pharmacol. 1995, 114(8), 




ellular Ca2+ rises and glutamate exocytosis in depolarized rat 
ng, 





 of neuroprotection by Ca2+ 
.1990, 
93. n-Lindholm, C.; 
emia by BIII 890 CL. Proc. Natl. 
94.
 Budd, D. C.; May, G. R.; Nicholls, D. G.; McCormack, J. G.  Inhibition by 
lifarizine of intrac
cerebrocortical synaptosomes and cultured neurons. Br. J. Pharmacol. 1996, 
118(1), 162-166.   
89. McBean, D. E.; Winters, V.; Wilson, A. D.; Oswald, C. B.; Alps, B. J.; Armstro
J. M.    Neuroprotective efficacy of lifarizine (RS-87476) in a simplified rat 
survival model
90. Brown, C. M.; Calder, C.; Linton, C.; Small, C.; Kenny, B. A.; Spedding, M.; 
Patmore, L. Neuroprotective properties of lifarizine compared with those of oth
agents in a mouse model of focal cerebral ischemia. Br. J. Pharmacol. 1995,  
115(8),  14
91. McGivern, J. G.; Patmore, L.; Sheridan, R. D. Effects of the neuroprote
KB-2796, on the voltage-dependent sodium current in mouse neuroblastoma, N1E-
115. Br. J. Pharmacol. (Proc. Suppl.) 1995, 137P. 
92. Pauwels, P. J.; Van Assouw, J. P.; Peeters, L.; Leysen, J. E. Neurotoxic action of
veratridine in rat brain neuronal cultures: mechanism
antagonists nonselective for slow Ca2+ channels. J. Pharmacol. Exp. Ther
255, 1117-1122. 
 Carter, A. J.; Grauert, M.; Pschorn, U.; Bechtel, W. D.; Bartman
Qu, Y.; Scheuer, T.; Catterall, W. A.; Weiser, T. Potent blockade of sodium 
channels and protection of brain tissue from isch
Acad. Sci. U. S. A. 2000, 97(9), 4944-9. 
 Owen, A. J.; Ijaz, S.; Miyashita, H.; Wishart, T.; Howlett, W.; Shuaib, A. 




ischemia: a histological, in vivo microdialysis and behavioural study. Brain 
1997, 770(1,2), 115-122. 




nal damage after global ischemia in the gerbils. Neurosci. Lett. 
96.  Ca2+- 
97.
sory 
, Suppl. 6, S133-S140. 
100 nticonvulsants in neuropathic pain: rationale and clinical 
101 2-
tamides 
2000, 281(2,3), 183-186. 
 Okuyama, K.; Kiuchi, S.; Okamoto, M.; Narita, H.; Kudo, Y. T-477, a novel
and Na+ channel blocker, prevents veratridine-induced neuronal injury. Eur. J. 
Pharmacol. 2000, 398(2), 209-216. 
 Waxman, S. G. The molecular pathophysiology of pain: abnormal expression of 
sodium channel genes and its contributions to hyperexcitability of primary sen
neurons. Pain. 1999
98. Rush, A. M.; Elliott, J. R. Phenytoin and carbamazepine: differential inhibition of 
sodium currents in small cells from adult rat dorsal root ganglia. Neurosci. Lett., 
1997, 226(2), 95-98. 
99. Chapman, V.; Dickenson, A. H. Inflammation reveals inhibition of noxious 
responses of rat spinal neurons by carbamazepine. NeuroReport 1997, 8(6), 1399-
1404. 
. Troels, S. J. A
evidence. Eur. J. Pain. 2002, 6 (Suppl. A), 61-68. 
. Pevarello, P.; Varasi, M.; Salvati, P.; Post, C. Substituted 2-benzylamino-
phenylacetamide compounds useful as sodium channel blockers. PCT Int. Appl. 
WO 9935123 A1, 15 Jul 1999, 20 pp. 
102. Lan, N. C.; Wang, Y.; Cai, S. X. Preparation of substituted 2-aminoace





 arrhythmia and as analgesics and anesthetics. PCT Int. 
104  
inistered membrane stabilizing drugs, bupivacaine and 
105
term models of hyperalgesia in rats. 
106
 4030W92, a New Antihyperalgesic 
107 .; 
ect of the Novel Sodium Channel Blocker 4030W92 in 
l. 




col. 1998, 357(1), 39-48. 
. Beatch, G. N.; Longley, C. J.; Walker, M. J. A.; Wall, R. A. Aminocycloalkyl
cinnamide compounds for
Appl. WO 2000051981 A1, 8 Sep 2000, 79 pp. 
. Chapman, V.; Wildman, M. A.; Dickenson, A. H. Distinct electrophysiological
effects of two spinally adm
lamotrigine. Pain 1997, 71(3), 285-295. 
. Klamt, J. G. Effects of intrathecally administered lamotrigine, a glutamate 
release inhibitor, on short- and long-
Anesthesiology 1998, 88(2), 487-494. 
. Trezise, D. J.; John, V. H.; Xie, X. M. Voltage- and Use-Dependent Inhibition 
of Na+ Channels in Rat Sensory Neurons by
Agent. Br. J. Pharmacol. 1998, 124, 953-963. 
. Clayton, N. H.; Collins, S. D.; Sargent, R.; Brown, T.; Nobbs, M.; Bountra, C
Trezise, D. J. The Eff
Models of Acute and Chronic Inflammatory Pain in the Rat. Br. J. Pharmaco
1998, 123, 79P. 
. Co
a Novel Sodium Channel Blocker, on the Treatment of Neuropathic Pain in 
Rat. Br. J. Pharmacol. 1998, 123, 16P. 
109. Gutser, U. T.; Friese, J.; Heubach, J. F.; Matthiesen, T.; Selve, N.; Wilffert, 
Gleitz, J. Mode of antinociceptive and toxic action of alkaloids of Aconitum spec
Naunyn-Schmiedeberg's Arch. Pharma
110. Ameri, A. The effects of Aconitum alkaloids on the central nervous system. 





111. Keith, R. QX-314 inhibits ectopic nerve activity associated with neuropathic 
pain. Brain Res. 1997, 771(2), 228-237. 
112. Berger, J.; Flippin, L. A.; Hunter, J. C.; Loughhead, D. G.; Weikert, R. J. 
Preparation of N-[2-(2,6-dimethylphenoxy-1-methylethyl)]ethylamine as sodium 
channel blocker. PCT Int. Appl. WO 9727169 A1, 31 Jul 1997, 37 pp. 
113. Perucca, E. The new generation of antiepileptic drugs: Advantages and 
disadvantages. Br. J. Clin. Pharmacol. 1996, 42, 531-543. 
114. Wang, G. K.; Strichartz, G. R. Therapeutic Na+ channel blockers beneficial for 
pain syndromes. Drug Dev. Res. 2001, 54(3), 154-158. 
115. Tasso, S. M.; Bruno-Blanch, Luis E.; Estiu, G. L. Pharmacophore model for 
antiepileptic drugs acting on sodium channels. J. Mol. Modeling 2001, 7(7), 231-
239.  
http://link.springer.de/link/service/journals/00894/papers/1007007/10070231.pdf   
116. Pevarello, P.; Bonsignori, A.; Caccia, C.; Amici, R.; McArthur, R. A.; Fariello, 
R. G.; Salvati, P.; Varasi, M. Sodium channel activity and sigma binding of 2-
aminopropanamide anticonvulsants. Bioorg. Med. Chem. Lett. 1999, 9, 2521-2524. 
117. Shimojo, M.; Takasugi, K.; Yamamoto, I.; Funato, H., Mochizuki, H.; Kohsaka, 
S. Neuroprotective action of a novel compound-50463- in primary cultured 
neurons. Brain Res. 1999, 815, 131-139. 
118. Zimanyi, I.; Weiss, S. R. B.; Lajtha, A.; Post, R. M.; Reith, M. E. A. Evidence 
for a common site of action of lidocaine and carbamazepine in voltage-dependent 
sodium channels. Eur. J. Pharmacol. 1989, 167, 419-422. 
119. Gleitz, J.; Friese, J.; Beile, A.; Ameri, A.; Peters, T. Anticonvulsive action of 
(±)-kavain estimated from its properties on stimulated synaptosomes and NaP+P 




120. Catterall, W. A.; Gainer, M. Interaction of Brevetoxin with a new receptor site 
on the sodium channel. Toxicon 1985, 23 (3), 497-504. 
121. Worley, P. F.; Baraban, J. M. Site of anticonvulsant action on sodium channel: 
autoradiographic and electrophysiological studies in rat brain. Proc. Natl. Acad. Sci. 
USA. 1987, 84, 3051-3055. 
122. Modest, E. J.; Farber, S.; Foley, G. E. Structure-biological activity relationships 
in a series of biologically active dihydrotriazines. Proc. Am. Ass. Cancer Res.  
1954, 1, 33. 
123. Modest E. J. Chemical and biological studies on 1,2-dihydro-s-triazines. II 
three-component synthesis. J. Org. Chem. 1956, 21, 1-13. 
124. Kim, K. H.; Dietrich, S. W.; Hansch, C. Inhibition of dihydrofolate reductase. 3. 
4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(2-subtituted-phenyl)-s-triazine inhibition 
of bovine liver and mouse tumor enzymes. J. Med. Chem. 1980, 23, 1248. 
125. Dietrich, S. W.; Smith, R. N.; Fukunaga, J. Y.; Olney, M.; Hansch, C. 
Dihydrofolate reductase inhibition by 2,4-dihydrotriazines: a structure-activity 
study. Arch. Biochem. Biophy. 1979, 194 (2), 600-611. 
126. Bami, H. L. Studies in dihdydrotriazines. Current Sci. 1954, 23, 124. 
127. Matthews, D. A.; Bolin, J. T.; Burridge J. M.; Filman D. J; Volz K. W.; Kraut J. 
Dihydrofolate reductase – the stereochemistry of inhibitor selectivity. J. Biol. 
Chem. 1985 260 (1), 392-399. 
128. Kim, K. H.; Dietrich, S. W.; Hansch, C. Inhibition of dihydrofolate reductase. 3. 
4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(2-substituted-phenyl)-s-triazine 




129. Dietrich, S. W.; Smith, R. N.; Fukunaga, J. Y.; Olney, M.; Hansch, C. 
Dihydrofolate reductase inhibition by 2,4-diaminotriazines: a structure-activity 
130
131  The Chemistry of the Carbon-nitrogen Double Bond; 
132
 Hall: London, 1982. 






VI. Study of conditions for the reaction of aceto- 
138
ects of tryptophan and its metabolites in the rat. Pharmaco. Res. 1998, 
38 (4), 243-250. 
study. Arch. Biochem. Biophy. 1979, 194 (2), 600. 
. Bami, H. L. Studies in dihydrotriazines. Current Sci. 1954, 23, 124. 
. Dayagi, S.; Degani, Y. In
Patai, S., Ed; Wiley-Interscience: New York, 1970; pp 61. 
. In Dictionary of Organic Compounds, 5th edition; Buckingham, J., Ed; 
Chapman and
133. Liu, K. J. Org. Chem. 1980, 45 (19), 3916-3918. 
. Sharghi, H; Sarvari, M. H. Selective synthesis of E and
Synlett. 2001, 1, 99-101. 
. Witek, S.; Bielawski, J.; Bielawski, A. New pesticides and intermediates. Part 
VII. Some azaalkenyl derivatives of N-phenylurea and N-phenylcarbamic a
Polish J. Chem. 1981, 55 (12), 2589-2600. 
 Gawinecki, R.; Kolehmainen, E.; Kauppinen, R. 1H and 13C NMR studies of 
para-substituted benzyloximes for evaluation of the electron donor properties of 
substituted amino groups. J. Chem Soc. Perkin Trans. 2 1998, 1, 25-30. 
 
. Trofinov, B. A.; Korostova, S. E.; Balabanova, L. N.; Mikhaleva, A. I. Pyrroles 
from ketoximes and acetylene. 
and propiophenone oximes with acetylene. Zhurnal Organicheskoi Khimii 1978, 
14 (8), 1733-1736. 
. Heyliger, S. O.; Goodman, C. B.; Ngong, J. M.; Soliman, K. F. A. The 
analgesic eff
 149
